AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON APRIL 18, 1996

REGISTRATION NO. 333-


SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

MERIDIAN DIAGNOSTICS, INC.
(Exact name of Registrant as specified in its charter)

             OHIO                                            31-0888197
(State or other jurisdiction of                             (IRS Employer
incorporation or organization)                         Identification Number)

3471 RIVER HILLS DRIVE
CINCINNATI, OHIO 45244
(513) 271-3700

(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

EDWARD E. STEINER, ESQ.
KEATING, MUETHING & KLEKAMP
1800 PROVIDENT TOWER
ONE EAST FOURTH STREET
CINCINNATI, OHIO 45202
(513) 579-6468

(Name, address, including zip code, and telephone number, including area code, of agent for service)

WITH COPIES TO:

PATRICK G. QUICK, ESQ.
FOLEY & LARDNER
FIRSTAR CENTER
777 EAST WISCONSIN AVENUE
MILWAUKEE, WISCONSIN 53202
(414) 271-2400

APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:
As soon as practicable after the effective date of this Registration Statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. / /

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 of the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, please check the following box. / /

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. / /

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. / /

If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. / /

CALCULATION OF REGISTRATION FEE

                                                         PROPOSED          PROPOSED
                                                         MAXIMUM           MAXIMUM          AMOUNT OF
         TITLE OF SHARES             AMOUNT TO BE     OFFERING PRICE  AGGREGATE OFFERING    REGISTRATION
         TO BE REGISTERED             REGISTERED        PER SHARE          PRICE(1)            FEE
- ----------------------------------------------------------------------------------------------------------
Common Stock, without par value...     1,725,000         $9.8125         $16,926,562          $5,837
=====================================================================================================

(1) Estimated pursuant to Rule 457(c) under the Securities Act of 1933 solely for the purpose of calculating the registration fee.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(a) OF THE SECURITIES ACT OF 1933, OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(a), MAY DETERMINE.



INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE.

SUBJECT TO COMPLETION, DATED APRIL 18, 1996

1,500,000 SHARES

[LOGO]

COMMON STOCK

All of the shares of Common Stock offered hereby are being sold by the Selling Shareholder. See "Principal Shareholders and Selling Shareholder." Meridian Diagnostics, Inc. (the "Company") will receive no proceeds from the sale of Common Stock by the Selling Shareholder. The Common Stock of the Company is quoted on the Nasdaq National Market under the symbol "KITS." On April 17, 1996, the last reported sale price of the Common Stock was $9.625 per share. See "Price Range of Common Stock."


SEE "RISK FACTORS" ON PAGE 6 FOR A DISCUSSION OF CERTAIN FACTORS THAT

SHOULD BE CONSIDERED BY PROSPECTIVE INVESTORS. THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.

- ------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------
                                                                                  PROCEEDS TO
                                                  PRICE TO       UNDERWRITING       SELLING
                                                   PUBLIC        DISCOUNT(1)     SHAREHOLDER(2)
- ------------------------------------------------------------------------------------------------
Per Share....................................        $                $                $
- ------------------------------------------------------------------------------------------------
Total(3).....................................        $                $                $
- ------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------

(1) The Company and the Selling Shareholder have agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933. See "Underwriting."

(2) Before deducting expenses of this Offering, all of which are payable by the Selling Shareholder, estimated at $350,000.

(3) The Selling Shareholder has granted to the Underwriters a 30-day option to purchase up to an additional 225,000 shares of Common Stock solely to cover over-allotments, if any, on the same terms and conditions as set forth above. If the option is exercised in full, the total Price to Public, total Underwriting Discount and total Proceeds to Selling Shareholder will be $ , $ and $ , respectively. See "Underwriting." The shares of Common Stock are offered by the several Underwriters when, as and if delivered to and accepted by the Underwriters and subject to various conditions, including their right to reject orders in whole or in part. It is expected that the shares of Common Stock will be ready for delivery on or about May , 1996.


CLEARY GULL REILAND & MCDEVITT INC.

THE OHIO COMPANY
RONEY & CO.

The date of this Prospectus is May , 1996.


The Company's diagnostic test kits are based on multiple core diagnostic technologies, each of which enable the visualization and identification of antigen/antibody reactions for specific pathogens. As a result, the Company is able to develop and manufacture diagnostic test kits in a variety of formats that satisfy customer needs and preferences. Shown above are various test formats, including Premier, ImmunoCard and Meritec, for Clostridium difficile, a serious pathogen of the gastrointestinal tract.

[Photogrpah of various test formats, including Premier, ImmunoCard and Meritec]


The Company's FiltraCheck-UTI product allows hospitals, laboratories and alternate site markets to rapidly screen for the presence of urinary tract infection. On those tests that show no presence of active infection, the need to culture the specimen, a time intensive and costly procedure, can be eliminated.

[photograph of Company's FiltraCheck-UTI product]


AVAILABLE INFORMATION

The Company is subject to the informational requirements of the Securities Exchange Act of 1934 (the "Exchange Act") and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the "Commission"). Such reports, proxy statements and other information filed by the Company with the Commission can be inspected and copied at the public reference facilities maintained by the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549, and at the Commission's regional offices located at Northwestern Atrium, 500 West Madison Street, Suite 1400, Chicago, Illinois, and at 7 World Trade Center, Suite 1300, New York, New York. Copies of such material can also be obtained, at prescribed rates, by mail from the Public Reference Section of the Commission at its Washington, D.C. address set forth above. In addition, material filed by the Company can be obtained and inspected at the offices of the Nasdaq Stock Market, Inc., 9513 Key West Avenue, Rockville, Maryland 20850, on which the Common Stock is quoted.

This Prospectus constitutes part of a Registration Statement on Form S-3 filed by the Company with the Commission under the Securities Act of 1933 (the "Securities Act"). This Prospectus omits certain of the information contained in the Registration Statement, and reference is hereby made to the Registration Statement and related exhibits for further information with respect to the Company and the Common Stock offered hereby. Any statements contained in this Prospectus as to the terms of any document are not necessarily complete, and in such instance reference is made to the copy of such document filed as an exhibit to the Registration Statement or otherwise filed with the Commission. Each such statement is qualified in its entirety by such reference.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

THIS PROSPECTUS INCORPORATES BY REFERENCE CERTAIN DOCUMENTS RELATING TO THE COMPANY WHICH ARE NOT DELIVERED HEREWITH. THESE DOCUMENTS (OTHER THAN THE EXHIBITS TO SUCH DOCUMENTS, UNLESS SUCH EXHIBITS ARE SPECIFICALLY INCORPORATED BY REFERENCE INTO SUCH DOCUMENTS) ARE AVAILABLE, WITHOUT CHARGE, ON ORAL OR WRITTEN REQUEST BY ANY PERSON TO WHOM THIS PROSPECTUS IS DELIVERED. Written or telephone requests should be directed to Gerard Blain, 3471 River Hills Drive, Cincinnati, Ohio 45244, telephone (513) 271-3700. The following documents, which have been filed by the Company with the Commission, are hereby incorporated by reference in this Prospectus:

(1) The Company's Annual Report on Form 10-K for the fiscal year ended September 30, 1995;

(2) The Company's Quarterly Reports on Form 10-Q for the quarters ended December 31, 1995 and March 31, 1996; and

(3) The description of the Common Stock contained in the Registration Statement on Form 8-A filed on August 15, 1986 and amended August 20, 1986.

All documents filed by Meridian Diagnostics, Inc. pursuant to Sections
13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this Offering shall be deemed to be incorporated by reference in this Prospectus. Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Prospectus to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Prospectus.

IN CONNECTION WITH THE OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMMON STOCK AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN MARKET. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME.

IN CONNECTION WITH THE OFFERING, CERTAIN UNDERWRITERS AND SELLING GROUP MEMBERS (IF ANY) OR THEIR RESPECTIVE AFFILIATES MAY ENGAGE IN PASSIVE MARKET MAKING TRANSACTIONS IN THE COMMON STOCK ON THE NASDAQ NATIONAL MARKET IN ACCORDANCE WITH RULE 10b-6A UNDER THE SECURITIES EXCHANGE ACT OF 1934. SEE "UNDERWRITING."

The Company owns the following trademarks: CALAS(R), FiltraCheck-UTI(R), ImmunoCard(TM), Merifluor(R), Meritec(TM), MeriStar(R), Macro-Con(R),
MONOLERT(R), MONOSPOT(R), ECOFIX(R), HYDROFLUOR(R) and Para-Pak(R).


[Insert gatefold here]


PROSPECTUS SUMMARY

The following summary is qualified in its entirety by the more detailed information and consolidated financial statements, including the notes thereto, appearing elsewhere in this Prospectus. Unless otherwise indicated, information in this Prospectus relating to share data reflects 3-for-2 stock splits effective March 27, 1992 and October 2, 1995, 3% stock dividends effective December 23, 1993 and December 8, 1994 and a 5% stock dividend effective December 14, 1992 and assumes that the Underwriters' over-allotment option is not exercised. The Company's fiscal year ends on September 30. See "Glossary of Selected Terms" for definitions of certain terms used herein.

THE COMPANY

Meridian Diagnostics, Inc. develops, manufactures and markets a diverse line of disposable diagnostic test kits and related diagnostic products used for the rapid diagnosis of infectious diseases. The Company's products aid in the diagnosis of such common medical conditions as gastrointestinal infections, mononucleosis, urinary tract infections and respiratory infections. The Company's products provide accuracy, simplicity and speed, enabling healthcare providers to reduce costs while improving quality. All of the Company's products are used in procedures performed in vitro (outside the body) and require little or no special instrumentation or equipment.

The global market for infectious disease tests continues to expand as new disease states are identified, new therapies become available and worldwide standards of living and access to healthcare improve. Technological advances permitting accurate diagnostic testing to occur outside the traditional hospital or laboratory setting have affected this market. These technological developments have contributed to the emergence of alternate site markets, such as physicians' offices, outpatient clinics, nursing homes and health maintenance organizations (HMOs), as important diagnostic product segments. The increasing pressures to contain global healthcare costs have accelerated this shift to alternate site markets and also increased the use of diagnostic tests. With rapid and accurate diagnosis of infectious disease, physicians can pinpoint therapies quickly, leading to faster recovery, shorter hospital stays and reduced expense. These technological advances should also contribute to the development of new markets, including veterinary laboratories, water treatment facilities and consumer self-testing in the over-the-counter market.

The Company's product line consists of over 100 diagnostic products relating to five disease states. The Company's diagnostic tests, which generally range from $1 per test to $13 per test, provide rapid results (often in minutes or hours) are easy to use and require less technical expertise than conventional tests. Conventional diagnostic testing requires highly skilled technicians to perform complicated test procedures that generally have turnaround times of 24 to 48 hours. For many of the disease states, the Company has the broadest product line or the only alternative to more expensive, time consuming conventional procedures.

The Company's products are based on multiple core diagnostic technologies, each of which enables visualization and identification of antigen/antibody reactions for specific pathogens. As a result, the Company is able to develop and manufacture diagnostic tests in a variety of formats that satisfy customer needs and preferences. The Company targets niche diagnostic test markets, which are characterized by a large number of low volume users. Historically, the larger diagnostic companies have not concentrated on this segment of the market.

The Company's marketing group utilizes industry contacts and key customer focus sessions to identify new product opportunities. Through the use of cross-functional teams that include marketing, research and development and manufacturing personnel, the marketing group guides the development process to meet customers' needs with products that are easier to use, require less technical expertise and yield faster results. The Company believes it is well positioned to develop partnerships with key customers because it is an integrated manufacturer, has a broad product line, offers tests in multiple formats and is willing to invest resources in building relationships and facilitating open communications with those customers. To illustrate, in January 1996, the Company signed a three-year exclusive agreement, with the Columbia/HCA Healthcare Corporation, a hospital alliance of approximately 350 hospitals, for all parasitology transport products and specific infectious disease diagnostic products. In April 1996, the Company signed a three-year, primary

3

source agreement with Laboratory Corporation of America, consisting of over 35 laboratories, for the supply of certain products for parasitology, virology and other infectious diseases.

The Company's research and development activities focus on developing diagnostic solutions. Over the past five years, the Company has developed internally 19 new products. The Company believes that its ability to bind various chemicals to various solid phases, including plastics, membranes, latex beads and immunofluorescent dyes to develop testing formats, gives it a competitive advantage. The Company estimates that, from the conceptualization of a product, it takes approximately 18 to 24 months to begin to generate revenues.

The Company markets its products through a direct sales force, in the U.S. and Italy, supplemented by a network of U.S. and international distributors. Over the last three years, the Company's international sales have nearly tripled from $2.1 million in fiscal 1992 to $5.8 million in fiscal 1995 and currently represent 23% of net sales.

The Company has developed and implemented a strategy for growth consisting of the following six principal elements:
- Developing New Product Applications from Core Technologies and Formats
- Acquiring and Licensing Products and Technology
- Increasing International Sales
- Developing Partnerships with Consolidated Healthcare Organizations
- Entering New Markets
- Accessing Alternate Site Markets for Diagnostic Testing

Since 1990, the Company has realized substantial growth in net sales and primary net earnings per share. Net sales increased to $25.1 million in fiscal 1995 from $8.5 million in fiscal 1990, a compound annual growth rate of approximately 24%. Over the same period, primary earnings per share increased at a compound annual growth rate of approximately 37%.

The Company is an Ohio corporation, its principal executive offices are located at 3471 River Hills Drive, Cincinnati, Ohio 45244, and its telephone number is (513) 271-3700.

THE OFFERING

Common Stock Offered by the Selling
Shareholder.............................      1,500,000 shares

Common Stock to be Outstanding after the
Offering................................     14,257,006 shares (1)

Use of Proceeds.........................     The Company will receive no
                                              proceeds from the sale of Common
                                              Stock offered hereby.

Nasdaq National Market Symbol...........     KITS
- ---------------

(1) Does not include 805,933 shares of Common Stock issuable upon the exercise of stock options outstanding at March 31, 1996.

4

SUMMARY CONSOLIDATED FINANCIAL DATA
(IN THOUSANDS, EXCEPT PER SHARE DATA)

                                                                                   SIX MONTHS ENDED
                                            YEARS ENDED SEPTEMBER 30,                  MARCH 31,
                                 -----------------------------------------------   -----------------
                                  1991      1992      1993      1994      1995      1995      1996
                                 -------   -------   -------   -------   -------   -------   -------
STATEMENT OF EARNINGS DATA
  Net sales..................... $11,085   $14,003   $16,171   $21,877   $25,110   $11,574   $12,776
  Gross profit..................   7,112     9,421    11,073    14,359    17,101     7,752     8,777
  Operating income..............   1,356     2,616     3,525     4,814     6,576     2,671     3,269
  Earnings before income
     taxes......................   1,518     2,605     3,101     3,983     5,960     2,376     3,345
  Net earnings..................     959     1,653     1,889     2,441     3,524     1,375     1,984
  Primary earnings per common
     share......................    0.08      0.13      0.15      0.20      0.29      0.11      0.14
  Dividends paid per common
     share
     Regular....................    0.02      0.04      0.06      0.08      0.10      0.05      0.06
     Special....................    0.02(1)    0.01(1)      --(1)      --(1)      --      --    0.03
  Primary weighted average
     number of common shares
     outstanding................  12,129    12,222    12,264    12,277    12,355    12,300    14,072(2)

                                                                                 MARCH 31, 1996
                                                                                 --------------
BALANCE SHEET DATA
  Cash and short-term investments..............................................     $ 10,244
  Working capital..............................................................       14,578
  Total assets.................................................................       35,915
  Long-term debt, including current maturities.................................        5,127
  Shareholders' equity.........................................................       27,090


(1) The Company paid a special 5% stock dividend in fiscal 1992 and special 3% stock dividends in fiscal 1993 and fiscal 1994. See "Dividend Policy."

(2) Reflects the effect of the conversion of the Company's 7 1/4% Convertible Subordinated Debentures into shares of Common Stock. See "Management's Discussion and Analysis of Financial Condition and Results of Operations -- Liquidity and Capital Resources."

5

RISK FACTORS

Prospective investors should carefully consider the factors set forth below, as well as other information included elsewhere herein or incorporated herein by reference, prior to purchasing the shares of Common Stock offered hereby.

NEW PRODUCT DEVELOPMENT AND ACQUISITIONS

The diagnostic test industry is characterized by ongoing technological developments and changing customer requirements. As a result, the Company's success and continued growth depend, in part, on its ability in a timely manner to develop or acquire rights to, and successfully introduce into the marketplace, enhancements of existing products or new products that incorporate technological advances, meet customer requirements and respond to products developed by the Company's competition. There can be no assurance that the Company will be successful in developing or acquiring such rights to products on a timely basis or that such products will adequately address the changing needs of the marketplace. See "Business -- Strategy," "-- Products," "-- Marketing and Sales" and "-- Research and Development."

INTERNATIONAL OPERATIONS

Approximately 23% of the Company's net sales for fiscal 1995 were attributable to international sales, primarily in Western Europe. Although the majority of the Company's international sales have been made in U.S. dollars, the Company is subject to the risks associated with fluctuations in currency exchange rates. The Company is also subject to other risks associated with international operations, including tariff regulations, requirements for export licenses and medical licensing and approval requirements. See "Business -- Strategy."

CHANGING MARKET CONDITIONS

The healthcare industry is in transition with a number of changes that affect the market for diagnostic test products. Changes in the healthcare delivery system have resulted in major consolidation among reference laboratories and in the formation of multi-hospital alliances, reducing the number of institutional customers for diagnostic test products. There can be no assurance that the Company will be able to enter into and/or sustain contractual or other marketing or distribution arrangements on a satisfactory commercial basis with these institutional customers. See "Business -- Market Trends."

COMPETITION

The market for the Company's products is characterized by substantial competition and rapid change. Hundreds of companies in the United States supply immunodiagnostic tests. These companies range from multinational healthcare entities, for which immunodiagnostics is one line of business, to small start-up companies. Many of the Company's competitors have significantly greater financial, technical, manufacturing and marketing resources than the Company. See "Business -- Competition."

DEPENDENCE ON KEY DISTRIBUTORS

The Company's sales to two of its distributors were approximately $8.6 million, or approximately 34% of total sales, in fiscal 1995. These distributors resell the Company's products and other laboratory products to end-user customers. The loss of either of these distributors could have a material adverse effect on the Company's sales and results of operations. See "Business -- Marketing and Sales" and "-- Customers."

GOVERNMENT REGULATION

The Company's products generally require governmental clearance before marketing in the U.S. and in certain foreign countries. The Company may be required to submit test data from clinical trials to establish "substantial equivalence" of its products with previously approved products. If so required, the Company may commence marketing in the U.S. only when the regulatory agency issues a written order finding such "substantial equivalence," which may take longer than the 90-to 120-day period estimated for such review. Any product for which "substantial equivalence" cannot be established must proceed through the more lengthy pre-market approval procedures. There is no assurance that the Company will be able to obtain the

6

necessary clearances or timely clearances to market future products. See "Business -- Government Regulation."

Third party payors (including state and federal governments) are increasingly concerned about escalating health care costs and can indirectly affect the pricing or the relative attractiveness of the Company's products by regulating the maximum amount of reimbursement they will provide for diagnostic testing services. If reimbursement amounts for diagnostic testing services are decreased in the future, such decreases may reduce the amount that will be reimbursed to hospitals or physicians for such services and consequently could reduce the price the Company can charge for its products.

In recent years, the federal government has been examining the nation's health care system from numerous standpoints, including the cost of and access to health care and health insurance. Proposals impacting the health care system are constantly under consideration and could be adopted at any time. It is unclear what effect the enactment of such proposals would have on the Company.

COMMON STOCK OWNERSHIP BY DIRECTORS AND EXECUTIVE OFFICERS

After the Offering, the Company's officers, directors, principal shareholders and their affiliates will beneficially own approximately 42% of the Company's outstanding Common Stock, all of which shares are eligible for sale under Securities and Exchange Commission Rule 144 under the Securities Act of 1933. As a result, these shareholders, if they were to act in concert, would have the ability to influence significantly most matters requiring approval by shareholders of the Company, including the election of a majority of the directors. In addition, the Board of Directors has the authority to issue up to 1,000,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions, including voting rights, of such shares without any future vote or action by the shareholders. The voting power of these principal shareholders, officers and directors or the issuance of preferred stock under certain circumstances could have the effect of delaying or preventing a change in control of the Company. Ohio corporation law contains provisions that may discourage takeover bids for the Company that have not been negotiated with the Board of Directors. Such provisions could limit the price that investors might be willing to pay in the future for shares of the Common Stock. In addition, sales of substantial amounts of such shares in the public market could adversely affect the market price of the Common Stock and the Company's ability to raise additional capital at a price favorable to the Company. Agreements with the Selling Shareholder and the Company's other officers and directors not to offer or otherwise dispose of Common Stock without the consent of Cleary Gull Reiland & McDevitt Inc. will expire 360 and 90 days, respectively, after the date of this Prospectus. See "Principal Shareholders and Selling Shareholder" and "Description of Capital Stock."

7

CAPITALIZATION

The table sets forth the capitalization of the Company at March 31, 1996. The table should be read in conjunction with the Company's Consolidated Financial Statements and related notes thereto appearing elsewhere in this Prospectus or incorporated herein by reference.

                                                                                 MARCH 31, 1996
                                                                                 --------------
                                                                                  (DOLLARS IN
                                                                                   THOUSANDS)
Long-term debt, including current maturities(1)................................     $  5,127
                                                                                 --------------
Shareholders' equity:
  Preferred stock, without par value; 1,000,000 shares authorized, none
     issued....................................................................           --
  Common stock, without par value; 50,000,000 shares authorized,
     14,257,006 shares outstanding(2)..........................................        2,373
  Additional paid-in capital...................................................       20,434
  Retained earnings............................................................        4,500
  Foreign currency translation adjustment......................................         (217)
                                                                                 --------------
     Total shareholders' equity................................................       27,090
                                                                                 --------------
          Total capitalization.................................................     $ 32,217
                                                                                 ===========


(1) The Company has an unused $6,000,000 line of credit with a commercial bank.
(2) As of March 31, 1996, options to acquire 805,933 shares of Common Stock were outstanding.

8

DIVIDEND POLICY

The Company follows a cash dividend policy consisting of regular quarterly and special year-end dividends. The Board has set a targeted payout ratio of 45% to 55% of annual net earnings. Approximately 30% to 35% of forecasted annual net earnings is intended to be paid in regular quarterly dividends with any balance being paid as a year-end special dividend. All or a portion of the year-end dividend may be paid in stock. The declaration and amount of dividends are determined by the Board of Directors in its discretion based upon its evaluation of earnings, cash flow requirements and future business developments. There is no assurance that dividends will continue.

On January 25, 1996, the Company increased its quarterly dividend rate to $0.035 per share. The second of such dividends will be paid on May 3, 1996 to shareholders of record on April 25, 1996.

The Company paid a $0.02 per share cash dividend in the first quarter of fiscal 1995 and paid $0.0267 per share cash dividends for each other quarter of fiscal 1995. In addition, the Company declared and paid a three-for-two stock split payable on October 2, 1995. On December 1, 1995, the Company paid a special fiscal 1995 year-end dividend of $0.025 per share.

The Company paid a $0.016 per share cash dividend in the first quarter of fiscal 1994 and $0.02 per share cash dividends for each other quarter of fiscal 1994. In addition, the Company declared and paid a special fiscal 1994 year-end dividend in the form of a 3% stock dividend effective December 1, 1993.

9

PRICE RANGE OF COMMON STOCK

The Common Stock is traded on the Nasdaq National Market under the symbol "KITS." The following table sets forth, for the fiscal periods indicated, the high and low closing sales prices for the Common Stock as reported on the Nasdaq National Market:

                                                                               HIGH     LOW
                                                                               ----     ----
FISCAL YEAR ENDED SEPTEMBER 30, 1994
  First Quarter.............................................................. $6 1/2   $5 1/4
  Second Quarter.............................................................  7 1/8    5 1/2
  Third Quarter..............................................................  6 1/8    5
  Fourth Quarter.............................................................  5 1/2    4 3/8
FISCAL YEAR ENDED SEPTEMBER 30, 1995
  First Quarter.............................................................   5        4 3/8
  Second Quarter.............................................................  6 1/2    4 5/8
  Third Quarter..............................................................  7 3/8    5 7/8
  Fourth Quarter.............................................................  9 1/2    6
FISCAL YEAR ENDED SEPTEMBER 30, 1996
  First Quarter..............................................................  12 1/4   7 3/4
  Second Quarter.............................................................  11 3/8   9 1/8
  Third Quarter (through April 17)...........................................  10 7/8   9 5/8

On April 17, 1996, the last reported sales price for the Common Stock on the Nasdaq National Market was $9 5/8 per share. As of March 31, 1996, there were approximately 825 holders of record of the Common Stock, which the Company believes represents a total of approximately 6,000 beneficial shareholders.

10

SELECTED CONSOLIDATED FINANCIAL DATA

The following table sets forth the Company's selected historical consolidated financial data for the fiscal years 1991 through 1995 and for the six months ended March 31, 1995 and 1996. The selected consolidated financial data for the five fiscal years in the period ended September 30, 1995 are derived from the financial statements of the Company which have been audited by Arthur Andersen LLP. The selected financial data for the six months ended March 31, 1995 and 1996 are derived from the Company's unaudited quarterly financial statements. In the opinion of management, the six month financial data reflect all adjustments necessary for a fair presentation of such data. The results for the first six months of fiscal 1996 are not necessarily indicative of the results to be expected for the full year. The information below should be read in conjunction with the Consolidated Financial Statements and notes thereto and "Management's Discussion and Analysis of Financial Condition and Results of Operations" appearing elsewhere in this Prospectus.

                                                                                    SIX MONTHS ENDED
                                             YEARS ENDED SEPTEMBER 30,                  MARCH 31,
                                  -----------------------------------------------   -----------------
                                   1991      1992      1993      1994      1995      1995      1996
                                  -------   -------   -------   -------   -------   -------   -------
                                                 (IN THOUSANDS, EXCEPT PER SHARE DATA)
STATEMENT OF EARNINGS DATA
  Net sales.....................  $11,085   $14,003   $16,171   $21,877   $25,110   $11,574   $12,776
  Cost of sales.................    3,973     4,582     5,098     7,518     8,009     3,822     3,999
                                  -------   -------   -------   -------   -------   -------   -------
          Gross profit..........    7,112     9,421    11,073    14,359    17,101     7,752     8,777
                                  -------   -------   -------   -------   -------   -------   -------
  Research and development......    1,102     1,157     1,165     1,433     1,432       713       697
  Selling and marketing.........    2,564     3,166     3,716     4,747     5,229     2,421     2,815
  General and administration....    2,090     2,482     2,667     3,365     3,864     1,947     1,996
                                  -------   -------   -------   -------   -------   -------   -------
          Total operating
            expenses............    5,756     6,805     7,548     9,545    10,525     5,081     5,508
                                  -------   -------   -------   -------   -------   -------   -------
          Operating income......    1,356     2,616     3,525     4,814     6,576     2,671     3,269
  Net interest (expense)
     income.....................      135       (39)     (122)     (839)     (699)     (366)        7
  Other (expense) income........       27        28      (302)        8        83        71        69
                                  -------   -------   -------   -------   -------   -------   -------
          Earnings before income
            taxes...............    1,518     2,605     3,101     3,983     5,960     2,376     3,345
  Income taxes..................      559       952     1,212     1,542     2,436     1,001     1,361
                                  -------   -------   -------   -------   -------   -------   -------
          Net earnings..........  $   959   $ 1,653   $ 1,889   $ 2,441   $ 3,524   $ 1,375   $ 1,984
                                  =======   =======   =======   =======   =======   =======   =======
  Primary earnings per common
     share......................  $  0.08   $  0.13   $  0.15   $  0.20   $  0.29   $  0.11   $  0.14
  Dividends paid per common
     share
     Regular....................     0.02      0.04      0.06      0.08      0.10      0.05      0.06
     Special....................     0.02      0.01        --        --        --        --      0.03
  Primary weighted average
     number of common shares
     outstanding................   12,129    12,222    12,264    12,277    12,355    12,300    14,072

                                                   SEPTEMBER 30,                        MARCH 31,
                                  -----------------------------------------------   -----------------
                                   1991      1992      1993      1994      1995      1995      1996
                                  -------   -------   -------   -------   -------   -------   -------
                                                            (IN THOUSANDS)
BALANCE SHEET DATA
  Cash and short-term
     investments................  $ 1,590   $ 1,810   $ 9,476   $ 8,832   $ 8,919   $ 8,161   $10,244
  Working capital...............    4,046     5,164    13,759    13,000    15,826    14,074    14,578
  Total assets..................   10,997    14,099    26,247    32,329    34,569    32,751    35,915
  Long-term debt, including
     current maturities.........       99     1,808    12,812    15,051    12,881    15,855     5,127
  Shareholders' equity..........    9,519    10,676    11,617    13,232    18,878    13,905    27,090

11

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with the Company's Consolidated Financial Statements and the Notes thereto appearing elsewhere in this Prospectus or incorporated herein by reference.

GENERAL

Since its founding in 1976, the Company has evolved into a fully integrated medical diagnostic company with a diverse product line, an established distribution network and a highly focused product development effort. Since 1991, the Company has realized substantial growth in net sales and net earnings, primarily as the result of developing, licensing, acquiring or entering into supply agreements for new products, improving these products, expanding international sales and realizing operating efficiencies.

The Company utilizes its core technologies to develop and offer products that aid in the diagnosis of various disease states. The Company's current product line consists of nearly 100 medical diagnostic products which test for specific diseases within five major disease states. The product lines which have the largest impact on Company sales are used for the collection, transportation and concentration of parasites, and products used to diagnose C. difficile and certain viral and respiratory diseases. See "Business-Products."

On October 10, 1995, the Company called for the redemption of the outstanding balance of its 7 1/4% Convertible Subordinated Debentures due in 2001. At that time, approximately $7,400,000 of the principal amount of the Debentures was outstanding. Of the originally issued $11,500,000 principal amount, $113,000 was redeemed for cash on November 30, 1995. The balance was converted into Common Stock at $5.97 per share.

RESULTS OF OPERATIONS

The following table sets forth certain statement of operations data as a percentage of net sales for the periods indicated.

                                                                                 SIX MONTHS ENDED
                                                   YEARS ENDED SEPTEMBER 30,         MARCH 31,
                                                   -------------------------     -----------------
                                                   1993      1994      1995      1995        1996
                                                   -----     -----     -----     -----       -----
Net sales........................................  100.0%    100.0%    100.0%    100.0%      100.0%
Cost of sales....................................   31.5      34.4      31.9      33.0        31.3
                                                   -----     -----     -----     -----       -----
          Gross profit...........................   68.5      65.6      68.1      67.0        68.7
                                                   -----     -----     -----     -----       -----
Research and development.........................    7.2       6.5       5.7       6.2         5.5
Selling and marketing............................   23.0      21.7      20.8      20.9        22.0
General and administrative.......................   16.5      15.4      15.4      16.8        15.6
                                                   -----     -----     -----     -----       -----
          Total operating expenses...............   46.7      43.6      41.9      43.9        43.1
                                                   -----     -----     -----     -----       -----
          Operating income.......................   21.8      22.0      26.2      23.1        25.6
Net interest (expense) income....................   (0.8)     (3.8)     (2.8)     (3.2)        0.1
Other expense (income)...........................   (1.8)       --       0.3       0.6         0.5
                                                   -----     -----     -----     -----       -----
          Earnings before income taxes...........   19.2      18.2      23.7      20.5        26.2
Income taxes.....................................    7.5       7.0       9.7       8.6        10.7
                                                   -----     -----     -----     -----       -----
          Net earnings...........................   11.7%     11.2%     14.0%     11.9%       15.5%
                                                   =====     =====     =====     =====       =====

Comparison of Six Months ended March 31, 1996 and 1995

Net sales increased $1,202,000, or 10% over the comparable fiscal 1995 period, to $12,776,000 for the six months ended March 31, 1996. These increases are attributable primarily to strong unit volume growth in the Premier, Para-Pak and ImmunoCard lines. In the Premier and ImmunoCard formats, this growth was attributable to those products used for identification of Toxin A, H. pylori, EHEC, Mycoplasma and Rotavirus. In Para-Pak, the growth was attributable to the core parasitology transport format plus Para-Pak

12

Ultra, introduced last fall. In addition, the Inova line of products, first licensed for sale in Italy in fiscal 1995, added over $170,000 of sales volume for the six months results.

The increase in sales of $1,202,000 was comprised of volume of $957,000, or 8%, pricing of $186,000, or 2%, and currency of $59,000.

European sales increased from $2,469,000 to $2,970,000, or 20%, for the six-month period principally from volume growth in the Premier, ImmunoCard and Para-Pak formats plus the new volume from the Inova line. This increase is comprised of volume of $389,000, or 16%, price of $53,000, or 2%, and currency of $59,000, or 2%.

Gross profit increased $1,025,000, or 13%, in the six months ended March 31, 1996, to $8,777,000, from $7,752,000 in the prior year period. As a percentage of net sales, gross profit improved to 68.7% for the six-month period from 67.0% in the prior year period. Product mix, driven by growth in excess of 20% for Premier and Para-Pak and 15% for ImmunoCard for the second fiscal quarter coupled with the positive effect of volume, price and currency and favorable inventory variances were the basis for this improvement in profitability.

Total operating expenses increased $427,000, or 8%, to $5,508,000 for the six months ended March 31, 1996, compared to $5,081,000 in the comparable prior year period. Total operating expenses were 43.1% of net sales for the six months, a decrease from 43.9% in the prior year period.

Research and development expenses decreased 2% to $697,000 for the six-month period compared to $713,000 in the prior year period. Increases in personnel costs and licensing fees were largely offset by reductions in outside contract research and casual labor, used more heavily last year, plus reductions in indirect expenses such as repairs, laboratory supplies and travel. Clinical trial expense did not vary materially from the prior year periods.

Selling and marketing expenses increased $394,000, or 16%, to $2,815,000 for the six-month period from $2,421,000 in the prior year period. The increase is attributable to personnel costs in the U.S. associated with the addition of a third sales region and, in Europe, from added personnel in the sales support and product management functions. Other increases included higher travel, promotion/advertising associated with new products (Premier Cryptosporidium, Premier EHEC, Premier HSV Plus, Para-Pak and the Inova line) plus depreciation expense associated with the new U.S. headquarters facility.

General and administrative expenses increased approximately 2% to $1,996,000 for the six-month period from $1,947,000 in the prior year period. Increased personnel costs, primarily in Europe and a one-time state filing fee associated with the increase in the number of authorized shares of Common Stock were the primary reasons for the increase. The overall increase was offset, in part, by a provision for doubtful accounts recorded in the second fiscal quarter of last year.

Operating income as a result of the above increased $599,000, or 22%, to $3,269,000 for the six months from $2,671,000 in the prior year period. As a percent of sales, operating income improved to 25.6% from 23.1% in the prior fiscal period.

Other income (net) increased $370,000 for the six month period ended March 31, 1996. Interest income (net) improved $372,000 for the six month period primarily from the reduction in interest expense as a result of the conversion of the Convertible Subordinated Debentures as of November 30, 1995.

Comparison of Fiscal Years ended September 30, 1995 and 1994

Net sales increased $3,233,000, or 15%, to $25,110,000 in fiscal 1995 from $21,877,000 in fiscal 1994. This increase was primarily from unit volume growth in the Premier, ImmunoCard, Merifluor and mononucleosis lines plus OEM sales of Epstein-Barr Virus. The major growth areas are in those tests used for identification of infectious diseases such as C. difficile, Toxin A, mononucleosis, Mycoplasma and Herpes simplex virus. Of the increase of $3,233,000, $1,112,000, or 34%, was attributable to the full year sales of the infectious disease product line acquired in January 1994 from an affiliate of Ortho Diagnostics Systems, Inc. (ODSI).

13

The increase in sales of $3,233,000 was more than accounted for by volume of $3,271,000, or 15%, offset marginally by price decreases of $38,000 with no impact from currency translation. European sales increased $1,175,000, or 30%, to $5,102,000 from $3,927,000 as a result of continued strong unit growth in the Premier line, up 45% (Toxin A, H. pylori and EHEC -- introduced during the second quarter); the mononucleosis line, up 21%; lmmunoCard, which almost tripled largely from new products (Mycoplasma, mononucleosis, Rotavirus and H. pylori); and Merifluor, up 81%. The increase in net sales was accounted for by volume, $951,000, or 24%, and price, $223,000, or 6%. The effect of currency translations was negligible.

Gross profit increased $2,742,000, or 19%, to $17,101,000 for fiscal 1995 from $14,359,000 in fiscal 1994. As a percentage of sales, gross profit increased to 68.1% in fiscal 1995 from 65.6% in fiscal 1994. This improvement was due primarily to the transfer and in-house manufacture of the product lines acquired from ODSI in June 1993 and January 1994, which prior to October 1994 were purchased under a supply agreement with ODSI. Fiscal 1994 costs also included integration of the ODSI infectious disease product line into Meridian's manufacturing facilities in Cincinnati. Other factors contributing to the improvement included continued favorable efficiency and volume variances from the sales increase, the new warehouse facilities, and the reduction in factory overhead including decreased rent expense from the new on-site warehouse, lower insurance and employee benefit expense, plus a reduction in travel.

Operating expenses increased $980,000, or 10%, to $10,525,000 for fiscal 1995 from $9,545,000 in fiscal 1994, but declined as a percentage of sales from 43.6% in fiscal 1994 to 41.9% in fiscal 1995. Research and development expenses were marginally lower than the prior year, and decreased from $1,433,000 in fiscal 1994 to $1,432,000 in fiscal 1995. Selling and marketing expenses increased $481,000, or 10%, versus fiscal 1994, mainly from higher personnel costs in the U.S. and Europe, higher convention, meeting, sample and promotion expenses associated with new product introductions and the full year impact of the infectious disease product line acquired from ODSI. General and administrative expenses increased $499,000, or 15%, due to increased personnel costs in the U.S. and Europe stemming from the higher level of business, an increase in depreciation from the expanded office facilities plus the full year impact of depreciation from assets acquired from ODSI and a general increase in the provision for doubtful accounts to reflect added coverage given the increasing sales level.

Operating income increased $1,762,000, or 37%, to $6,576,000 in fiscal 1995 from $4,814,000 in fiscal 1994 primarily due to the factors described above. As a percent of sales, operating income improved to 26.2% in fiscal 1995 compared to 22.0% in fiscal 1994.

Other expenses decreased $214,000, or 26%, to $616,000 compared to $831,000 in fiscal 1994. This decrease was more than accounted for from higher investment income stemming from an improvement in interest rates compared to fiscal 1994 plus commission income related to the sale of certain tissue culture products acquired from ODSI and sold to VAI Diagnostics, Inc. in March 1994. Gains/losses in foreign exchange were not material in either fiscal year. The cumulative foreign currency translation adjustment changed by $32,000 during the year as a result of strengthening of the U.S. dollar against the lira during the period.

The Company's effective tax rate increased for the year as a result of a higher proportion of income from the Company's European subsidiary in Italy, which is taxed at a significantly higher rate than the U.S. domestic rate. The effective tax rate was 40.9% in fiscal 1995 compared to 38.7% for the prior year.

Comparison of Fiscal Years ended September 30, 1994 and 1993

Net sales increased $5,706,000, or 35%, to $21,877,000 in fiscal 1994 from $16,171,000 in fiscal 1993. This increase resulted primarily from higher unit volumes resulting from the June 1993 acquisition of the infectious mononucleosis product line and the January 1994 acquisition of the infectious disease product line from ODSI, plus strong unit growth in the lmmunoCard and Merifluor product lines.

The increase in sales of $5,706,000 was comprised of volume of $5,139,000, or 32%, price of $899,000, or 5%, offset by currency of ($332,000) or (2%). European sales increased $1,447,000, or 58%, to $3,927,000 from $2,480,000 largely due to MONOSPOT and MONOLERT products acquired from ODSI in June 1993, plus unit growth in the Para-Pak, Merifluor and Premier product lines. This increase in net sales was attributed to volume of $1,114,000, or 45%, price of $665,000, or 27%, offset by currency of ($332,000), or

14

(14%). The increase from pricing stemmed from the expiration in fiscal 1994 of contract supply prices in effect at the time of the mononucleosis product line acquisition in fiscal 1993.

Gross profit increased $3,286,000, or 30%, to $14,359,000 for the year, from $11,073,000 in fiscal 1993. As a percentage of sales, gross profit declined to 65.6% in fiscal 1994 from 68.5% in fiscal 1993. This decline is due to several factors including the impact of the lower margin ODSI product line acquisitions -- in part provided under a supply agreement -- which ended June 30, 1994, except for MONOSPOT which ended in October 1995. Other factors impacting gross profit were increased manufacturing costs, higher scrap and obsolescence costs stemming from product development including validation batches, minor product discontinuations and additional costs associated with packaging standardization. Also impacting manufacturing cost was the transfer and integration of the ODSI infectious disease product line into Meridian's facilities in Cincinnati.

Operating expenses increased $1,997,000, or 26%, to $9,545,000 for fiscal 1994 from $7,548,000 in fiscal 1993, but declined as a percentage of sales to 43.6% in fiscal 1994 from 46.7% in fiscal 1993. Research and development expense increased $268,000, or 23%, over fiscal 1993 primarily from higher personnel costs, increased clinical trial activity and laboratory supplies associated with new product development and depreciation expense stemming from equipment acquired during the year from ODSI. Selling and marketing expenses increased $1,031,000, or 28%, primarily as a result of the amortization of the purchase price of the ODSI product line acquisitions, higher personnel costs in the U.S. and Europe from the addition of sales representatives and higher promotional expenses in the U.S. associated with new products and, in Europe, from the expansion of the direct sales and distribution to customers in Italy. General and administrative expenses increased $698,000, or 26%, due to amortization of the ODSI acquisitions, increased personnel costs in the U.S. and Europe to support the continued growth in the business, higher depreciation expense related to equipment acquired from ODSI plus an increase in the provision for potential doubtful accounts.

Operating income as a result of the above increased $1,289,000, or 37%, to $4,814,000 in fiscal 1994 from $3,525,000 in fiscal 1993.

Other expense increased in fiscal 1994 by $406,000, which was more than accounted for by higher interest expense and amortization of debt expenses attributed to the $11,500,000 of 7 1/4% Convertible Subordinated Debentures issued in September 1993. These increases in debenture-related expenses were offset by the one time write-off of $405,000 in fiscal 1993 of expenses associated with the Company's planned offering of Common Stock, which was withdrawn on July 29, 1993. The after tax impact on earnings of this withdrawal cost was $255,000 or $0.02 per share in 1993, as adjusted.

The Company's effective tax rate declined marginally for the year as a result of a higher proportion of the income in the U.S. which is taxed at a significantly lower rate than in Italy. The effective tax rate was 38.7% in fiscal 1994 compared to 39.1% in fiscal 1993. Effective October 1, 1993 the Company adopted Financial Accounting Standards Statement No. 109, "Accounting for Income Taxes." Prior period financial statements have not been restated to reflect the new accounting method since the cumulative effect of this change as well as the effect of this new standard on income tax expense for Fiscal 1994 was not material.

QUARTERLY RESULTS OF OPERATIONS

The following table presents selected unaudited consolidated quarterly results of operations of the Company for fiscal 1994, fiscal 1995 and the first two quarters of fiscal 1996. Historically, the fourth quarter of the fiscal year has been the strongest. The results of operations for any quarter are not necessarily indicative of results for any future period. Quarterly earnings per share do not necessarily total to year-end amounts due to rounding.

                                     FISCAL 1994                             FISCAL 1995                   FISCAL 1996
                        --------------------------------------  --------------------------------------  -----------------
                        DEC. 31  MAR. 31   JUNE 30   SEPT. 30   DEC. 31  MAR. 31   JUNE 30   SEPT. 30   DEC. 31  MAR. 31
                        -------  --------  --------  ---------  -------  --------  --------  ---------  -------  --------
                                                      (IN THOUSANDS, EXCEPT PER SHARE DATA)
Net sales.............. $3,625    $5,891    $5,717    $ 6,644   $5,106    $6,469    $6,782    $ 6,753   $5,522    $7,255
Net earnings...........    200       610       603      1,028      430       945       985      1,164      629     1,355
Primary earnings per
  common share.........    .01       .05       .05        .09      .04       .08       .08        .09      .05       .10

15

LIQUIDITY AND CAPITAL RESOURCES

At March 31, 1996, the Company had cash and short-term investments of $10,244,000 and working capital of $14,577,745. Trade accounts receivable increased $51,000 or 1% while inventories increased $298,000 or 10% compared to September 30, 1995. Receivables decreased in the U.S. by $395,000, primarily from special extended payment terms at September 30, 1995 which have been remitted. Receivables in Europe increased $446,000 in line with the increase in sales of 20% for this six month period versus last year. The change in inventories reflects higher stock levels associated with projected sales.

On October 10, 1995, the Company called for the redemption of the outstanding balance of its 7 1/4% Convertible Subordinated Debentures due in 2001. At that time approximately $7,400,000 of the principal amount of the Debentures was outstanding. Of the originally issued $11,500,000 principal amount, $113,000 was redeemed for cash on November 30, 1995. The balance was converted into Common Stock at $5.97 per share.

Construction of 19,000 square feet of additional and renovated manufacturing and administrative space, which began in August 1994, was completed in September 1995 at a total cost of $1,400,000. This construction was funded by a construction loan which was repaid on April 16, 1996 and which reduced long-term debt by $2,418,000. Total capital expenditures for the year, including the above mentioned project, were $2,500,000. The Company commenced renovation of the former administrative offices and laboratory manufacturing space in October 1995 at an estimated cost of $1,200,000 which will complete the Company's expansion project begun in late 1993. Completion of this phase is expected to be June 1996. The Company's anticipated total capital expenditures for fiscal 1996 are $1,900,000.

Cash flow from operations is expected to continue to fund working capital requirements for the foreseeable future. Currently, the Company has available a $6,000,000 line of credit with a commercial bank.

RECENTLY ISSUED ACCOUNTING STANDARDS

In March 1995, the Financial Accounting Standards Board (FASB) issued Statement No. 121 (Statement 121) on accounting for the impairment of long-lived assets to be held and used. Statement 121 also establishes accounting standards for long-lived assets that are to be disposed. Statement 121 is required to be applied prospectively for assets to be held and used. The initial application of Statement 121 to assets held for disposal is required to be reported as the cumulative effect of a change in accounting principle. The Company is required to adopt Statement 121 no later than fiscal 1997. The Company has not yet determined when it will adopt Statement 121 and the impact, if any, that the adoption will have on its financial position or results of operations.

In October 1995, the FASB issued Statement No. 123 (Statement 123) establishing financial accounting and reporting standards for stock-based employee compensation plans. Statement 123 encourages the use of the fair value based method to measure compensation cost for stock-based employee compensation plans, however, it also continues to allow the intrinsic value based method of accounting as prescribed by APB Opinion NO. 25, which is currently used by the Company. If the intrinsic value based method continues to be used, Statement 123 requires pro forma disclosures of net income and earnings per share, as if the fair value based method of accounting had been applied. The fair value based method requires that compensation cost be measured at the grant date based upon the value of the award and recognized over the service period, which is normally the vesting period. The Company is required to adopt Statement 123 no later than fiscal 1997. The Company has not yet determined when it will adopt Statement 123 or the valuation method it will use.

16

BUSINESS

GENERAL

The Company develops, manufactures and markets a diverse line of disposable diagnostic test kits and related diagnostic products used for the rapid diagnosis of infectious diseases. To meet market demands, the Company's products provide accuracy, simplicity and speed, leading to opportunities for improvements in diagnosis and reductions in health care costs. All of the Company's products are used in procedures performed in vitro (outside the body) and require little or no special instrumentation or equipment.

The Company's product development strategy is to combine existing technologies with new product designs both through internal product development and through product acquisitions, licensing or supply arrangements. Internal product development activities focus on the development or enhancement of immunodiagnostic technologies and applications to simplify, accelerate or increase the accuracy of diagnoses of certain infectious diseases. Since 1991, the Company has also acquired or obtained rights to distribute a number of products and technologies.

The Company utilizes its resources to serve each of the strategic domestic and international medical markets it has targeted: hospital networks and clinical and hospital laboratories; alternate site markets, including physicians' offices, outpatient clinics, nursing homes and health maintenance organizations (HMOs); and new markets, including veterinary laboratories, water treatment facilities and consumer self-testing. The Company currently markets approximately 100 products representing five major disease states through a direct sales force, in the U.S. and Italy, supplemented by a network of national and international distributors. International sales in approximately 50 countries were approximately 23% of total fiscal 1995 sales, with approximately 88% of international sales originating in Western Europe. The majority of the remaining international sales were in Canada, Mexico and the Pacific Rim.

IMMUNODIAGNOSTICS OVERVIEW

In vitro diagnostic testing is the process of analyzing constituents of blood, urine, stool, other bodily fluids or tissue for the presence of specific infectious diseases. Immunodiagnostic testing, which is the leading method of in vitro testing for infectious diseases, tests for antigens and antibodies. When an infectious disease caused by pathogens, such as bacteria, viruses and fungi, and their related antigens is present, the body responds by producing an (homologus) antibody. The antibody binds specifically with the antigen in a lock-and-key fashion and initiates a biochemical reaction to attempt to neutralize and ultimately to eliminate the antigen. The ability of an antibody to bind with a specific antigen provides the basis for immunodiagnostic testing.

Immunodiagnostic testing detects the presence of specific infectious diseases through the "visualization," such as color changes or the formation of visible aggregates, of the biochemical reactions caused by the antigen/antibody. Most immunodiagnostic tests utilize one of two alternative methods to determine the presence of a specific disease in a patient specimen. In one method, the test employs the antibody to detect directly the presence of an antigen. When the antigen is difficult to detect, a test employs the antigen to detect the presence of an antibody.

MARKET TRENDS

The global market for infectious disease tests continues to expand as new disease states are identified, new therapies become available and worldwide standards of living and access to healthcare improve. More importantly, within this market there is a continuing shift from conventional testing, which requires highly trained personnel and lengthy turnaround times for test results, to more technologically advanced testing which can be performed and completed in minutes or hours by less highly trained personnel.

Technological advances permitting accurate testing to occur outside the traditional hospital or laboratory setting have also affected the diagnostic products market. These technological developments have contributed to the emergence of alternate site markets, such as physicians' offices, outpatient clinics, nursing homes and health maintenance organizations (HMOs), as important diagnostic market segments. These technological

17

advances should also contribute to the development of new markets for the Company's products, including veterinary laboratories, water treatment facilities and consumer self-testing in the over-the-counter market.

The increasing pressures to contain total healthcare costs have accelerated the increased use of diagnostic testing and the market shift to alternate sites. With rapid and accurate diagnoses of infectious disease, physicians can pinpoint appropriate therapies quickly, leading to faster recovery, shorter hospital stays and less expense. In addition, these pressures have led to a major consolidation among reference laboratories and the formation of multi-hospital alliances that has reduced the number of institutional customers for diagnostic products and resulted in changes in buying practices. Specifically, multi-year exclusive or primary source marketing or distribution contracts with institutional customers have become more common, replacing less formal distribution arrangements of shorter duration and involving lower product volumes.

STRATEGY

The Company continues to execute its long-term strategy consisting of the following elements:

- Developing New Product Applications from Core Technologies and Formats. The Company employs a market-driven product development strategy to adapt or enhance diagnostic testing technologies and product formats in response to newly identified disease states and to customer demands for improvements in product accuracy, simplicity, speed and cost-efficiency. The Company accomplishes this by monitoring existing markets, interacting closely with customers and recognizing emerging diseases and therapies. Since 1991, the Company has developed and introduced 19 internally developed products.

- Acquiring and Licensing Products and Technology. The Company intends to acquire, license or enter into supply arrangements to obtain innovative diagnostic testing technologies and product formats that complement its existing operations and address the needs of the Company's existing and targeted customer base. Management regularly identifies and reviews opportunities through its broad industry contacts and recognized position in the industry. Since 1991, the Company has acquired, licensed or entered into supply arrangements relating to 19 products. In fiscal 1996, the Company entered into a supply arrangement to market an additional 64 products through Baxter Healthcare Corporation.

- Increasing International Sales. The Company has targeted increasing international sales as an attractive source of growth. The Company has made recent investments to develop a major presence in Italy through its Italian subsidiary Meridian Diagnostics Europe srl ("MDE"), added management to expand its ability to serve Latin American markets and strengthened its distribution channels into the European market. Over the last three years, the Company's international sales have almost tripled from $2.1 million in fiscal 1992 to $5.8 million in fiscal 1995 and represented 23% of total consolidated sales in fiscal 1995.

- Developing Partnerships With Consolidated Healthcare Organizations. The Company seeks to develop strategic partnerships with the major reference laboratories and other consolidated healthcare providers. The Company believes it is well positioned to develop partnerships with key customers because it is an integrated manufacturer, has a broad product line, offers tests in multiple formats, and is willing to invest resources in building relationships and facilitating open communications with those customers. In January 1996, the Company signed a three-year exclusive agreement with the Columbia/HCA Healthcare Corporation, a hospital alliance of approximately 350 hospitals, for the Company to provide all parasitology transport products and specific infectious disease diagnostic products. In April 1996, the Company signed a three-year, primary source agreement with Laboratory Corporation of America, consisting of over 35 laboratories, for the supply of certain products for parasitology, virology and other infectious diseases.

- Entering New Markets. The Company continues to monitor and identify the emergence of new immunodiagnostic testing opportunities arising from the discovery of new pathogens or new linkages between existing pathogens and new diseases. In April 1995, the Company introduced the first immunodiagnostic test for toxigenic E. coli, a bacteria found in inadequately cooked meats. The Company plans to apply for approvals to test both animals (United States Department of Agriculture (USDA)) and food products (Association of Analytical Chemists (AOAC)) that may contain this highly toxic organism. In July 1994, the Company agreed to provide its Hydrofluor product, the first

18

product that tests for water-borne parasitic pathogens, specifically Giardiasis and Cryptosporidiosis, for distribution through an independent supplier to water treatment facilities. The Company has entered into an agreement with Johnson & Johnson to market the Company's rapid diagnostic test for urinary tract infections to the consumer market, subject to pre-market approval by the FDA, the timing of which cannot be predicted.

- Accessing Alternate Site Markets for Diagnostic Testing. The Company seeks strong licensing/ distribution partners having sales and marketing strengths to enable it to more effectively promote the Company's products into alternate site markets. The Company believes that its products are readily adaptable for use in alternate site markets. In August 1995, the Company entered into an exclusive licensing agreement with a third party which through its 120 representatives will distribute the Company's urinary tract infection product to the physician office market. The Company continues to evaluate the suitability of certain of its other products for the consumer market.

PRODUCTS

The Company has expertise in the development and manufacture of products based on multiple core diagnostic technologies, each of which enables the visualization and identification of antigen/antibody reactions for specific pathogens. As a result, the Company is able to develop and manufacture diagnostic tests in a variety of formats that satisfy customer needs and preferences, whether in a hospital, commercial or reference laboratory or alternate site location. These technologies include enzyme immunoassay, immunofluorescence, particle agglutination, membrane filtration/concentration, immunodiffusion, complement fixation and chemical stains.

Enzyme Immunoassay (EIA). Products incorporating the EIA technology achieve extremely high levels of accuracy in detecting disease-related antigens or antibodies through the use of special color-based enzyme-substrate reactions. The Company utilizes this technology in its multiple test format -- Premier -- for large volume users, and in its single test formats -- ImmunoCard and MONOLERT -- for single physician users.

Immunofluorescence. When the microscopic visualization of an antigen-antibody reaction is necessary or desired, immunofluorescence technology is frequently utilized. Fluorescing immunochemicals, in the presence of the target antigen or antibody, can be viewed via a special microscope. The Company utilizes this technology in its Merifluor products.

Particle Agglutination. This technology utilizes microparticles (e.g., latex, red blood cells) coated with specific antigens or antibodies that form visible aggregates in the presence of a specimen containing the complementary antigen or antibody. This technology is rapid and economical and is used in the Company's Meritec, MeriStar and MONOSPOT products.

Membrane Filtration/Concentration. The Company utilizes this technology to detect infection-causing bacteria present in human urine. These bacteria are concentrated on a unique filter membrane for detection via the addition of a special dye solution. This technology is utilized in the Company's proprietary rapid, single-unit FiltraCheck-UTI test format.

Other Technologies. The Company utilizes other technologies that include immunodiffusion, complement fixation and chemical stains. The Company also manufactures and markets specimen collection transportation, preservation and concentration products, such as Para-Pak and Macro-Con.

19

The Company's product line consists of nearly 100 medical diagnostic products representing five major disease states. Currently, the most important product lines from the perspective of sales are Para-Pak and related products and products to diagnose C. difficile, viral diseases and respiratory diseases. The Company's products generally range in list price from $1 per test to $13 per test. A discussion of the Company's key products and their competitive advantage is reflected in the table below:

     INFECTIOUS DISEASE CATEGORY                KEY PRODUCT(S)                      PRODUCT APPLICATION
  ------------------------------------------------------------------------------------------------------------------
  PARASITIC DISEASES
  -- Giardiasis                           Para-Pak, Premier, Meritec     Products for the diagnosis and collection,
  -- Cryptosporidiosis                          Para-Pak Ultra           preservation, transportation and
  -- Amebiasis                                 Macro-Con Ultra           concentration of parasites.
- ------------------------------------------------------------------------------------------------------------------
  GASTROINTESTINAL DISEASES
  -- Stomach Ulcers (H. pylori)              Premier, ImmunoCard         U.S. patients make 20 million annual
                                                                         visits to their physicians for gastric
                                                                         distress. The H. pylori bacteria has been
                                                                         associated with more than 90% of duodenal
                                                                         ulcers and may be related to cancer of the
                                                                         stomach.
  -- Toxigenic E. coli                             Premier               E. coli is a potentially lethal bacteria
                                                                         that infects undercooked food and can
                                                                         cause kidney failure.
  -- Antibiotic-associated Diarrhea      Premier, ImmunoCard, Meritec    Toxin producing strains of C. difficile
    (C. difficile)                                                       can cause PMC (pseudomembranous colitis)
                                                                         that results in rapid colon degeneration.
  -- Pediatric Diarrhea (Rotavirus)          ImmunoCard, Meritec         This viral disease, which causes rapid
                                                                         dehydration, is transmitted rapidly
                                                                         through pediatric populations in
                                                                         hospitals, schools and daycare settings.
- ------------------------------------------------------------------------------------------------------------------
  RESPIRATORY DISEASES
  -- Pneumonia (Mycoplasma                   ImmunoCard, MeriStar        Pneumonia is the fifth leading cause of
    pneumoniae)                                                          death worldwide, 20% of which is caused by
                                                                         Mycoplasma pneumoniae
  -- Valley Fever (Coccidioides                Premier, Meritec          Fungal pathogens can cause flu-like
    immitis)                                                             illness and/or severe pneumonia, that are
                                                                         life-threatening in AIDS and other
                                                                         immuno-compromised patients.
- ------------------------------------------------------------------------------------------------------------------
  UROGENITAL DISEASE
  -- Urinary Tract Infection                   FiltraCheck-UTI           In the U.S., 65 million cultures are
                                                                         performed yearly to detect potential
                                                                         urinary tract infection.
  -- Chlamydia                                Premier, Merifluor         Chlamydia is the leading
                                                                         sexually-transmitted disease.
- ------------------------------------------------------------------------------------------------------------------
  VIRAL DISEASES
  -- Infectious Mononucleosis               ImmunoCard, MONOLERT,        Infectious mononucleosis, a viral disease
                                                   MONOSPOT              common among young adolescents, is
                                                                         transmitted easily from person-to-person.
  -- Herpes simplex Virus (HSVI and                Premier               Oral Herpes infections affect up to 80% of
    HSVII)                                                               the population. Genital Herpes can be
                                                                         life-threatening to newborns.
  -- Cytomegalovirus                              Merifluor              Cytomegalovirus infections are potentially
                                                                         deadly in transplant procedures and among
                                                                         immuno-compromised blood recipients.
- ------------------------------------------------------------------------------------------------------------------

20


                THE COMPANY'S COMPETITIVE ADVANTAGE                                MARKET
 ----------------------------------------------------------------------------------------------------
  Leading supplier of parasitology diagnostics. In October 1995,       - Hospital Laboratories
  introduced two new products that resulted in easier processing,      - Reference Laboratories
  safer handling and reduced processing time of the specimen and       - Veterinary Laboratories
  lower cost disposal of the transport container.
- ----------------------------------------------------------------------------------------------------
  Historically, a physician-performed endoscopy, an extremely          - Hospital Laboratories
  uncomfortable and expensive procedure, was employed to diagnose      - Reference Laboratories
  gastric distress. The Company's tests allow accurate, quick          - Veterinary Laboratories
  diagnoses utilizing patient blood serum. The Company is the only
  manufacturer to provide testing formats which accommodate both
  small and large volume users.
  In November 1995, introduced the first and only FDA cleared
  diagnostic test that detects all toxigenic strains of E. coli
  directly from stool samples. Previous techniques required a
  minimum of 24 hours to culture E. coli organisms.
  Market leader with a broad range of products.
  Offers the clinician rapid results which are critical in
  preventing the spread of this highly infectious virus.
- ----------------------------------------------------------------------------------------------------
  The Company provides the broadest range of diagnostic reagents       - Hospital Laboratories
  for detecting respiratory diseases. The product is the only rapid    - Reference Laboratories
  test providing results in only ten minutes. The product provides     - State Health Laboratories
  increased accuracy over common diagnostic methods, allowing for a    - Veterinary Laboratories
  safer, more effective treatment.
- ----------------------------------------------------------------------------------------------------
  This product allows for rapid screening for the presence of          - Hospital Laboratories
  urinary tract infection. Therapy can be rapidly administered,        - Reference Laboratories
  often while the patient is still in the physician's office.          - Physicians' Office
                                                                       Laboratories
                                                                       - Consumer (pending)
                                                                       - Public Health Laboratories
  Both product formats enable rapid, accurate testing.
- ----------------------------------------------------------------------------------------------------
  The Company provides a broad range of innovative technologies        - Hospital Laboratories
  including MONOLERT which use synthetic peptides to detect the        - Reference Laboratories
  virus which causes mononucleosis.                                    - Physicians' Office
                                                                       Laboratories
                                                                       - Student Health Laboratories
  Premier HSV Plus detects both HSVI and HSVII rapidly from a
  variety of body sites.
  Quickly detects "immediate early antigen" in a rapid, direct
  fluorescence format.
- ----------------------------------------------------------------------------------------------------

21

MARKETING AND SALES

The Company's marketing efforts are focused on a continual process of seeking ways to assist healthcare providers in improving outcomes for patients exposed to serious infectious diseases. Rapid, accurate diagnosis can mean faster recovery, shorter hospital stays and less expense, both for the patient and the healthcare system.

The Company believes that its marketing goals are best served by forming partnerships with key customers to develop concepts for future products and technology applications. These partnerships facilitate close customer interaction, including product strategy sessions.

Marketing utilizes its strong industry contacts, plus key customer focus sessions, to identify new product and other opportunities. Through the use of cross-functional teams that include marketing, research and development and manufacturing personnel, marketing guides the development process to meet customers' needs with products that are easier to use, require less technical expertise, and yield faster results -- often in minutes or hours rather than days.

Changes in the healthcare delivery system have resulted in major consolidation among reference laboratories and the formation of multi-hospital alliances. The Company has structured its marketing, selling and customer service to anticipate and respond to these changes. This involved the addition of sales and marketing personnel; the expansion of technical services staff to support the Company's customers and distribution network through a toll-free service hotline; and the implementation of major marketing programs to target key customers.

The Company markets products through direct sales forces, both domestically and in Italy, and national and international independent distributors. In the United States, the Company's direct sales force consists of a director of sales, three regional sales managers, three regional virology specialists and 17 technical sales representatives. Where the Company utilizes distributors, the Company nonetheless participates in selling efforts involving key customers. In Italy, the Company's direct sales force consists of a director of sales, a product specialist and seven technical sales representatives.

The Company's sales and marketing efforts in Europe, North Africa and the Middle East are managed through MDE's European headquarters in Milan, Italy. MDE's strategy has been to appoint one or two distributors in each of the countries in its targeted markets, and to maintain a direct sales organization within Italy. The Company has approximately 50 independent distributors in approximately 50 foreign countries. The Company has additional key distributor relationships in Canada, Latin America and the Pacific Rim.

RESEARCH AND DEVELOPMENT

The Company's research and development activities focus on developing diagnostic solutions. Working in conjunction with the marketing department, the Company's research and development department focuses its activities on enhancements to and new applications for the Company's technologies. Over the past five years the Company has developed internally 19 new products. The research and development department has access to a number of diagnostic technologies, each of which can be applied to satisfy new product specifications that marketing has established. A critical expertise of the Company's product development staff is its ability to bind various chemicals to various solid phases, including plastics, membranes, latex beads and immunofluorescent dyes, to develop testing formats. The Company believes that it has certain proprietary know-how in these areas.

The research and development department initiates the Company's quality process through its technology transfer mechanism which begins the establishment of manufacturing standards. By working closely with the manufacturing department, the same standards can be imposed to ensure consistently high-quality products. The Company estimates that, from the conceptualization of a product, it takes approximately 18 to 24 months to begin to generate revenues.

The research and development department is comprised of the Vice President of Research and Development and 15 research scientists. The disciplines represented in the group include biochemistry, immunology, mycology, bacteriology, virology and parasitology. In fiscal 1994 and 1995 and the six months

22

ended March 31, 1996, the Company spent $1,433,000, $1,432,000 and $697,000, respectively, on its research and development activities.

CUSTOMERS

The principal customers for the Company's products are hospitals, commercial and reference laboratories and, to an increasing degree, alternate site markets, such as physicians' offices, outpatient clinics, nursing homes and HMOs, and new markets, such as veterinary laboratories, water treatment facilities and consumer self-testing. No end-use customer comprised more than 5% of the Company's sales in fiscal 1995. Two distributors together accounted for approximately 34% of the Company's fiscal 1995 sales. However, the Company does not believe that the loss of either of these distributors would have a long-term material adverse effect on the Company because of its ability to sell to the end-use customers served by these distributors through alternative means.

MANUFACTURING

The Company's manufacturing is performed at its Cincinnati facility. All manufacturing operations are regulated by, and in compliance with, FDA-mandated Good Manufacturing Practices ("GMPs") for medical devices. To maintain the highest quality standards, the Company utilizes both external and internal quality auditors who routinely evaluate the Company's manufacturing processes. The Company's immunodiagnostic products require the production of highly specific and sensitive antigens and antibodies. The Company produces substantially all of its own requirements including: monoclonal antibodies, polyclonal antibodies, synthetic peptides, plus a variety of fungal, bacterial and viral antigens. For the majority of its raw materials acquired from third parties, the Company has developed dual sources. As a result, the Company believes it has access to sufficient raw materials for its products. Products are generally produced for inventory and products are sold to customers out of its finished goods inventory. The Company believes it has sufficient manufacturing capacity for anticipated growth. Manufacturing backlog is not an element of the Company's industry. See "-- Properties."

COMPETITION

The market for diagnostic tests is a multi-billion dollar international industry which is highly competitive. Many of the Company's competitors are larger with greater financial, research, manufacturing, and marketing resources. Important competitive factors of the Company's products include product quality, price, ease of use, customer service and reputation. In a broader sense, industry competition is based upon scientific and technological capability, proprietary know-how, access to adequate capital, the ability to develop and market products and processes, the ability to attract and retain qualified personnel and the availability of patent protection. To the extent that the Company's product lines do not reflect technological advances, the Company's ability to compete in those product lines could be adversely affected.

Companies competing in the diagnostic test industry generally focus on a limited number of tests or limited segments of the market. As a result, the diagnostic test industry is highly fragmented and segmented. Hundreds of companies in the United States alone supply immunodiagnostic tests. These companies range from multi-national healthcare companies, for which immunodiagnostics is one line of business, to small start-up companies. Of central importance in the industry are mid-sized medical diagnostic specialty companies, like the Company, that offer multiple, broad product lines and have the ability to deliver high value new products quickly to the marketplace. Among the companies with which the Company competes in the marketing of one or more of its products are Abbott Laboratories, Becton, Dickinson and Company, Diagnostic Products Corporation, QUIDEL Corporation and the Wampole Laboratories Division of Carter-Wallace, Inc.

INTELLECTUAL PROPERTY, PATENTS AND LICENSES

In general, the Company does not seek patent protection for its products and instead strives to maintain the confidentiality of its proprietary know-how. The Company owns or licenses U.S. and foreign patents for 11 of its products. The patents or licenses thereof for these products were acquired in connection with the purchase of the products or the licensing of the technology on which the products are based. In the absence of patent protection, the Company may be vulnerable to competitors who successfully replicate the Company's

23

production and manufacturing techniques and processes. The Company's laboratory and research personnel are required to execute confidentiality agreements designed to protect the Company's proprietary products.

The Company has no reason to believe that its products and proprietary rights infringe the proprietary rights of any third parties. There can be no assurance, however, that third parties will not assert infringement claims in the future.

GOVERNMENT REGULATION

FDA Regulation of Medical Devices. The Company's products are regulated by the FDA as "devices" pursuant to the Federal Food, Drug and Cosmetic Act (the "FDCA"). Under the FDCA, medical devices are classified into one of three classes (i.e., Class I, II or III). Class I and II devices are not expressly approved by the FDA but, instead, are "cleared" for marketing. Class III devices generally must receive "pre-market approval" from the FDA as to safety and effectiveness.

A 510(k) clearance will be granted if the submitted data establishes that the proposed device is "substantially equivalent" to an existing Class I or Class II medical device or to a Class III medical device for which the FDA has not required pre-market approval. The 510(k) clearance process for "substantially equivalent" devices allows product sales to be made after the filing of an application and upon acknowledgment by the FDA, typically within 90 to 120 days after submission. If the FDA requests additional information, the product cannot be sold until the application has been supplemented and upon acknowledgment by the FDA within 90 to 120 days of the supplemental application. If there are no existing FDA-approved products or processes comparable to a diagnostic product or process, approval by the FDA involves the more lengthy pre-market approval procedures.

Each of the products currently marketed by the Company has been cleared by the FDA pursuant to the 510(k) clearance process or is exempt from such requirements. The Company believes that most, but not all, products under development will be classified as Class I or II medical devices and will be eligible for 510(k) clearance. One example of a product in development that is subject to the FDA's more lengthy pre-market approval process is the adaptation of the Company's rapid diagnostic test for urinary tract infections to the consumer market.

Other Medical Device Regulation. Sales of the Company's products in foreign countries are subject to foreign government regulation, the requirements of which vary substantially from country to country. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA approval, and the requirements may differ.

Other Approvals. The Company intends to seek appropriate certifications and approvals from the Association of Analytical Chemists (AOAC) and the United States Department of Agriculture (USDA) to enable the Company to market an immunodiagnostic test for toxigenic E. coli in both food products and animals. The Company has no direct experience in obtaining these certifications and approvals, but the Company believes the time required and applicable procedures will be similar to those required for FDA approval. However, there is no assurance that the Company will receive these certifications and approvals.

The Clinical Laboratory Improvement Act of 1988 ("CLIA 88") prohibits laboratories from performing in vitro tests for the purpose of providing information for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of, the health of human beings unless there is in effect for such laboratories a certificate issued by the U.S. Department of Health and Human Services ("HHS") applicable to the category of examination or procedure performed.

The Company is an exempt small quantity generator of hazardous waste and has a U.S. Environmental Protection Agency identification number. All hazardous waste is manifested and disposed of properly. The Company is in compliance with the applicable portions of the Federal and state hazardous waste regulations and has never been a party to any environmental proceeding.

24

EMPLOYEES

As of March 31, 1996, the Company had 161 full-time employees, including 40 in sales, marketing and technical support, 74 in manufacturing, 17 in research and product development and 30 in administration and finance.

None of the Company's employees is represented by a labor organization and the Company is not a party to any collective bargaining agreement. The Company has never experienced any strike or work stoppage and considers its relationship with its employees to be excellent.

PROPERTIES

The Company's corporate offices, manufacturing facility and research and development facility are located in two buildings totaling 75,000 square feet on 4.1 acres of land in a suburb of Cincinnati. These properties are owned by the Company. The Company believes these facilities are in good condition, well maintained and suitable for its long-term needs.

The Company believes its manufacturing and laboratory facilities are in compliance with all applicable rules and regulations and maintained in a manner consistent with GMPs.

MDE conducts its operations in a two-story building in the Milan, Italy area consisting of approximately 18,000 square feet. The Company believes these facilities are in good condition, well maintained and suitable for MDE's long-term operations.

25

MANAGEMENT

The following table sets forth certain information with respect to the directors and executive officers of the Company as of April 17, 1996:

                 NAME                    AGE          POSITION WITH THE COMPANY
---------------------------------------  ---   ---------------------------------------
William J. Motto.......................  54    Chairman of the Board, Chief Executive
                                                 Officer and Director
John A. Kraeutler......................  47    President and Chief Operating Officer
Gerard Blain...........................  56    Vice President and Chief Financial
                                               Officer
Christine A. Meda......................  47    Vice President, Marketing
Ching Sui Arthur Yi, Ph.D..............  49    Vice President, Research and
                                               Development
Antonio A. Interno.....................  47    Vice President
James A. Buzard, Ph.D.(1)(2)...........  68    Director
Gary P. Kreider(1)(2)..................  57    Director
Robert J. Ready(1)(2)..................  56    Director
Jerry L. Ruyan.........................  49    Director


(1) Audit Committee Member
(2) Compensation Committee Member

William J. Motto has more than 25 years experience in the pharmaceutical and diagnostics products industries, is a founder of the Company and has been Chairman of the Board since March 1977. From that date until June 1986 Mr. Motto served as President. He served as Chief Executive Officer from June 1986 until September 1989, and assumed that title again May 1995. Before forming the Company, Mr. Motto served in various capacities for Wampole Laboratories, Marion Laboratories, Inc. and Analytab Products, Inc., a division of American Home Products Corp.

John A. Kraeutler has more than 20 years of experience in the medical diagnostics industry and joined the Company as Executive Vice President and Chief Operating Officer in January 1992. In July 1992, Mr. Kraeutler was named President of the Company. Mr. Kraeutler most recently served as Vice President, General Manager for a division of Carter-Wallace, Inc. Prior to that, he held key marketing and technical positions with Becton, Dickinson and Company and Organon, Inc.

Gerard Blain joined the Company as Vice President and Chief Financial Officer on March 1, 1994. Prior to joining the Company, Mr. Blain was Vice President and Controller of Marion Merrell Dow, Inc. Mr. Blain had been with Marion Merrell Dow, Inc. and its predecessor companies since 1966.

Christine A. Meda has 15 years of experience in the diagnostics industry and joined the Company as Senior Director of Marketing in July 1994. In October 1995, she was appointed Vice President of Marketing. Ms. Meda served as Director of Sales and Marketing of Diagnostic Products Corporation from 1991 until joining the Company. During the period 1984 to 1991, she held various other management positions in both sales and marketing at Diagnostic Products Corporation.

Ching Sui Arthur Yi, Ph.D., has more than 17 years experience in the diagnostics industry and has been Vice President, Research and Development of the Company since August 1989. From May 1986 until he joined the Company, he was Director of Product Development of Cambridge BioScience Corporation. Previously he was a partner of BioClinical System Inc. from July 1983 to April 1986, Manager of Research and Development, Terumo Medical Corporation From March 1982 to June 1983 and Senior Scientist of Leeco Diagnostics from August 1979 to February 1982.

Antonio A. Interno was appointed as a Vice President in August 1991. He has been Managing Director of MDE since February 1990. Prior to that time, he was the marketing manager for Diagnostics International Distribution SPA, a major Italian diagnostics distributor.

James A. Buzard, Ph.D., has been a Director of the Company since May 1990 and serves as Chairman of the Compensation Committee. From March 1981 until December 1989, he was Executive Vice President of

26

Merrell Dow Pharmaceuticals Inc. From December 1989 until his retirement in February 1990 he was Vice President of Marion Merrell Dow Inc. He has been a business consultant since February 1990.

Gary P. Kreider has been a Director since 1991. For over five years Mr. Kreider has been a Senior Partner of the Cincinnati law firm of Keating, Muething & Klekamp, counsel to the Company.

Robert J. Ready has been a Director of the Company since May 1986 and serves as Chairman of the Audit Committee. In 1976, Mr. Ready founded LSI Industries, Inc., Cincinnati, Ohio, which engineers, manufactures and markets commercial/industrial lighting and graphics products, and has served as its President and Chairman of its Board of Directors since that time.

Jerry L. Ruyan has more than 20 years experience in the diagnostics products and medical industries, is a founder of the Company, has been a Director of the Company since March 1977 and served as Chief Executive Officer from July 1992 to May 1995. In May 1995, Mr. Ruyan reduced his day-to-day involvement in the Company in order to pursue outside interests. He relinquished the title of Chief Executive Officer at that time and continues to serve as a Director. Mr. Ruyan served as the President of the Company from June 1986 to July 1992. From June 1986 through January 1992, Mr. Ruyan served as Chief Operating Officer, and from March 1977 through June 1986 he served as Vice President. Before forming the Company, Mr. Ruyan served as a technical representative for Analytab Products, Inc. and prior to that as a Senior Microbiologist for Henry Ford Hospital, Detroit, Michigan.

27

PRINCIPAL SHAREHOLDERS AND SELLING SHAREHOLDER

The following table sets forth beneficial ownership of Common Stock at March 31, 1996, and after this offering by the Selling Shareholder.

                                    PRIOR TO THE OFFERING                              AFTER THE OFFERING
                              ----------------------------------               ----------------------------------
                                  COMMON STOCK                     SHARES TO       COMMON STOCK
            NAME              BENEFICIALLY OWNED(1)   PERCENTAGE    BE SOLD    BENEFICIALLY OWNED(1)   PERCENTAGE
- ----------------------------  ---------------------   ----------   ---------   ---------------------   ----------
William J. Motto(2)(3)......        4,625,918            32.3%            --         4,625,918             32.3%
Jerry L. Ruyan(2)(4)........        2,503,516            17.5%     1,500,000         1,003,516              7.0%
John A. Kraeutler...........           63,378                *            --            63,378                *
Gerard Blain................           11,482                *            --            11,482                *
Christine A. Meda...........            3,225                *            --             3,225                *
Ching Sui Arthur Yi, Ph.D...           21,255                *            --            21,255                *
Antonio A. Interno..........          351,553             2.4%            --           351,553              2.4%
James A. Buzard, Ph.D.......           14,807                *            --            14,807                *
Gary P. Kreider.............           30,916                *            --            30,916                *
Robert J. Ready.............           16,063                *            --            16,063                *
                              ---------------------   ----------   ---------   ---------------------   ----------
All Directors and Executive
  Officers as a Group (Ten
  Persons)..................        7,642,113            52.0%     1,500,000         6,142,113             41.8%


* Less than 1%.

(1) Includes exercisable stock options for Mr. Motto of 44,840 shares, Mr. Ruyan of 44,840 shares, Mr. Buzard of 13,556 shares, Mr. Ready of 16,063 shares, Mr. Kreider of 11,050 shares, Mr. Kraeutler of 59,659 shares, Mr. Blain of 9,607 shares, Dr. Yi of 5,642 shares, Mr. Interno of 229,236 shares and Ms. Meda of 3,225 shares.
(2) Messrs. Motto and Ruyan are parties to an agreement with the Company pursuant to which they must offer their shares for sale to the Company, and if it declines to purchase, to the other individual, based on the current market price, if either of them desires to sell more than 1% of the Common Stock in any three-month period.
(3) Includes 80,226 shares owned by Mr. Motto's three children in their individual capacities and 462,873 shares owned as trustees. Mr. Motto disclaims beneficial ownership of all shares held by his children in their individual capacities. Also includes 61,146 shares of Common Stock held by the William J. Motto Charitable Remainder Unitrust.
(4) Includes 125,765 shares held by Mr. Ruyan as Trustee of the Ruyan Family Charitable Remainder Unitrust and 4,081 shares held as custodian for his son.

28

DESCRIPTION OF CAPITAL STOCK

The Company's authorized capital stock consists of 50,000,000 shares of Common Stock, without par value, and 1,000,000 shares of preferred stock, without par value. The following description of certain matters relating to the capital stock of the Company is a summary and is qualified in its entirety of the provisions of the Company's Articles of Incorporation and Code of Regulations.

COMMON STOCK

The Company had 14,257,006 shares issued and outstanding immediately prior to the date of this Prospectus. Holders of Common Stock are entitled to one vote for each share held of record on all matters submitted to a vote of shareholders. Shareholders have the right to cumulate their votes in the election of directors.

Subject to preferences which may be granted to holders of preferred stock, holders of Common Stock are entitled to share in such dividends as the Board of Directors, in its discretion, may validly declare from funds legally available. In the event of liquidation, each outstanding share of Common Stock entitles its holder to participate ratably in the assets remaining after payment of liabilities and any preferred stock liquidation preferences.

Shareholders have no preemptive or other rights to subscribe for or purchase additional shares of any class of stock or any other securities of the Company and there are no redemption or sinking fund provisions with regard to the Common Stock. All outstanding shares of Common Stock are fully paid, validly issued, and non-assessable.

The vote of the holders of 66 2/3% of all outstanding shares is required to amend the Articles of Incorporation and to approve mergers, reorganizations and similar transactions.

PREFERRED STOCK

Preferred stock may be issued from time to time in series having such designated preferences and rights, qualifications and limitations as the Board of Directors may determine without any approval of shareholders. Preferred stock could be given voting and conversion rights which would adversely affect the voting power and equity of holders of Common Stock and could have preference to Common Stock with respect to dividend and liquidation rights. The preferred stock could have the effect of acting as an anti-takeover device to prevent a change of control of the Company. None of the preferred stock is outstanding and the Company has no plans at present to issue any such shares.

PROVISIONS AFFECTING BUSINESS COMBINATIONS

Ohio law governs the rights of shareholders of the Company. Chapter 1704 of the Ohio Revised Code may be viewed as having an antitakeover effect. This statute, in general, prohibits an "issuing public corporation" (the definition of which would include the Company) from entering into a "Chapter 1704 Transaction" with the beneficial owner (or affiliates of such beneficial owner) of 10% or more of the outstanding shares of the corporation (an "interested shareholder") for at least three years following the date on which the interested shareholder attains such 10% ownership, unless the board of directors of the corporation approves, prior to such person becoming an interested shareholder, either the transaction or the acquisition of shares resulting in a 10% ownership. A "Chapter 1704 Transaction" is broadly defined to include, among other things, a merger or consolidation with, sale of substantial assets to, or the receipt of a loan, guaranty or other financial benefit (which is not proportionately received by all shareholders) by the interested shareholder. Following the expiration of such three-year period, a Chapter 1704 Transaction with the interested shareholder is permitted only if either (i) the transaction is approved by the holders of at least two-thirds of the voting power of the corporation (or such different proportion as set forth in the corporation's articles of incorporation), including a majority of the outstanding shares, excluding those owned by the interested shareholder, or (ii) the business combination results in the shareholders other than the interested shareholder receiving a prescribed "fair price" for their shares. One significant effect of Chapter 1704 is to cause an interested shareholder to negotiate with the board of directors of a corporation prior to becoming an interested shareholder.

29

In addition, Section 1707.043 of the Ohio Revised Code requires a person or entity that makes a proposal to acquire the control of a corporation to repay to that corporation any profits made from trades in the corporation's stock within 18 months after making the control proposal.

Section 1701.831 of the Ohio Revised Code contains provisions which permit a "control share acquisition" of an "issuing public corporation" only with the prior authorization of a majority of the disinterested shareholders, which could operate as a deterrent to an acquisition of the Company. However, as permitted by this Section, the Company's Articles of Incorporation contain a provision exempting the Company from the operation of this Section. As a result, these provisions of the Ohio Revised Code will not act as a deterrent to an acquisition of the Company or the accumulation of a large amount of the Company's Common Shares. However, the Company's Articles of Incorporation could be amended in the future to make Section 1701.831 applicable to the Company with the vote of two-thirds of the shares eligible to vote on the proposal.

TRANSFER AGENT AND REGISTRAR

The registrar and transfer agent for the Company's Common Stock is The Fifth Third Bank, Cincinnati, Ohio.

30

UNDERWRITING

The several Underwriters named below have severally agreed, subject to the terms and conditions contained in the Underwriting Agreement, to purchase from the Selling Shareholder the aggregate number of shares of Common Stock (assuming the Underwriters' over-allotment option is not exercised) set forth below opposite their respective names.

                                                                             NUMBER
                               UNDERWRITERS                                 OF SHARES
--------------------------------------------------------------------------  ---------
Cleary Gull Reiland & McDevitt Inc........................................
The Ohio Company..........................................................
Roney & Co................................................................
                                                                            ---------
          Total...........................................................  1,500,000
                                                                             ========

The Underwriting Agreement provides that all of the Common Stock being offered, excluding shares covered by the over-allotment option granted to the Underwriters, must be purchased if any are purchased.

The Company has been advised that the several Underwriters propose to offer the Common Stock to the public at the public offering price set forth on the cover page of this Prospectus and may offer to selected dealers at such price less a concession of not more than $ per share; that the Underwriters may allow and such dealers may reallow a concession of $ per share on sales to certain other dealers; and that the public offering price and concessions and reallowances to dealers may be changed by the Underwriters.

The Selling Shareholder has granted the Underwriters an option, exercisable within 30 days after the date of this Prospectus, to purchase up to an additional 225,000 shares of Common Stock to cover over-allotments, at the same price per share being paid by the Underwriters for the other shares offered hereby. If the Underwriters exercise this option in whole or in part, each of the Underwriters will be committed to purchase such additional shares in approximately the same proportion as set forth in the above table. The Underwriters may purchase such shares only to cover over-allotments, if any, made in connection with the Offering made hereby.

The Company and its present executive officers and directors and the Selling Shareholder have agreed with the Underwriters that they will not offer or sell any shares of Common Stock for 90 days and 360 days, respectively, from the effective date of the Registration Statement without the prior written consent of Cleary Gull Reiland & McDevitt Inc.

The Underwriting Agreement provides that the Company and the Selling Shareholder will indemnify the several Underwriters against certain liabilities, including civil liabilities under the Securities Act, or will contribute to payments the Underwriters may be required to make in respect thereof.

In connection with this offering, the Underwriters and selling group members (if any) may engage in passive market making transactions in the Common Stock on the Nasdaq National Market immediately prior to the commencement of sales in this offering, in accordance with Rule 10b-6A under the Exchange Act. Passive market making consists of displaying bids on the Nasdaq National Market limited by the bid prices of independent market makers and purchases limited by such prices and effected in response to order flow. Net purchases by a passive market maker on each day are limited to a specific percentage of the passive market maker's average daily trading volume in the Common Stock during a specified prior period and must be discontinued when such limit is reached. Passive market making may stabilize the market price of the Common Stock at a level above that which might otherwise prevail and, if commenced, may be discontinued at any time.

LEGAL MATTERS

Certain legal matters in connection with the Common Stock offered hereby will be passed upon for the Company by Keating, Muething & Klekamp, Cincinnati, Ohio. Gary P. Kreider, a partner in Keating, Muething & Klekamp, serves as a director of the Company. Members of that firm beneficially own 34,357 shares of Common Stock. Certain legal matters in connection with the Offering will be passed upon for the Underwriters by Foley & Lardner, Milwaukee, Wisconsin.

31

EXPERTS

The audited financial statements and schedules included or incorporated by reference in this Prospectus have been audited by Arthur Andersen LLP, independent public accountants, as indicated in their reports with respect thereto, and are included herein in reliance upon the authority of said firm as experts in giving said reports.

32

GLOSSARY OF SELECTED TERMS

The following glossary defines terms used to describe the Company's business.

ANTIBODY. Highly specific proteins that bind with and counteract antigens. Immunoassays make use of the specific binding properties of antibodies with antigens in diagnostic tests.

ANTIGEN. A foreign substance, generally produced by a bacterium, virus or fungus which immunoassays measure, that induces the formation of antibodies.

ASPERGILLUS. A fungus which is an opportunistic pathogen and may produce a severe and persistent infection.

ASSAY. Any test procedure used to detect or measure a specific substance in body fluids.

BLASTOMYCES. A fungus which causes infection due to inhalation through the pulmonary route. Infection is marked by tumors in the skin or by lesions in the lungs, bones, tissues, liver, spleen and kidneys.

C. DIFFICILE. A bacteria (Clostridium difficile) which causes a series diarrheal disease affecting the digestive system. Toxigenic strains of C. difficile produce two toxins having pathogenic effects in humans. Toxin A causes enteric fluid accumulation, diarrhea and intestinal hemorrhaging. It has been hypothesized that, once the colon is damaged by toxin A, toxin B can enter the circulatory system and cause widespread tissue deterioration.

COCCIDIOIDES. A fungus which causes infection due to the inhalation of spores. The primary form of the disease is an acute respiratory infection. It is primarily endemic in arid areas such as southern Arizona and Southern California and is commonly known as "Valley Fever".

CRYPTOCOCCUS. An opportunistic yeastlike organism which infects humans, causing an infection involving the skin, lungs, brain and spinal column, commonly associated with immunocompromised patients, such as those suffering from AIDS and cancer.

CRYPTOSPORIDIUM. A severe parasitic infection of the gastrointestinal tract causing severe diarrhea, abdominal pain and electrolyte imbalance.

CYTOMEGALOVIRUS. One of a group of herpes viruses that infect humans. This virus can cause a variety of symptoms, but the majority of infections are very mild or subclinical.

ENZYME. Protein which accelerates reactions between substances; used to produce a color in enzyme immunoassays.

ENZYME IMMUNOASSAY ("EIA"). Immunoassay using an enzyme conjugated to the antigen or a specific antibody which is used to detect its homologous antibody or antigen.

FUNGAL SEROLOGY. Diagnosis of fungus-related systemic and respiratory infections.

GIARDIA. The most common single-celled parasite which is spread via contaminated food and water and direct person-to-person contact. Representing the most common parasitic disease, it infects the small intestine, producing diarrhea, gastrointestinal discomfort, electrolyte imbalance, nausea and weight loss.

H. PYLORI. Helicobacter pylori is the most common and important cause of gastritis and has been linked to the cause of chronic recurrent duodenal ulcers. Treatments that eradicate H. pylori have produced dramatic reductions in ulcer recurrence.

HERPES SIMPLEX VIRUS. A herpes virus which is characterized by the formation of clusters of small vesicles and causes an inflammatory skin disease.

HISTOPLASMA. A fungus which causes infection due to the inhalation or ingestion of spores. The infection is usually asymptomatic, but may cause acute pneumonia.

IMMUNOASSAY. Procedure using antigens and antibodies to detect and measure minute concentrations of biological materials; includes radioimmunoassay and nonisotopic assays, which do not use radioactive materials, such as enzyme immunoassay.

IMMUNODIAGNOSTIC. Diagnosis based on blood serum reactions to antigens.

33

IMMUNODIFFUSION. A technique of study of antigen-antibody reactions by observing precipitates formed by the combination of specific antigens and antibodies which have diffused in a gel in which they had been separately placed.

IMMUNOFLUORESCENCE. The use of fluorescence-labeled antibodies to identify bacterial, viral or other antigenic material specific to the labeled antibody.

IN VITRO. Outside the living body, for example, in a test tube.

MONONUCLEOSIS. A common, acute, self-limited disease caused by the Epstein-Barr virus.

MONOCLONAL ANTIBODY. An antibody produced from a single clone of a plasma cell against a single antigenic epitope.

PARASITOLOGY. The study of the diseased condition resulting from parasitic infection.

PARTICLE AGGLUTINATION. A test format in which antigens or antibodies bind to solid particles enabling visualization of test result.

PATHOGEN. An agent that causes disease such as a bacterium, virus or fungi.

PNEUMOCYSTIS. A microorganism which is the causative agent of a highly contagious, epidemic pneumonia.

POLYCLONAL ANTIBODY. Antibodies produced from a series of plasma cells against a variety of antigenic epitopes.

REAGENTS. Biological chemicals required to perform immunoassays; includes antibodies and antigens.

STREP A. A classification of streptococci based upon cell-wall carbohydrate antigens. Streptococci Group A are bacteria which cause conditions such as septic sore throat, scarlet fever, and rheumatic fever.

34

MERIDIAN DIAGNOSTICS, INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

                                                                                      PAGE
                                                                                    --------
Report of Independent Public Accountants............................................    F-2
Consolidated Balance Sheets as of September 30, 1995 and 1994.......................    F-3
Consolidated Statements of Earnings for the Years Ended September 30, 1995, 1994 and
  1993..............................................................................    F-4
Consolidated Statements of Shareholders' Equity for the Years Ended September 30,
  1995, 1994 and 1993...............................................................    F-5
Consolidated Statements of Cash Flows for the Years Ended September 30, 1995, 1994
  and 1993..........................................................................    F-6
Notes to Consolidated Financial Statements..........................................    F-7
Consolidated Balance Sheets as of March 31, 1996 (unaudited) and September 30,
  1995..............................................................................   F-16
Consolidated Statements of Earnings for the Six Months Ended March 31, 1996 and 1995
  (unaudited).......................................................................   F-18
Consolidated Statements of Shareholders' Equity for the Six Months Ended March 31,
  1996 (unaudited)..................................................................   F-19
Consolidated Statements of Cash Flows for the Six Months Ended March 31, 1996 and
  1995 (unaudited)..................................................................   F-20
Notes to Consolidated Financial Statements (unaudited)..............................   F-21

F-1

REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS

To Meridian Diagnostics, Inc.:

We have audited the accompanying consolidated balance sheets of MERIDIAN DIAGNOSTICS, INC. and subsidiaries as of September 30, 1995 and 1994, and the related consolidated statements of earnings, shareholders' equity, and cash flows for each of the three years in the period ended September 30, 1995. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Meridian Diagnostics, Inc. and subsidiaries as of September 30, 1995 and 1994, and the results of their operations and their cash flows for each of the three years in the period ended September 30, 1995, in conformity with generally accepted accounting principles.

ARTHUR ANDERSEN LLP

Cincinnati, Ohio,
November 10, 1995

F-2

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

                                                                                  AS OF SEPTEMBER 30,
                                                                              ---------------------------
                                                                                 1995            1994
                                                                              -----------     -----------
ASSETS
Current Assets:
  Cash and short-term investments (Note 2)..................................  $ 8,918,637     $ 8,831,983
  Accounts receivable, less allowance of $164,136 in 1995 and $113,183 in
    1994 for doubtful accounts..............................................    6,482,999       5,169,989
  Inventories (Note 3)......................................................    3,032,655       3,020,071
  Prepaid expenses and other................................................      321,775         108,423
  Deferred tax assets.......................................................      324,910         282,929
                                                                                  -------         -------
         Total current assets...............................................   19,080,976      17,413,395
                                                                                  -------         -------
Property, Plant and Equipment:
  Land......................................................................      269,217         273,688
  Buildings and improvements................................................    6,162,668       3,716,649
  Machinery, equipment and furniture........................................    5,525,455       4,595,550
  Construction in progress..................................................           --       1,063,702
                                                                                  -------         -------
                                                                               11,957,340       9,649,589
  Less -- accumulated depreciation and amortization.........................    4,816,905       4,248,561
                                                                                  -------         -------
         Net property, plant and equipment..................................    7,140,435       5,401,028
                                                                                  -------         -------
Other Assets (Notes 1 and 4):
  Long-term receivable......................................................       12,670              --
  Deferred tax assets.......................................................       87,879          59,841
  Deferred debenture offering costs, net of accumulated amortization of
    $133,357 in 1995 and $96,876 in 1994....................................      395,731         665,595
  Covenants not to compete, net of accumulated amortization of $1,827,718 in
    1995 and $1,337,375 in 1994.............................................    2,432,876       2,923,219
  License agreements, net of accumulated amortization of $772,433 in 1995
    and $714,878 in 1994....................................................      362,680         420,235
  Patent, tradenames and distributorships, net of accumulated amortization
    of $475,762 in 1995 and $267,365 in 1994................................    1,837,238       2,045,635
  Other intangible assets, net of accumulated amortization of $85,570 in
    1995 and $43,503 in 1994................................................      620,192         685,218
  Cost in excess of net assets acquired, net of accumulated amortization of
    $458,482 in 1995 and $255,753 in 1994...................................    2,598,511       2,714,964
                                                                                  -------         -------
         Total other assets.................................................    8,347,777       9,514,707
                                                                                  -------         -------
         Total assets.......................................................  $34,569,188     $32,329,130
                                                                                  =======         =======
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
  Current portion of long-term obligations (Note 5).........................  $   381,932     $   367,969
  Current portion of capital lease obligations (Note 5).....................       63,561              --
  Accounts payable..........................................................      689,869       1,843,489
  Accrued payroll and payroll taxes.........................................      723,946         650,530
  Other accrued expenses....................................................      937,348         649,732
  Income taxes payable......................................................      458,707         902,069
                                                                                  -------         -------
         Total current liabilities..........................................    3,255,363       4,413,789
                                                                                  -------         -------
Long-Term Obligations (Note 5)..............................................   12,285,668      14,683,369
                                                                                  -------         -------
Capital Lease Obligations (Note 5)..........................................      149,925              --
                                                                                  -------         -------
Shareholders' Equity (Note 7):
  Preferred stock, no par value, 1,000,000 shares authorized; none issued...           --              --
  Common stock, no par value, 25,000,000 shares authorized; 12,924,814 and
    12,292,935 shares issued and outstanding, respectively, stated at.......    1,487,159       1,179,583
  Additional paid-in capital................................................   13,895,901      10,824,012
  Retained earnings.........................................................    3,747,930       1,448,736
  Cumulative foreign currency translation adjustment........................     (252,758)       (220,359)
                                                                                  -------         -------
         Total shareholders' equity.........................................   18,878,232      13,231,972
                                                                                  -------         -------
         Total liabilities and shareholders' equity.........................  $34,569,188     $32,329,130
                                                                                  =======         =======

The accompanying notes to consolidated financial statements are an integral part of these balance sheets.

F-3

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EARNINGS

                                                           FOR THE YEARS ENDED SEPTEMBER 30,
                                                      -------------------------------------------
                                                         1995            1994            1993
                                                      -----------     -----------     -----------
Net Sales...........................................  $25,109,711     $21,876,773     $16,170,990
Cost of Sales.......................................    8,008,529       7,518,179       5,097,988
                                                      -----------     -----------     -----------
          Gross profit..............................   17,101,182      14,358,594      11,073,002
                                                      -----------     -----------     -----------
Operating Expenses:
  Research and development..........................    1,432,315       1,432,928       1,165,210
  Selling and marketing.............................    5,228,717       4,747,398       3,715,517
  General and administrative........................    3,864,294       3,364,584       2,667,172
                                                      -----------     -----------     -----------
          Total operating expenses..................   10,525,326       9,544,910       7,547,899
                                                      -----------     -----------     -----------
          Operating income..........................    6,575,856       4,813,684       3,525,103
Other Income (Expense):
  Licensing and related fees........................      102,698              --          55,000
  Interest income...................................      435,686         253,644          56,551
  Interest expense..................................   (1,134,844)     (1,092,345)       (178,950)
  Cost of withdrawn stock offering..................           --              --        (404,499)
  Other, net........................................      (19,470)          8,420          48,153
                                                      -----------     -----------     -----------
          Total other income (expense)..............     (615,930)       (830,281)       (423,745)
                                                      -----------     -----------     -----------
          Earnings before income taxes..............    5,959,926       3,983,403       3,101,358
Income Taxes (Note 6)...............................    2,435,815       1,542,282       1,211,904
                                                      -----------     -----------     -----------
          Net earnings..............................  $ 3,524,111     $ 2,441,121     $ 1,889,454
                                                      ===========     ===========     ===========
Primary Weighted Average Number of Common Shares
  Outstanding.......................................   12,354,752      12,277,392      12,263,791
                                                      ===========     ===========     ===========
Primary Earnings Per Common Share...................  $       .29     $       .20     $       .15
                                                      ===========     ===========     ===========
Fully Diluted Weighted Average Number of Common
  Shares Outstanding................................   14,541,603              NA              NA
                                                      ===========     ===========     ===========
Fully Diluted Earnings Per Common Share.............  $       .28              NA              NA
                                                      ===========     ===========     ===========

The accompanying notes to consolidated financial statements are an integral part of these statements.

F-4

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

                                   NUMBER OF                                             CUMULATIVE
                                    COMMON                                                FOREIGN
                                    SHARES                   ADDITIONAL                  CURRENCY
                                  ISSUED AND      COMMON       PAID-IN      RETAINED     TRANSLATION
                                  OUTSTANDING     STOCK        CAPITAL      EARNINGS     ADJUSTMENT     TOTAL
                                  -----------   ----------   -----------   -----------   ---------   -----------
Balance at September 30, 1992...    7,705,453   $  851,975   $ 7,563,763   $ 2,258,187   $   2,560   $10,676,485
Net earnings....................           --           --            --     1,889,454          --     1,889,454
Cash dividends paid -- $.06 per
  share as adjusted.............           --           --            --      (702,325)         --      (702,325)
Exercise of stock options.......        1,249          900         4,839            --          --         5,739
3% stock dividend...............      231,201      154,142     1,811,067    (1,965,209)         --            --
Foreign currency translation
  adjustment....................           --           --            --            --    (252,341)     (252,341)
                                  -----------   ----------   -----------    ----------   ---------   -----------
Balance at September 30, 1993...    7,937,903    1,007,017     9,379,669     1,480,107    (249,781)   11,617,012
Net earnings....................           --           --            --     2,441,121          --     2,441,121
Cash dividends paid -- $.08 per
  share as adjusted.............           --           --            --      (908,209)         --      (908,209)
Exercise of stock options.......       18,689       12,638        39,988            --          --        52,626
3% stock dividend...............      238,698      159,928     1,404,355    (1,564,283)         --            --
Foreign currency translation
  adjustment....................           --           --            --            --      29,422        29,422
                                  -----------   ----------   -----------    ----------   ---------   -----------
Balance at September 30, 1994...    8,195,290    1,179,583    10,824,012     1,448,736    (220,359)   13,231,972
Net earnings....................           --           --            --     3,524,111          --     3,524,111
Fractional shares...............         (570)        (293)       (3,049)           --          --        (3,342)
Cash dividends paid -- $.10 per
  share as adjusted.............           --           --            --    (1,224,917)         --    (1,224,917)
Exercise of stock options.......       42,849       14,961        34,131            --          --        49,092
3 for 2 stock split.............    4,097,645           --            --            --          --            --
Debenture Conversions (Note
  5)............................      589,600      292,908     3,040,807            --          --     3,333,715
Foreign currency translation
  adjustment....................           --           --            --            --     (32,399)      (32,399)
                                  -----------   ----------   -----------    ----------   ---------   -----------
Balance at September 30, 1995...   12,924,814   $1,487,159   $13,895,901   $ 3,747,930   $(252,758)  $18,878,232
                                  ===========   ==========   ===========    ==========   =========   ===========

The accompanying notes to consolidated financial statements are an integral part of these statements.

F-5

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

                                                                    FOR THE YEARS ENDED SEPTEMBER 30,
                                                               -------------------------------------------
                                                                  1995            1994            1993
                                                               -----------     -----------     -----------
Cash Flows from Operating Activities:
  Net earnings...............................................  $ 3,524,111     $ 2,441,121     $ 1,889,454
  Non-cash items --
     Depreciation and amortization of property, plant and
       equipment.............................................      863,436         703,190         580,979
     Amortization of intangible assets.......................    1,147,987       1,009,950         471,045
     Deferred interest expense...............................      154,950          94,978              --
     Revenues received in advance recorded in income.........           --              --         (55,000)
     Deferred income taxes...................................      (70,019)       (263,977)         28,079
  Changes in current assets excluding cash and short-term
     investments.............................................   (1,611,612)     (1,865,471)     (1,328,516)
  Changes in current liabilities excluding current portion of
     long-term obligations...................................   (1,150,277)      2,305,066         516,355
  Long-term receivable and payable...........................       (2,470)             --              --
                                                               -----------     -----------     -----------
          Net cash provided by operating activities..........    2,856,106       4,424,857       2,102,396
                                                               -----------     -----------     -----------
Cash Flows from Investing Activities:
  Property, plant, and equipment acquired, net...............   (2,472,177)     (1,426,485)       (718,135)
  Product line acquisition --
     Inventory and equipment.................................           --        (571,446)       (262,972)
     Covenants not to compete................................           --      (1,100,000)     (1,500,000)
     Patent, tradenames, customer lists and other............           --      (1,375,000)     (1,394,000)
     Cost in excess of net assets acquired...................           --        (346,434)       (297,722)
  Proceeds from sale of product line.........................           --         500,000              --
  Acquisition of license agreements..........................           --         (55,898)        (80,000)
  Advance royalties paid.....................................           --         (25,000)             --
                                                               -----------     -----------     -----------
          Net cash used for investing activities.............   (2,472,177)     (4,400,263)     (4,252,829)
                                                               -----------     -----------     -----------
Cash Flows from Financing Activities:
  Proceeds from subordinated debentures, net of offering
     costs...................................................           --              --      10,737,530
  Proceeds from other long-term obligations..................    1,284,005         634,970              --
  Repayment of long-term obligations.........................     (388,246)       (462,339)       (219,145)
  Dividends paid.............................................   (1,224,917)       (908,209)       (702,325)
  Proceeds from issuance of common stock.....................       45,750          52,626           5,739
  Effect of exchange rate changes on cash....................      (13,867)         14,749          (6,229)
                                                               -----------     -----------     -----------
          Net cash provided by (used for) financing
            activities.......................................     (297,275)       (668,203)      9,815,570
                                                               -----------     -----------     -----------
Net Increase (Decrease) in Cash and Short-Term Investments...       86,654        (643,609)      7,665,137
Cash and Short-Term Investments at Beginning of Period.......    8,831,983       9,475,592       1,810,455
                                                               -----------     -----------     -----------
Cash and Short-Term Investments at End of Period.............  $ 8,918,637     $ 8,831,983     $ 9,475,592
                                                               ===========     ===========     ===========
Supplemental Disclosure of Cash Flow Information:
  Cash paid during the year for --
     Income taxes............................................  $ 2,882,336     $ 1,034,000     $ 1,195,000
     Interest................................................      883,356         852,265         160,062
  Capitalized lease obligations..............................      259,240              --              --
  Estimated contingent consideration related to product line
     acquisitions (Note 5)...................................           --       1,972,000              --
  Conversion of debentures to common stock, net of
     amortization of deferred debenture offering costs of
     $186,285 (Note 5).......................................    3,333,715              --              --

The accompanying notes to consolidated financial statements are an integral part of these statements.

F-6

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) PRINCIPLES OF CONSOLIDATION -- The consolidated financial statements include the accounts of Meridian Diagnostics, Inc. and its subsidiaries, Omega Technologies, Inc., Meridian Diagnostics Europe s.r.1. ("MDE") and Meridian Diagnostics International, Inc. (collectively, "Meridian" or the "Company"). All significant intercompany accounts and transactions have been eliminated in consolidation.

(b) SHORT-TERM INVESTMENTS -- The Company adopted Statement of Accounting Standards No. 115, "Accounting for Certain Investments in Debt and Equity Securities" (FAS 115), in 1995. In accordance with FAS 115, prior years' financial statements have not been restated to reflect the change in accounting method. There was no cumulative effect as a result of adopting FAS 115 in 1995.

Debt securities for which the Company does not have the intent or ability to hold to maturity are classified as available for sale, along with any equity securities. At September 30, 1995, the Company's investments in debt and equity securities were classified as cash and short-term investments due to their short-term nature. These investments are diversified among high credit quality securities. The estimated fair value of cash investments approximates cost, and therefore, there are no unrealized gains or losses as of September 30, 1995.

(c) INVENTORIES -- Inventories are stated at the lower of cost, determined on a first-in, first-out basis, or market.

(d) PROPERTY, PLANT AND EQUIPMENT -- Property, plant and equipment are stated at cost. Upon retirement or other disposition of property, plant and equipment, the cost and related accumulated depreciation and amortization are removed from the accounts and the resulting gain or loss is reflected in earnings. Maintenance and repairs are expensed as incurred. Depreciation and amortization are computed on the straight-line method in amounts sufficient to writeoff the cost over the estimated useful lives as follows:

Buildings and improvements -- 5 to 33 years

Machinery, equipment and furniture -- 3 to 10 years

(e) OTHER ASSETS -- Other assets are stated at cost less accumulated amortization and are being amortized on a straight line basis over their estimated useful lives:

Covenants not to compete -- 7 to 10 years

License agreements -- 3 to 10 years

Patents, tradenames and distributorships -- 10 to 15 years

Cost in excess of net assets acquired and other intangible assets -- 15 years

Deferred debenture offering costs -- 8 years

Subsequent to their acquisition, the Company continually evaluates whether subsequent events and circumstances have occurred that indicate the remaining estimated useful lives of intangible assets may warrant revision or that the remaining balances of these assets may not be recoverable. When factors indicate that an intangible asset should be evaluated for possible impairment, the Company uses an estimate of the related product line's cash flow over the remaining life of the asset in measuring whether the asset is recoverable.

(f) INCOME TAXES -- The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between income for financial reporting and income for tax purposes. Research and experimentation credits are reflected as a reduction in income taxes when realized.

F-7

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

Effective October 1, 1993, the Company adopted Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes". Prior period financial statements have not been restated to reflect the new accounting method. The cumulative effect of this change, as well as the effect of this new standard on income tax expense for the year ended September 30, 1994, and for each of the quarters in the period then ended, is not material.

(g) EARNINGS PER COMMON SHARE -- Primary earnings per common share are based on the weighted average number of common shares outstanding during the year. No material dilution results from outstanding stock options which are the only common stock equivalent. Fully diluted earnings per share are dilutive for fiscal 1995 only and include the impact of assuming the convertible subordinated debentures are converted, net of the impact of pro forma interest expense.

On September 12, 1995, the Company's Board of Directors declared a three-for-two stock split to shareholders of record on September 22, 1995. On November 16, 1994, the Company's Board of Directors declared a 3% stock dividend. On December 1, 1993, the Company's Board of Directors declared a 3% stock dividend. On November 23, 1992, the Company's Board of Directors declared a 5% stock dividend, and in March 1992, the Company's Board of Directors declared a three-for-two stock split. All data with respect to earnings per share, dividends per share and weighted average number of shares outstanding has been retroactively adjusted to reflect the stock splits and stock dividends.

(h) RESEARCH AND DEVELOPMENT COSTS -- Research and development costs are charged to earnings as incurred.

(i) REVENUE RECOGNITION -- Revenue is recognized from sales when a product is shipped. Income from licensing agreements is recognized as earned and as stipulated by the respective agreements.

(j) TRANSLATION OF FOREIGN CURRENCY -- Assets and liabilities of foreign operations are translated using year-end exchange rates and revenues and expenses are translated using exchange rates prevailing during the year, with gains or losses resulting from translation included in a separate component of shareholders' equity. Gains and losses resulting from transactions in foreign currencies were immaterial.

(k) SEGMENT DATA AND MAJOR CUSTOMERS -- The Company was formed in June 1976 and functions as a research, development, manufacturing, marketing and sales organization with primary emphasis in the field of diagnostic tests for infectious diseases. The Company grants credit under normal terms to its customers, primarily to hospitals, commercial laboratories and distributors in the United States and Europe.

A summary of the Company's international operations is as follows:

                                                    1995           1994           1993
                                                 ----------     ----------     ----------
Net sales......................................  $5,811,000     $4,609,000     $2,930,000
Operating profit...............................   1,233,000        801,000        462,000
Pre-tax income.................................     979,000        579,000        446,000
Identifiable assets............................   4,583,000      3,904,000      2,657,000
Accounts receivable............................   2,538,000      2,052,000      1,313,000

Consolidated sales in thousands of dollars to individual customers constituting 10% or more of net sales were as follows:

                                                    YEARS ENDED SEPTEMBER 30,
                                        -------------------------------------------------
                                            1995              1994              1993
                                        -------------     -------------     -------------
Customer A............................  $6,033   (24%)    $5,042   (23%)    $4,254   (26%)
Customer B............................   2,569   (10%)     2,073    (9%)     1,823   (11%)

F-8

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

(2) CASH AND SHORT-TERM INVESTMENTS

Cash and short-term investments (with maturities of less than 4 months) are comprised of the following:

                                                                    SEPTEMBER 30,
                                                              -------------------------
                                                                 1995           1994
                                                              ----------     ----------
Cash and money market funds.................................  $1,562,795     $2,865,966
Commercial paper............................................   3,655,842      3,996,017
Corporate and municipal put bonds...........................   3,700,000      1,970,000
                                                              ----------     ----------
                                                              $8,918,637     $8,831,983
                                                              ==========     ==========

At September 30, 1995 and 1994, the market value of the Company's investments approximated cost. The municipal put bonds are putable every seven days and the principal balance is secured by a bank letter of credit.

(3) INVENTORIES

Inventories are comprised of the following:

                                                                    SEPTEMBER 30,
                                                              -------------------------
                                                                 1995           1994
                                                              ----------     ----------
Raw materials...............................................  $1,165,319     $1,354,412
Work-in-process.............................................     626,077        649,205
Finished goods..............................................   1,241,259      1,016,454
                                                              ----------     ----------
                                                              $3,032,655     $3,020,071
                                                              ==========     ==========

(4) PRODUCT AND LICENSE AGREEMENT ACQUISITIONS

(a) PRODUCT LINES -- In January 1994, the Company acquired a product line from an affiliate of Ortho Diagnostic Systems, Inc. ("ODSI"), a subsidiary of Johnson & Johnson, comprised of products used primarily for the detection of certain infectious diseases including Chlamydia, Herpes and various viral respiratory infections. The Company also acquired inventory, equipment, certain license rights, a trademark, customer lists, a noncompetition agreement and technical information for the manufacture of the products.

The purchase included $3,300,000 in cash paid to ODSI and $82,000 of expenses. As additional consideration, Meridian will pay ODSI up to 6% of product sales made during the nine-year period beginning in January 1995. The Company has recorded the estimated present value of this additional consideration (Note 5).

In a separate agreement dated March 14, 1994, the Company sold to VAI Diagnostics, Inc. certain tissue culture products and assets acquired in January 1994 from the affiliate of ODSI mentioned above. The $650,000 proceeds consisted of cash of $500,000, which was paid upon execution of the agreement, and $150,000 in an unsecured promissory note due in mid-1997. No gain or loss was recognized on this transaction.

Also, in June 1993, the Company acquired a product line from ODSI which consisted of the branded products MONOSPOT and MONOLERT, which are rapid tests for infectious mononucleosis. The acquisition included certain patent and trademark rights, customer lists, inventory, technical information for the manufacture of the products, certain equipment and a noncompetition agreement.

The purchase included $3,100,000 in cash paid to ODSI at the acquisition date, inventory purchased at unit prices specified in the agreement which aggregated approximately $233,000 and $122,000 of expenses. As

F-9

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

additional consideration, Meridian will pay ODSI 6% of product sales made during the three-year period beginning July 1, 1996. The Company has recorded the estimated present value of this additional consideration (Note 5). The Company also assumed ODSI's royalty obligations (equal to 4.25% of MONOLERT sales) to The Scripps Research Institute ("Scripps"). The obligation to pay royalties to Scripps expires in 2009.

(b) LICENSE AGREEMENTS -- The Company has entered various license agreements as follows:

DATE ACQUIRED        LICENSOR/PRODUCT                   TERM                        COST
- --------------    -----------------------    --------------------------    -----------------------
October 1993      New England Medical        fifteen years                 $81,000 of which
                  Center Hospital/E. coli                                  $25,000 to be offset
                  Test                                                     against future
                                                                           royalties
January 1993      Tacoma Trading             ten years                     $80,000
                  Company/parasitology
                  concentration and
                  transport system
July 1991         Texas BioResource          five years, option to         $100,000 to be offset
                  Corp./bacterial urinary    extend for two additional     against future
                  tract infection test       five-year terms               royalties, option to
                                                                           purchase 25,062 shares
                                                                           of common stock which
                                                                           vests at the end of the
                                                                           agreement
April 1991        Disease Detection          ten years, option to          $442,000
                  International,             extend for two additional
                  Inc./rapid tests for       ten-year terms
                  the detection of strep
                  throat, pregnancy,
                  Toxoplasma, Rubella,
                  Cytomegalovirus and
                  Herpes

F-10

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

(5) LONG-TERM OBLIGATIONS, BANK CREDIT ARRANGEMENTS AND COMMITMENTS

(a) LONG-TERM OBLIGATIONS -- Long-term obligations is comprised of the following at:

                                                                   SEPTEMBER 30,
                                                            ---------------------------
                                                               1995            1994
                                                            -----------     -----------
Convertible Subordinated Debentures, unsecured, 7 1/4%
  annual interest payable semi-annually on March 1 and
  September 1, principal due September 1, 2001............  $ 7,980,000     $11,500,000
Domestic bank notes payable, secured by real estate and
  accounts receivable:
  Interest at 5.5%, payable in monthly installments of
     $16,276 with a balloon payment of $32,552 in March
     1996.................................................      113,932         292,969
  Interest at prime + 1/2% (9.25% at September 30, 1995),
     payable in monthly installments of $6,250 with a
     balloon payment of $375,000 in March 1997............      481,250         556,250
Construction loan, interest at 7% to be converted to a 7%,
  twenty-year amortization mortgage note, payable in
  monthly installments of $14,878 beginning August 1996
  and a balloon payment of $1,478,357 due July 2003.......    1,918,975         634,970
Estimated contingent consideration payable to ODSI,
  discounted at 7.25%, payable in quarterly variable
  installments, based on a percent of certain product
  sales, from 1995 to 2004 (Note 4).......................    2,163,244       2,067,149
Other.....................................................       10,199              --
                                                            -----------     -----------
                                                             12,667,600      15,051,338
Less -- Current portion...................................      381,932         367,969
                                                            -----------     -----------
                                                            $12,285,668     $14,683,369
                                                            ===========     ===========

The Convertible Debentures were called for redemption on October 10, 1995. Holders of the Debentures have the option of converting their Debentures into shares of Meridian Diagnostics' common stock prior to the redemption date of November 30, 1995, at a conversion price of $5.97 per share or, upon delivery of the Debentures, receiving cash. The Debentures will be redeemed at 105% of their face amount plus accrued interest. The conversion price of $5.97 per share is equivalent to a conversion rate of 167.5 shares per each $1,000 principal amount of Debentures. Through September 30, 1995, $3,520,000 of Debentures were converted to common stock net of $186,000 of deferred debenture offering costs, which were charged to additional paid-in capital. As of November 10, 1995, $1,074,000 of Debentures were outstanding.

On a pro forma basis, assuming full conversion of the Debentures as of October 1, 1994, primary earnings per share for the year ended September 30, 1995 would have been reduced by $0.01 per share from $0.29 per share to $0.28 per share.

The domestic bank notes payable are part of a bank credit arrangement which also includes a $6,000,000 line of credit which calls for interest at the prime rate and is part of the same security agreement. There were no borrowings outstanding on the line of credit at September 30, 1995. In connection with the bank credit arrangement, the Company has agreed, among other things, to meet certain financial ratio requirements and to limit additional indebtedness.

F-11

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

Maturities on the above long-term obligations are as follows:

1996............................................................  $   381,932
1997............................................................      771,672
1998............................................................      379,451
1999............................................................      372,479
2000............................................................      285,985
Thereafter......................................................   10,476,081
                                                                  -----------
                                                                  $12,667,600
                                                                  ===========

(b) CAPITAL LEASE OBLIGATIONS -- The Company leases equipment with cost and related accumulated depreciation of $259,240 and $56,953, respectively, under capital leases expiring in various years through 2002. Amortization of assets under capital leases is included in depreciation expense.

The future minimum annual rentals under the capital leases at September 30, 1995 are as follows:

1996............................................................    $ 73,623
1997............................................................      75,325
1998............................................................      22,851
1999............................................................      22,851
2000............................................................      21,791
Thereafter......................................................      34,148
                                                                    --------
Subtotal........................................................    $250,589
Less portion of payments representing interest..................     (37,103)
                                                                    --------
Present value of lease payments.................................    $213,486
                                                                    ========

(c) COMMITMENTS -- The Company has royalty agreements with various parties which require the Company to pay a specified percentage of the sales of certain products (1% to 10%). Royalty expenses for the years ended September 30, 1995, 1994 and 1993 were approximately $408,000, $357,000 and $280,000 respectively.

F-12

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

(6) INCOME TAXES

The provision for income taxes includes the following components:

                                                        YEARS ENDED SEPTEMBER 30,
                                                 ----------------------------------------
                                                    1995           1994           1993
                                                 ----------     ----------     ----------
Federal:
  Currently payable............................  $1,866,090     $1,337,356     $  884,296
  Temporary differences --
     Revenue received in advance...............          --             --         18,700
     Tax depreciation greater (less) than book
       depreciation............................     (26,842)        (6,800)        (6,561)
     State franchise taxes.....................     (14,335)       (26,520)         2,959
     Currently nondeductible expenses..........     (13,720)       (42,745)         8,809
     Intangible asset amortization.............    (155,693)      (134,627)            --
     Other, net................................     117,224         (5,100)           598
                                                 ----------     ----------     ----------
                                                  1,772,724      1,121,564        908,801
State and local................................     240,662        201,000        104,116
Foreign........................................     422,429        219,718        198,987
                                                 ----------     ----------     ----------
          Total provision for income taxes.....  $2,435,815     $1,542,282     $1,211,904
                                                 ==========     ==========     ==========

The following is a reconciliation between the statutory federal income tax rate and the effective rate derived by dividing the provision for income taxes by earnings before income taxes:

                                                  YEARS ENDED SEPTEMBER 30,
                                -------------------------------------------------------------
                                      1995                  1994                  1993
                                -----------------     -----------------     -----------------
                                  AMOUNT     RATE       AMOUNT     RATE       AMOUNT     RATE
                                ----------   ----     ----------   ----     ----------   ----
Computed provision for income
  taxes at statutory rate.....  $2,026,375   34.0%    $1,354,357   34.0%    $1,054,462   34.0%
Increase/(decrease) in taxes
  resulting from --
  State and local income
     taxes, net of federal
     income tax effect........     158,837    2.7        132,660    3.3         68,684    2.2
  Foreign taxes...............     154,399    2.6         64,703    1.6         69,453    2.2
  Research and experimentation
     tax credits..............          --     --             --     --         (4,000)   (.1)
  Amortization of cost in
     excess of net assets
     acquired.................       8,033     .1          8,033     .2          8,033     .3
  Tax exempt income...........     (38,003)   (.6)       (14,022)   (.4)        (2,608)   (.1)
  Foreign Sales Corporation
     benefit..................     (34,250)   (.6)       (18,333)   (.4)        (2,000)   (.1)
  Officers Life Insurance.....      22,384     .4             --     --             --     --
  Other, net..................     138,040    2.3         14,884     .4         19,880     .7
                                ----------   ----     ----------   ----     ----------   ----
          Actual provision for
            income taxes......  $2,435,815   40.9%    $1,542,282   38.7%    $1,211,904   39.1%
                                ==========   ====     ==========   ====     ==========   ====

F-13

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

The components of the net deferred tax assets were as follows at:

                                                                    SEPTEMBER 30,
                                                               -----------------------
                                                                 1995          1994
                                                               ---------     ---------
Deferred tax assets:
  State income taxes.........................................  $  67,966     $  60,573
  Currently nondeductible expenses...........................    126,663       104,073
  Intangible asset amortization..............................    321,843       173,686
  Other......................................................    135,455       118,283
                                                               ---------     ---------
          Total..............................................  $ 651,927     $ 456,615
                                                               ---------     ---------
Deferred tax liabilities:
  Depreciation...............................................    (27,295)     (113,845)
  Other......................................................   (211,843)           --
                                                               ---------     ---------
          Total..............................................  $(239,138)    $(113,845)
                                                               ---------     ---------
          Net deferred tax assets............................  $ 412,789     $ 342,770
                                                               =========     =========

No valuation allowances are recorded against deferred tax assets or deferred tax liabilities at September 30, 1995 or 1994.

(7) EMPLOYEE BENEFITS

(a) SAVINGS AND INVESTMENT PLAN -- The Company has a profit sharing and retirement savings plan covering substantially all full-time employees. Profit sharing contributions to the plan, which are discretionary, are determined by the Board of Directors. The plan permits participants to contribute to the plan through salary reduction. Under terms of the plan, the Company will match up to 3% of the employee contributions. Discretionary and matching contributions by the Company to the plan amounted to approximately $273,000, $270,000, and $219,000, during 1995, 1994 and 1993, respectively.

(b) STOCK OPTIONS -- At September 30, 1995, 1,431,235 of the authorized but unissued common shares of the Company were reserved for issuance to directors, executives, key employees and consultants for stock options. Of the reserved shares, 773,663 were subject to options outstanding at September 30, 1995. Options may be granted at exercise prices from 95% to 110% of the market value of the underlying common stock on the date of grant and become exercisable on vesting schedules established at the time of grant. All options contain provisions restricting their transferability and limiting their exercise in the event of termination of employment or the disability or death of the optionee. Options may be granted both as Incentive Stock Options designed to provide certain tax benefits under the Internal Revenue Code and as Nonqualified Options without such tax benefits.

F-14

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

Transactions involving the stock options are shown in the table below:

                                                           YEARS ENDED SEPTEMBER 30,
                                                        -------------------------------
                                                         1995        1994        1993
                                                        -------     -------     -------
Outstanding at beginning of period (from $1.05 to
  $7.57 per share)....................................  659,715     518,580     395,671
Granted (from $4.69 to $6.42 per share)...............  189,188     185,422     125,413
Expired or canceled...................................  (17,817)     (8,950)       (517)
Exercised*............................................  (57,423)    (35,337)     (1,987)
                                                        -------     -------     -------
Outstanding at end of period (from $1.05 to $7.57 per
  share)..............................................  773,663     659,715     518,580
                                                        =======     =======     =======
Exercisable at end of period (from $1.05 to $7.57 per
  share)..............................................  353,541     227,136     135,477
                                                        =======     =======     =======


* Includes 14,574 shares surrendered in conjunction with the exercise of stock options.

(c) OTHER BENEFITS -- The Company does not provide postretirement or postemployment benefits to its employees.

(8) QUARTERLY FINANCIAL DATA -- UNAUDITED (Amounts in thousands, except for per share data)

                                                         FOR THE QUARTER ENDED IN FISCAL 1995
                                                 -----------------------------------------------------
                                                 DECEMBER 31     MARCH 31     JUNE 30     SEPTEMBER 30
                                                 -----------     --------     -------     ------------
Net sales......................................    $ 5,106        $6,469      $ 6,782        $6,753
Gross profit...................................      3,397         4,355        4,525         4,824
Net earnings...................................        430           945          985         1,164
Primary earnings per common share..............        .04           .08          .08           .09
Cash dividends per common share................        .02           .02          .03           .03

                                                         FOR THE QUARTER ENDED IN FISCAL 1994
                                                 -----------------------------------------------------
                                                 DECEMBER 31     MARCH 31     JUNE 30     SEPTEMBER 30
                                                 -----------     --------     -------     ------------
Net sales......................................    $ 3,625        $5,891      $ 5,717        $6,644
Gross profit...................................      2,486         3,557        3,685         4,631
Net earnings...................................        200           610          603         1,028
Primary earnings per common share..............        .01           .05          .05           .09
Cash dividends per common share................        .02           .02          .02           .02

F-15

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

                                                                     MARCH 31,      SEPTEMBER 30,
                                                                       1996             1995
                                                                    -----------     -------------
                                   ASSETS
CURRENT ASSETS:
  Cash and short-term investments.................................  $10,244,476      $  8,918,637
  Accounts receivable, less allowance of $150,755 and $164,136
     for doubtful accounts........................................    6,534,178         6,482,999
  Inventories.....................................................    3,330,673         3,032,655
  Prepaid expenses and other......................................      588,299           165,553
  Deferred tax assets.............................................      409,605           324,910
                                                                    -----------     -------------
     Total current assets.........................................   21,107,231        18,924,754
                                                                    -----------     -------------
PROPERTY, PLANT AND EQUIPMENT:
  Land............................................................      273,822           269,217
  Building improvements...........................................    5,968,729         6,162,668
  Machinery, equipment and furniture..............................    5,727,552         5,525,455
  Construction in progress........................................       77,280                --
                                                                    -----------     -------------
                                                                     12,047,383        11,957,340
  Less -- Accumulated depreciation and amortization...............    4,975,620         4,816,905
                                                                    -----------     -------------
     Net property, plant and equipment............................    7,071,763         7,140,435
                                                                    -----------     -------------
OTHER ASSETS:
  Long-term receivables, including cash surrender value of
     insurance policies...........................................      184,804           168,892
  Deferred royalties..............................................       97,946            74,762
  Deferred tax assets.............................................      177,879            87,879
  Deferred debenture offering costs, net of accumulated
     amortization of $133,357.....................................          -0-           395,731
  Covenants not to compete, net of accumulated amortization
     of $2,072,892 and $1,827,718.................................    2,187,702         2,432,876
  License agreements, net of accumulated amortization of
     $801,210 and $772,433........................................      333,903           362,680
  Patents, trade names, customer lists and distributorships, net
     of accumulated amortization of $579,960 and $475,762.........    1,733,040         1,837,238
  Other intangible assets, net of accumulated amortization of
     $106,603 and $85,570.........................................      524,397           545,430
  Costs in excess of net assets acquired, net of accumulated
     amortization of $560,630 and $458,482........................    2,496,363         2,598,511
                                                                    -----------     -------------
     Total other assets...........................................    7,736,034         8,503,999
                                                                    -----------     -------------
     Total assets.................................................  $35,915,028      $ 34,569,188
                                                                     ==========        ==========

F-16

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

                                                                     MARCH 31,      SEPTEMBER 30,
                                                                       1996             1995
                                                                    -----------     -------------
                  LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
  Current portion of long-term obligations........................  $ 2,723,000      $    381,932
  Current portion of capital lease obligations....................      108,649            63,561
  Accounts payable................................................      786,117           689,869
  Accrued payroll and payroll taxes...............................      505,387           723,946
  Other accrued expenses..........................................    1,109,513           937,348
  Income taxes payable............................................    1,296,820           458,707
                                                                    -----------     -------------
       Total current liabilities..................................    6,529,486         3,255,363
                                                                    -----------     -------------
LONG-TERM OBLIGATIONS.............................................    1,907,959        12,285,668
                                                                    -----------     -------------
CAPITAL LEASE OBLIGATIONS.........................................      387,438           149,925
                                                                    -----------     -------------
SHAREHOLDERS' EQUITY:
  Preferred stock, no par value, 1,000,000 shares authorized; none
     issued
  Common stock, no par value, 50,000,000 shares authorized;
     14,257,006 and 12,924,814 shares issued and outstanding
     respectively, stated at......................................    2,372,646         1,487,159
  Additional paid-in capital......................................   20,434,464        13,895,901
  Retained earnings...............................................    4,500,496         3,747,930
  Foreign currency translation adjustment.........................     (217,461)         (252,758)
                                                                    -----------     -------------
       Total shareholders' equity.................................   27,090,145        18,878,232
                                                                    -----------     -------------
       Total liabilities and shareholders' equity.................  $35,915,028      $ 34,569,188
                                                                     ==========        ==========

F-17

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF EARNINGS
(UNAUDITED)

                                                                          SIX MONTHS ENDED
                                                                              MARCH 31,
                                                                    -----------------------------
                                                                       1996             1995
                                                                    -----------     -------------
NET SALES.........................................................  $12,776,481      $ 11,574,417
COST OF SALES.....................................................    3,999,094         3,821,956
                                                                    -----------     -------------
       Gross Profit...............................................    8,777,387         7,752,461
                                                                    -----------     -------------
OPERATING EXPENSES:
  Research and development........................................      696,639           713,223
  Selling and marketing...........................................    2,814,787         2,420,944
  General and administrative......................................    1,996,180         1,947,312
                                                                    -----------     -------------
       Total operating expenses...................................    5,507,606         5,081,479
                                                                    -----------     -------------
       Operating income...........................................    3,269,781         2,670,982
                                                                    -----------     -------------
OTHER INCOME (EXPENSE):
  Licensing and commission fees...................................       32,938            66,403
  Investment income...............................................      242,632           195,940
  Interest expense and amortization of debt expenses..............     (236,018)         (561,483)
  Other, net......................................................       12,076               874
  Currency gains/(losses).........................................       23,631             3,506
                                                                    -----------     -------------
       Total other income (expense)...............................       75,259          (294,760)
                                                                    -----------     -------------
       Earnings before income taxes...............................    3,345,040         2,376,222
INCOME TAXES......................................................    1,360,910         1,000,886
                                                                    -----------     -------------
       Net earnings...............................................  $ 1,984,130      $  1,375,336
                                                                     ==========        ==========
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING.....................   14,071,922        12,299,598
                                                                     ==========        ==========
EARNINGS PER COMMON SHARE.........................................  $       .14      $        .11
                                                                     ==========        ==========

F-18

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(UNAUDITED)

                                  NUMBER OF                                             CUMULATIVE
                                   COMMON                                                 FOREIGN
                                   SHARES                   ADDITIONAL                   CURRENCY
                                 ISSUED AND      COMMON       PAID-IN      RETAINED     TRANSLATION
                                 OUTSTANDING     STOCK        CAPITAL      EARNINGS     ADJUSTMENT       TOTAL
                                 -----------   ----------   -----------   -----------   -----------   -----------
Balance at September 30,
  1995.........................   12,924,814   $1,487,159   $13,895,901   $ 3,747,930   $  (252,758)  $18,878,232
Net earnings...................           --           --            --     1,984,130            --     1,984,130
Cash dividends paid --                    --           --            --    (1,231,564)           --    (1,231,564)
Exercise of stock options......       14,308        2,144        10,806            --            --        12,950
Other awards...................          172          117         1,479            --            --         1,596
Debenture conversion, net......    1,317,712      883,226     6,526,278            --            --     7,409,504
Foreign currency translation
  adjustment...................           --           --            --            --        35,297        35,297
                                 -----------   ----------   -----------    ----------     ---------   -----------
Balance at March 31, 1996......   14,257,006   $2,372,646   $20,434,464   $ 4,500,496   $  (217,461)  $27,090,145
                                 ===========   ==========   ===========    ==========     =========   ===========

F-19

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)

                                                                          SIX MONTHS ENDED
                                                                              MARCH 31,
                                                                    -----------------------------
                                                                       1996             1995
                                                                    -----------     -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
  Net earnings....................................................  $ 1,984,130      $  1,375,336
  Noncash items --
     Loss on disposal of fixed assets.............................        5,869                --
     Amortization of royalties....................................       14,316                --
     Depreciation of property, plant and equipment................      495,255           456,464
     Amortization of intangible assets............................      517,214           468,833
     Deferred interest expense....................................       82,097            77,475
     Deferred income taxes........................................     (174,695)         (206,530)
     Long term receivables........................................      (15,912)               --
  Changes in other current assets and current liabilities --
     Accounts receivable, net.....................................      (51,179)         (600,667)
     Inventories..................................................     (298,018)         (114,718)
     Prepaid expenses and other...................................     (422,746)         (188,143)
     Accounts payable.............................................       96,248        (1,246,015)
     Accrued expenses.............................................      (46,394)          377,174
     Income taxes payable.........................................      838,113           (44,440)
                                                                    -----------     -------------
       Net cash provided by operating activities..................    3,024,298           354,769
                                                                    -----------     -------------
CASH FLOWS FROM INVESTING ACTIVITIES:
  Property, plant and equipment acquired, net.....................     (361,858)       (1,185,438)
  Royalty advanced................................................      (37,500)               --
                                                                    -----------     -------------
       Net cash used for investing activities.....................     (399,358)       (1,185,438)
                                                                    -----------     -------------
CASH FLOWS FROM FINANCING ACTIVITIES:
  Repayment of long-term obligations..............................     (364,713)         (166,417)
  Proceeds from long-term obligations.............................      395,576           907,317
  Dividends paid..................................................   (1,231,564)         (566,571)
  Proceeds from issuance of common stock, net.....................      (63,103)           22,646
  Effect of exchange rate changes on cash.........................      (35,297)          (36,895)
                                                                    -----------     -------------
       Net cash provided by (used for) financing activities.......   (1,299,101)          160,080
                                                                    -----------     -------------
NET INCREASE (DECREASE) IN CASH AND SHORT-TERM INVESTMENTS........    1,325,839          (670,589)
CASH AND SHORT-TERM INVESTMENTS AT BEGINNING OF PERIOD............    8,918,637         8,831,983
                                                                    -----------     -------------
CASH AND SHORT-TERM INVESTMENTS AT END OF PERIOD..................  $10,244,476      $  8,161,394
                                                                     ==========        ==========
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
  Cash paid during the period for --
     Income taxes.................................................  $   916,625      $  1,193,950
                                                                     ==========        ==========
     Interest.....................................................  $    78,515      $    447,071
                                                                     ==========        ==========
  Non-cash activities --
     Common stock issued from conversion of subordinated
      debentures, net of amortization of deferred debenture
      offering cost of $379,847 and net conversion costs of
      $77,649.....................................................  $ 7,409,504      $         --
                                                                     ==========        ==========

F-20

MERIDIAN DIAGNOSTICS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(1) BASIS OF PRESENTATION

The consolidated financial statements included herein have not been examined by independent public accountants, but include all adjustments (consisting of normal recurring entries) which are, in the opinion of management, necessary for a fair presentation of the results for such periods.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been omitted pursuant to the requirements of the Securities and Exchange Commission, although the Company believes that the disclosures included in these financial statements are adequate to make the information not misleading.

It is suggested that these consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company's latest annual report on Form 10-K.

The results of operations for the interim periods are not necessarily indicative of the results to be expected for the year.

(2) INVENTORIES

Inventories are comprised of the following:

                                                             MARCH 31,      SEPTEMBER 30,
                                                                1996            1995
                                                             ----------     -------------
Raw materials..............................................  $1,086,710      $ 1,165,319
Work-in-process............................................     909,404          626,077
Finished goods.............................................   1,334,559        1,241,259
                                                             ----------     -------------
                                                             $3,330,673      $ 3,032,655
                                                              =========       ==========

(3) INCOME TAXES

The provisions for income taxes were computed at the estimated annualized effective tax rates utilizing current tax law in effect, after giving effect to research and experimentation credits.

(4) EARNINGS PER COMMON SHARE

Net earnings per share has been computed based upon the weighted average number of shares outstanding during the periods including the effect of the conversion of the subordinated debentures into common stock. No material dilution results from outstanding stock options, the only common stock equivalent. All share and per share information has been adjusted to reflect the 3 for 2 stock split in October 1995. Additionally, all share and per share information has been adjusted for a 3% stock dividend in November 1994.

(5) TRANSLATION OF FOREIGN CURRENCY

Assets and liabilities of foreign operations are translated using quarter-end exchange rates, and revenues and expenses are translated using exchange rates prevailing during the year with gains or losses resulting from translation included in a separate component of shareholders' equity. Gains and losses resulting from transactions in foreign currencies were immaterial.

(6) RECLASSIFICATIONS

Certain reclassifications have been made to the accompanying financial statements to conform to the March 31, 1996 presentation.

F-21

Cryptosporidium and Giardia, common intestinal parasites, can infect the gastrointestinal tract causing severe diarrhea, abdominal pain, nausea and weight loss. The Company's Merifluor C/G utilizes fluorescent dyes to illuminate the organisms making them easier to identify, reducing processing time. This test is the only test in the marketplace which allows the simultaneous detection of both Cryptosporidium and Giardia. (photograph depicts fluorescing Cryptosporidium and Giardia in a patient's specimen)

The Company is the leading supplier of parasitology diagnostic tests and related products. The Company's broad product offering includes the Premier Giardia Lamblia targeted to large volume users such as large hospitals and reference laboratories. (photograph of Premier product)

In October 1995, the Company introduced the Para-Pak ECOfix and Para-Pak Ultra ECOfix. These products result in easier, safer and faster specimen processing and lower-cost disposal of the transport container. (photograph of Para-Pak ECOfix and Para-Pak Ultra ECOfix products)




NO DEALER, SALESPERSON OR OTHER PERSON HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATIONS IN CONNECTION WITH THIS OFFERING OTHER THAN THOSE CONTAINED IN THIS PROSPECTUS, AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY, THE SELLING SHAREHOLDER OR ANY OF THE UNDERWRITERS. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY OF THE SECURITIES OFFERED HEREBY BY ANYONE IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION IS NOT AUTHORIZED OR IN WHICH THE PERSON MAKING SUCH OFFER OR SOLICITATION IS NOT QUALIFIED TO DO SO OR TO ANY PERSON TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO ITS DATE.


TABLE OF CONTENTS

                                                PAGE
                                                ----
Prospectus Summary............................    3
Risk Factors..................................    6
Capitalization................................    8
Dividend Policy...............................    9
Price Range of Common Stock...................   10
Selected Consolidated Financial
  Data........................................   11
Management's Discussion and Analysis of
  Financial Condition and Results of
  Operations..................................   12
Business......................................   17
Management....................................   26
Principal Shareholders and Selling
  Shareholder.................................   28
Description of Capital Stock..................   29
Underwriting..................................   31
Legal Matters.................................   31
Experts.......................................   32
Glossary of Selected Terms....................   33
Index to Consolidated Financial Statements....  F-1





1,500,000 SHARES
[LOGO]
COMMON STOCK

PROSPECTUS
CLEARY GULL REILAND & MCDEVITT INC.

THE OHIO COMPANY

RONEY & CO.
MAY , 1996



PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.

The following table sets forth the expenses in connection with the offering described in this Registration Statement:

Securities and Exchange Commission registration fee*......................  $  5,837
National Association of Securities Dealers, Inc. filing fee*..............     2,193
Accounting fees and expenses..............................................    30,000
Legal fees and expenses...................................................    40,000
Blue Sky fees and expenses................................................    10,000
Printing and engraving expenses...........................................    90,000
Marketing expenses........................................................    10,000
Miscellaneous.............................................................   161,970
                                                                            --------
          TOTAL...........................................................  $350,000
                                                                            ========


* Actual; other expenses are estimated

ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

Ohio Revised Code, Section 1701.13(E), allows indemnification by the Registrant to any person made or threatened to be made a party to any proceedings, other than a proceeding by or in the right of the Registrant, by reason of the fact that he is or was a director, officer, employee or agent of the Registrant, against expenses, including judgment and fines, if he acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the Registrant and, with respect to criminal actions, in which he had no reasonable cause to believe that his conduct was unlawful. Similar provisions apply to actions brought by or in the right of the Registrant, except that no indemnification shall be made in such cases when the person shall have been adjudged to be liable for negligence or misconduct to the Registrant unless otherwise deemed appropriate by the court. Indemnification is to be made by a majority vote of a quorum of disinterested directors or the written opinion of independent counsel or by the shareholders or by the court. The Registrant's Code of Regulations extends such indemnification.

ITEM 16. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.

EXHIBIT
NUMBER                                     DESCRIPTION OF DOCUMENT
- ------       -----------------------------------------------------------------------------------
  1       -- Form of Proposed Underwriting Agreement
  3.1     -- Articles of Incorporation
  3.2     -- Code of Regulations (incorporated by reference to Registration Statement No.
             33-6052 filed under the Securities Act of 1933)
  5       -- Opinion of Keating, Muething & Klekamp as to legality of the Common Stock
 23.1     -- Consent of Independent Public Accountants
 23.3     -- Consent of Keating, Muething & Klekamp (Contained on Exhibit 5)
 24       -- Powers of Attorney (contained on the signature page)


* Incorporated by reference as indicated.

II-1


ITEM 17. UNDERTAKINGS.

(a) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

(b) That, for purposes of determining any liability under the Securities Act, each filing of the Registrant's Annual Report pursuant to Section 13(a) or
Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(i)(1) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in the form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective.

(i)(2) For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new Registration Statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II-2


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has fully caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Cincinnati, State of Ohio, as of the 18th day of April, 1996.

MERIDIAN DIAGNOSTICS, INC.

By:     /s/  William J. Motto

  ------------------------------------
            William J. Motto
         Chairman of the Board
      and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. The persons whose names are marked an asterisk (*) below hereby designate John A. Kraeutler or Gerard Blain to sign all amendments, including post-effective amendments to this Registration Statement as well as any related registration statement (or amendment thereto) filed pursuant to Rule 462(b) promulgated under the Securities Act of 1933.

                  SIGNATURE                                CAPACITY                   DATE
- ---------------------------------------------  --------------------------------  ---------------
         *          /s/  William J.            Chairman of the Board and Chief
                     Motto                       Executive Officer (Principal
- ---------------------------------------------    Executive Officer)
              William J. Motto                                                   April 18, 1996
          *            /s/  Gerard             Vice President, Chief Financial
                     Blain                       Officer and Treasurer
- ---------------------------------------------    (Principal Financial Officer
                Gerard Blain                     and Principal Accounting
                                                 Officer)                        April 18, 1996
          *           /s/  Jerry L.            Director
                     Ruyan
- ---------------------------------------------
               Jerry L. Ruyan                                                    April 18, 1996
          *          /s/  James A.             Director
                    Buzard
- ---------------------------------------------
               James A. Buzard                                                   April 18, 1996
          *           /s/  Gary P.             Director
                   Kreider
- ---------------------------------------------
               Gary P. Kreider                                                   April 18, 1996
         *           /s/  Robert J.            Director
                     Ready
- ---------------------------------------------
               Robert J. Ready                                                   April 18, 1996

II-3


Exhibit 1

MERIDIAN DIAGNOSTICS, INC.

1,500,000 SHARES OF COMMON STOCK*

UNDERWRITING AGREEMENT

_____________, 1996

CLEARY GULL REILAND & MCDEVITT INC.
THE OHIO COMPANY
RONEY & CO.
As Representatives of the
Several Underwriters Named Herein
c/o Cleary Gull Reiland & McDevitt Inc.
100 East Wisconsin Avenue, Suite 2400
Milwaukee, Wisconsin 53202

Ladies and Gentlemen:

Meridian Diagnostics, Inc., an Ohio Corporation (the "Company"), and Jerry L. Ruyan (the "Selling Shareholder") confirm their respective agreements with you (the "Representatives") and each of the other underwriters identified on Schedule I annexed hereto (collectively, the "Underwriters"), as set forth below:

1. SECURITIES. Subject to the terms and conditions herein contained, the Selling Shareholder proposes to issue and sell to the Underwriters an aggregate of 1,500,000 shares (the "Firm Shares") of common stock, no par value per share, of the Company (the "Common Stock"). In addition, the Selling Shareholder has agreed to grant to the Underwriters an option to purchase up to 225,000 additional shares of Common Stock, as provided in Section 3 hereof. The Firm Shares and, to the extent such option is exercised, the Option Shares are collectively referred to herein as the "Shares."

2. REPRESENTATIONS AND WARRANTIES.

(a) The Company and the Selling Shareholder, jointly and severally, represent and warrant to, and agree with, each of the Underwriters, and shall be deemed to represent and warrant to each of the Underwriters on each Closing Date (as hereafter defined) that:


* Plus an option to acquire up to 225,000 additional shares of Common Stock from the Selling Shareholder to cover over-allotments.


(i) The Company meets the requirements for use of Form S-3 under the Securities Act of 1933, as amended (the "Act"). The Company has filed a registration statement on such Form (Reg. No. 333-_____) with respect to the Shares, including a prospectus subject to completion, with the Securities and Exchange Commission (the "Commission") under the Act, and one or more amendments to such registration statement may have been so filed. After the execution of this Agreement, the Company will file with the Commission either (A) if the Commission has declared such registration statement, as it may have been amended, effective under the Act, a prospectus in the form most recently included in an amendment to such registration statement (or, if no such amendment shall have been filed, in such registration statement), with such changes or insertions as are required by Rule 430A under the Act or permitted by Rule 424(b) under the Act and as have been provided to and approved by the Underwriters prior to the execution of this Agreement, or (B) if the Commission has not declared such registration statement, as it may have been amended, effective under the Act, an amendment to such registration statement, including a form of prospectus, a copy of which amendment has been furnished to and approved by the Underwriters prior to the execution of this Agreement. As used in this Agreement, the term "Registration Statement" means such registration statement, as amended at the time when it was or is declared effective, including (1) all financial schedules and exhibits thereto, (2) all documents (or portions thereof) incorporated by reference therein filed under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including any documents filed after the date of the Preliminary Prospectus (as hereinafter defined) or Prospectus (as hereinafter defined) and so incorporated by reference and (3) any information omitted therefrom pursuant to Rule 430A under the Act and included in the Prospectus (as hereinafter defined); the term "Preliminary Prospectus" means each prospectus subject to completion filed with such registration statement or any amendment thereto (including the prospectus subject to completion, if any, included in the Registration Statement or any amendment thereto at the time it was or is declared effective), including all documents (or portions thereof) incorporated by reference therein filed under the Exchange Act, as well any additional registration statement, and any amendments thereto, filed with the Commission after the effectiveness of the foregoing registration statement and prior to the execution of this Agreement or hereafter in accordance with this Agreement for purposes of registering a portion of the Shares under the Act; and the term "Prospectus" means the prospectus first filed with the Commission pursuant to Rule 424(b) under the Act or, if no prospectus is required to be filed pursuant to said Rule 424(b), such term means the prospectus included in the Registration Statement, in either case including all documents (or portions thereof) incorporated by reference therein filed under the Exchange Act.

(ii) Neither the Commission nor any state securities commission has issued any order preventing or suspending the use of any Preliminary Prospectus nor, to the knowledge of the Company and the Selling Shareholder, have any proceedings for that purpose been initiated or threatened. When any Preliminary Prospectus was filed with the Commission, it (A) contained (or incorporated by reference) all statements

-2-

required to be stated therein in accordance with, and complied in all material respects with the requirements of, the Act, the Exchange Act and the respective rules and regulations of the Commission thereunder and (B) did not include (or incorporate by reference) any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. When the Registration Statement or any amendment thereto was or is declared effective, it (1) contained (or incorporated by reference) or will contain (or incorporate by reference) all statements required to be stated therein in accordance with, and complied or will comply in all material respects with the requirements of, the Act, the Exchange Act and the respective rules and regulations of the Commission thereunder and (2) did not or will not include (or incorporate by reference) any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. When the Prospectus or any amendment or supplement thereto is filed with the Commission pursuant to Rule 424(b) (or, if the Prospectus or such amendment or supplement is not required to be so filed, when the Registration Statement or the amendment thereto containing such amendment or supplement to the Prospectus was or is declared effective), on the date when the Prospectus is otherwise amended or supplemented and on the Firm Closing Date and any Option Closing Date (both as hereinafter defined), the Prospectus, as amended or supplemented at any such time, (AA) contained (or incorporated by reference) or will contain (or incorporate by reference) all statements required to be stated therein in accordance with, and complied or will comply in all material respects with the requirements of, the Act, the Exchange Act and the respective rules and regulations of the Commission thereunder and (BB) did not or will not include (or incorporate by reference) any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The foregoing provisions of this subsection (ii) do not apply to statements or omissions made in any Preliminary Prospectus, the Registration Statement or any amendment thereto or the Prospectus or any amendment or supplement thereto with respect to the last paragraph on the outside front cover of the Prospectus concerning the terms of the offering by the Underwriters, the paragraphs on the inside front cover page of the Prospectus relating to stabilization practices and passive market making and the concession and reallowance amounts appearing under the caption "Underwriting." Neither the Company nor any person that controls, is controlled by or in under common control with the Company has distributed or will distribute prior to each Closing Date any offering material in connection with the offering and sale of the Shares other than a Preliminary Prospectus, the Prospectus, the Registration Statement or other materials permitted by the Act and provided to the Representatives.

(iii) The documents that are incorporated by reference in each Preliminary Prospectus, the Prospectus or the Registration Statement or from which information is so incorporated by reference, when they became effective or were filed with the Commission, as the case may be, complied with the requirements of the Act or

-3-

the Exchange Act, as applicable, and any document so filed and incorporated by reference subsequent to the effective date of the Registration Statement shall, when it is filed with the Commission, comply with the requirements of the Act and the Exchange Act, as applicable, and when read together with the other information included in such Preliminary Prospectus, the Prospectus or the Registration Statement, as the case may be, do not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

(iv) The Company's only subsidiaries are listed in Exhibit A hereto (the "Subsidiaries"). The Company and the Subsidiaries have been duly organized and are validly existing as corporations in good standing under the laws of their respective jurisdictions of incorporation. The Company and each of the Subsidiaries are duly qualified to transact business as foreign corporations and are in good standing under the laws of all other jurisdictions where the ownership or leasing of their respective properties or the conduct of their respective businesses requires such qualification, except where the failure to be so qualified does not amount to a material liability or disability to the Company and the Subsidiaries, taken as a whole.

(v) The Company and each of the Subsidiaries have full power (corporate and other) to own or lease their respective properties and conduct their respective businesses as described in the Registration Statement and the Prospectus or, if the Prospectus is not in existence, the most recent Preliminary Prospectus; and the Company has full power (corporate and other) to enter into this Agreement and to carry out all the terms and provisions hereof to be carried out by it.

(vi) The issued shares of capital stock of each of the Company's directly-owned Subsidiaries as set forth in Exhibit A hereto have been duly authorized and validly issued; are fully paid and nonassessable and are all owned beneficially by the Company free and clear of any security interests, liens, encumbrances, equities or claims. The outstanding quotas of Meridian Diagnostics Europe, s.r.l. ("MDE") have been duly authorized and validly issued, are fully paid and nonassessable and are owned beneficially as set forth in Exhibit A hereto free and clear of any security interests, liens, encumbrances, equities or claims. There are no outstanding options, warrants or other rights of any description, contractual or otherwise, entitling any person to subscribe for or purchase any shares of capital stock of any Subsidiary.

(vii) The Company has an authorized, issued and outstanding capitalization as set forth in the Prospectus or, if the Prospectus is not in existence, the most recent Preliminary Prospectus. All of the issued shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and nonassessable. No holder of outstanding shares of capital stock of the Company is entitled as such to any preemptive or other rights to subscribe for any of the Shares or any other Common Stock, and no shares of Common Stock have been issued in violation

-4-

of such rights. No holder of securities of the Company has any right, which has not been fully exercised or waived, to require the Company to register the offer or sale of any securities owned by such holder under the Act in the public offering contemplated by this Agreement.

(viii) The capital stock of the Company conforms to the description thereof contained in the Prospectus or, if the Prospectus is not in existence, the most recent Preliminary Prospectus. There are no outstanding options, warrants or other rights to subscribe for or purchase Common Stock, except as described in the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

(ix) The consolidated financial statements and schedules, if any, of the Company and the Subsidiaries included, and incorporated by reference, in the Registration Statement and the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus) fairly present the financial position of the Company and the Subsidiaries and their results of operations and changes in financial condition as of the dates and periods therein specified. Such financial statements and schedules have been prepared in accordance with generally accepted accounting principles consistently applied throughout the periods involved (except as otherwise noted therein). The selected financial data set forth under the caption "Selected Consolidated Financial Data" in the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus) fairly presents on the basis stated in the Prospectus (or such Preliminary Prospectus) the information included therein.

(x) Arthur Andersen LLP, who have certified certain financial statements of the Company and the Subsidiaries and delivered their report with respect to the audited consolidated financial statements and schedules included, or incorporated by reference, in the Registration Statement and the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus), are independent public accountants as required by the Act, the Exchange Act and the related published rules and regulations thereunder.

(xi) The execution and delivery of this Agreement has been duly authorized by the Company. This Agreement has been duly executed and delivered by the Company and, assuming due execution by the other parties hereto, is the legal, valid and binding obligation of the Company, enforceable by any such party against the Company in accordance with its terms.

(xii) No legal or governmental proceedings are pending to which the Company or any of the Subsidiaries is a party or to which the property of the Company or any of the Subsidiaries is subject that are required to be described in the Registration Statement or the Prospectus and are not described therein (or, if the Prospectus is not in existence, the most recent preliminary Prospectus), and no such proceedings have been threatened against the Company or any of the Subsidiaries or with respect to any of their

-5-

respective properties; and no contract or other document is required to be described in the Registration Statement or the Prospectus or to be filed as an exhibit to the Registration Statement that is not described therein (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus) or filed as required.

(xiii) The compliance by the Company with the provisions of this Agreement and the consummation of the other transactions herein contemplated do not (A) require the consent, approval, authorization, registration or qualification of or with any governmental authority or regulatory body, except such as have been obtained or such as may be required under state securities or blue sky laws ("Blue Sky Laws"), the National Association of Securities Dealers, Inc. ("NASD") and, if the Registration Statement (as amended) filed with respect to the Shares is not effective under the Act as of the time of execution hereof, such as may be required (and shall be obtained as provided in this Agreement) under the Act, or (B) conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under, any indenture, mortgage, deed of trust, lease or other agreement or instrument to which the Company or any of the Subsidiaries is a party or by which the Company or any of the Subsidiaries or any of their respective properties are bound, or the charter documents, Code of Regulations or by-laws of the Company or any of the Subsidiaries, or any statute or any judgment, decree, order, rule or regulation of any court or other governmental authority or any arbitrator applicable to the Company or any of the Subsidiaries.

(xiv) The Company has not, directly or indirectly, (A) taken any action designed to cause or to result in, or that has constituted or which might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares or (B) since the filing of the Registration Statement (1) sold, bid for, purchased, or paid anyone any compensation for soliciting purchases of, the Shares or any Common Stock or (2) paid or agreed to pay to any person any compensation for soliciting another to purchase any other securities of the Company.

(xv) Subsequent to the respective dates as of which information is given in the Registration Statement and the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus), (A) the Company and the Subsidiaries have not incurred any material liability or obligation, direct or contingent, nor entered into any material transaction not in the ordinary course of business; (B) the Company has not purchased any of its outstanding capital stock, nor declared, paid or otherwise made any dividend or distribution of any kind on its capital stock; and (C) there has not been any material change in the capital stock, short-term debt or long-term debt of the Company and the Subsidiaries or any change or development involving or that could be expected to involve a material adverse change in the condition (financial or otherwise), management, business, prospects, net worth or results of operations of the Company and the Subsidiaries ("Material Adverse Change"), except in each case as

-6-

described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

(xvi) The Company and each of the Subsidiaries have good and marketable title in fee simple to all items of real property and marketable title to all personal property owned by each of them, in each case free and clear of any security interests, liens, encumbrances, equities, claims and other defects, except such as do not materially and adversely affect the value of such property and do not interfere with the use made or proposed to be made of such property by the Company or such Subsidiary, and any real property and buildings held under lease by the Company or any such Subsidiary are held under valid, subsisting and enforceable leases, with such exceptions as are not material and do not interfere with the use made or proposed to be made of such property and buildings by the Company or such Subsidiary, in each case mentioned in this paragraph except as described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

(xvii) No labor dispute with the employees of the Company or any of the Subsidiaries exists or is threatened or imminent that could result in a Material Adverse Change, except as described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

(xviii) The Company and the Subsidiaries own or possess, or can acquire on reasonable terms, all material patents, patent applications, trademarks, service marks, trade names, licenses, copyrights and proprietary or other confidential information currently employed by them in connection with their respective businesses, and neither the Company nor any such Subsidiary has received any notice of infringement of or conflict with asserted rights of any third party with respect to any of the foregoing which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change, except as described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus). The Company and the Subsidiaries have taken reasonable action to protect proprietary or other confidential information currently employed by them in connection with their respective businesses, including without limitation causing appropriate employees to execute enforceable confidentiality agreements. The patents, registered trademarks and registered service marks described in the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus) have been issued or registered as so described, and the Company has maintained such patents and registrations in accordance with applicable requirements.

(xix) The Company and each of the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which they are engaged; neither the Company nor any such Subsidiary has been refused any insurance coverage sought or applied for; and neither the Company nor any such Subsidiary has any reason

-7-

to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not result in a Material Adverse Change, except as described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

(xx) No Subsidiary is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such Subsidiary's capital stock, from repaying to the Company any loans or advances to such Subsidiary from the Company or from transferring any of such Subsidiary's property or assets to the Company or any other subsidiary of the Company, except as described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

(xxi) The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Change, except as described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

(xxii) Neither the Company nor any Subsidiary is an "investment company", an "affiliated person" of or "promoter" or "principal underwriter" for an "investment company", as such terms are defined in the Investment Company Act of 1940, as amended. The Company will conduct its operations in a manner that will not subject it to registration as an "investment company" under such act.

(xxiii) The Company has filed all foreign, federal, state and local tax returns that are required to be filed or has requested extensions thereof (except in any case in which the failure so to file would not result in a Material Adverse Change) and has paid all taxes required to be paid by it and any other assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except for any such assessment, fine or penalty that is currently being contested in good faith or as described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

(xxiv) Neither the Company nor any of the Subsidiaries is in violation of any federal, state or foreign law or regulation relating to occupational safety and health, the environment or the storage, handling or transportation of hazardous or toxic materials, pollutants or contaminants, including, without limitation, all rules and requirements of the State of Ohio Fire Marshall, Bureau of Underground Storage Tank Regulations, and the Company and the Subsidiaries have received all permits, licenses

-8-

or other approvals required of them under applicable federal, state and foreign occupational safety and health and environmental laws and regulations to conduct their respective businesses, and the Company and each Subsidiary is in compliance with all terms and conditions of any such permit, license or approval, except any such violation of laws or regulations, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals which would not, singly or in the aggregate, result in a Material Adverse Change, except as described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

(xxv) Each certificate signed by any officer of the Company and delivered to the Underwriters or counsel for the Underwriters shall be deemed to be a representation and warranty by the Company and the Selling Shareholder to each Underwriter as to the matters covered thereby.

(xxvi) Except for the shares of capital stock of each of the Subsidiaries owned by the Company and such Subsidiaries, neither the Company nor any Subsidiary owns any material amount of shares of stock or any other equity securities of any corporation or has any equity interest in any firm, partnership, association or other entity, except as described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

(xxvii) The Company and each of the Subsidiaries maintains a system of internal accounting controls sufficient to provide reasonable assurance that (A) transactions are executed in accordance with management's general or specific authorizations; (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability;
(C) access to assets is permitted only in accordance with management's general or specific authorization; and (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

(xxviii) Neither the Company nor any Subsidiary is, nor with the giving of notice or passage of time or both, would be, in violation or in breach of: (A) its respective Articles of Incorporation or By-laws (or other corporate governing documents); (B) any statute, ordinance, order, rule or regulation applicable to the Company or such Subsidiary; (C) any order or decree of any court, regulatory body, arbitrator, administrative agency or other instrumentality of the United States or other country or jurisdiction having jurisdiction over the Company or such Subsidiary; or (D) any provision of any agreement, lease, franchise, license, indenture, permit, mortgage, deed of trust, evidence of indebtedness or other instrument to which the Company or such Subsidiary is a party or by which any property owned or leased by the Company or such Subsidiary is bound or affected, except where such violation or breach would not result in a Material Adverse Change, except as described in or contemplated by the Prospectus (or, if the Prospectus is not in existence, the most recent Preliminary Prospectus).

-9-

(xxix) Neither the Company nor any person that controls, is controlled by (including the Subsidiaries) or is under common control with the Company has, directly or indirectly: (A) made any unlawful contribution to any candidate for political office, or failed to disclose fully any contribution in violation of law; or (B) made any payment to any federal, state or foreign governmental officer or official, or other person charged with similar public or quasi-public duties, other than payments required or permitted by the laws of the United States or any jurisdiction thereof or applicable foreign jurisdictions, except where such illegal contribution, payment or failure to disclose would not result in a Material Adverse Change.

(xxx) The Company and the Subsidiaries are in compliance with the requirements of the Employee Retirement Income Security Act of 1974, as amended, and the regulations thereunder, except to the extent that failure to be in such compliance would not result in a Material Adverse Change.

(xxxi) Neither the Company nor any of the Subsidiaries nor any affiliate of the Company or any of the Subsidiaries does business with the government of Cuba or with any person or affiliate located in Cuba within the meaning of Section 517.075 of the Florida Statutes, and the Company agrees to comply with such Section if, prior to the completion of the distribution of the Shares, the Company, any of its Subsidiaries or any affiliate of the Company or any of its Subsidiaries commences doing such business.

(xxxii) The Company has obtained for the benefit of the Underwriters the written agreement, enforceable by the Representatives, of each of the officers and directors of the Company, that for a period commencing on the date of such agreement and continuing until 90 days after the date of the Prospectus, such persons will not, without the prior written consent of Cleary Gull Reiland & McDevitt Inc. ("Cleary Gull"), directly or indirectly, offer, sell, transfer, or pledge, contract to sell, transfer or pledge, or cause or in any way permit to be sold, transferred, pledged, or otherwise disposed of, any: (A) shares of Common Stock; (B) rights to purchase shares of Common Stock (including, without limitation, shares of Common Stock that may be deemed to be beneficially owned by any such shareholder in accordance with the applicable regulations of the Commission and shares of Common Stock that may be issued upon the exercise of a stock option, warrant or other convertible security); or (C) securities that are convertible or exchangeable into shares of Common Stock, except as may be provided in any such written agreement.

(xxxiii) None of the Company, any Subsidiary, any officer or director of the Company or any Subsidiary, or any person who owns, of record or beneficially, five percent (5%) or more of any class of securities issued by the Company is: (A) an officer, director or partner of any brokerage firm, broker or dealer that is a member of the NASD ("NASD Member") or (B) directly or indirectly, a "person associated with" an NASD Member or an "affiliate" of an NASD Member, as such terms are used in the NASD Rules of Fair Practice. In addition, neither the Company nor any Subsidiary has issued or transferred

-10-

any Common Stock, warrants, options or other securities, or any other items of value, to any of the Underwriters or any "related person" of any Underwriter, as such term is used in the NASD Rules of Fair Practice, except as provided in this Agreement.

(b) The Selling Shareholder represents and warrants to and agrees with the several Underwriters and the Company, and shall be deemed to represent and warrant to the several Underwriters and the Company on each Closing Date, that:

(i) The Selling Shareholder has duly executed a durable power of attorney and custody agreement ("Durable Power of Attorney and Custody Agreement") naming __________ and __________, or either of them, as the Selling Shareholder's attorney(s)-in-fact ("Attorneys-in-Fact") for the purpose of entering into and carrying out this Agreement and naming __________ as custodian ("Custodian") of the Shares of the Selling Shareholder for the purpose of selling the Shares to the Underwriters on each Closing Date and receiving payment therefor.

(ii) All consents, approvals, authorizations and orders necessary for the execution and delivery by the Selling Shareholder of this Agreement and the Durable Power of Attorney and Custody Agreement and for the sale and delivery of the Shares have been obtained. The Selling Shareholder has, and at the time of delivery thereof hereunder the Selling Shareholder will have, good and valid title to the Shares, free and clear of all voting trust arrangements, liens, encumbrances, security interests, equities, claims and community or marital property rights, other than any created by the Durable Power of Attorney and Custody Agreement or this Agreement for the benefit of the Underwriters. The Selling Shareholder has full right, power and authority to enter into this Agreement and the Durable Power of Attorney and Custody Agreement and to sell, assign, transfer and deliver the Shares hereunder, free and clear of all voting trust arrangements, liens, encumbrances, security interests, equities, claims and community or marital property rights, other than any created by the Durable Power of Attorney and Custody Agreement or this Agreement for the benefit of the Underwriters. Upon delivery of and payment for such Shares hereunder, the Underwriters will acquire good and valid title thereto, free and clear of all voting trust arrangements, liens, encumbrances, security interests, equities, claims and community or marital property rights.

(iii) The Selling Shareholder has not distributed and will not distribute any Preliminary Prospectus, the Prospectus or any other material in connection with the offering and sale of the Shares. The Selling Shareholder has not taken and will not take, directly or indirectly, any action designed to or which could cause or result in, under the Exchange Act or otherwise, stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Common Stock.

(iv) The execution, delivery and performance by the Selling Shareholder of this Agreement and the Durable Power of Attorney and Custody

-11-

Agreement will not, if applicable, constitute a breach, or be in contravention, of any provision of any agreement, franchise, license, indenture, mortgage, deed of trust or other instrument to which the Selling Shareholder is a party or by which the Selling Shareholder or the Selling Shareholder's property may be bound or affected, or any statute, rule or regulation applicable to the Selling Shareholder, or violate any order or decree of any court, regulatory body, administrative agency or other governmental body having jurisdiction over the Selling Shareholder or any of such Selling Shareholder's property. No consent, approval, authorization or other order of any court, regulatory body, administrative agency or other governmental body is required for the execution and delivery of, and performance under, this Agreement by the Selling Shareholder or the consummation by the Selling Shareholder of the transactions contemplated by this Agreement, except for compliance with the Act, the Exchange Act, the Blue Sky Laws applicable to the public offering of the Shares by the Underwriters and the clearance of such offering with the NASD. The Selling Shareholder hereby represents and warrants that each Attorney-in-Fact has been duly appointed as attorney-in-fact by the Selling Shareholder for the purpose of entering into and carrying out this Agreement, and the Durable Power of Attorney and Custody Agreement has been duly executed and delivered by or on behalf of the Selling Shareholder to the Representative.

(v) This Agreement and the Durable Power of Attorney and Custody Agreement are each valid and binding agreements of the Selling Shareholder enforceable in accordance with their respective terms.

(vi) The Selling Shareholder has deposited in custody, under the Durable Power of Attorney and Custody Agreement, certificates in negotiable form for the Shares (including the maximum number of Option Shares) for the purpose of further delivery pursuant to this Agreement. The Selling Shareholder agrees that the Shares on deposit with the Custodian are subject to the interests of the Underwriters, that the arrangements made for such custody, and the appointment of the Attorneys-in-Fact pursuant to the Durable Power of Attorney and Custody Agreement, are to that extent irrevocable, and that the obligations of the Selling Shareholder hereunder and under the Durable Power of Attorney and Custody Agreement shall not be terminated, except as provided in this Agreement and the Durable Power of Attorney and Custody Agreement, by any act of the Selling Shareholder, by operation of law, whether by the death or incapacity of the Selling Shareholder or by the occurrence of any other event. If the Selling Shareholder should die or become incapacitated or if any other event should occur before the delivery of the Shares hereunder, the certificates for Shares then on deposit with the Custodian shall, to the extent such Shares are purchased by the Underwriters, be delivered by the Custodian in accordance with the terms and conditions of this Agreement and the Durable Power of Attorney and Custody Agreement as if such death, incapacity or other event had not occurred, regardless of whether or not the Custodian shall have received notice thereof. The Selling Shareholder represents that each Attorney-in-Fact has been authorized by the Selling Shareholder to execute and deliver this Agreement and the Custodian has been authorized to receive and acknowledge receipt

-12-

of the proceeds of sale of the Shares sold by the Selling Shareholder against delivery thereof and otherwise to act on behalf of the Selling Shareholder.

(vii) Insofar as it relates to the Selling Shareholder, each Preliminary Prospectus, as of its date, has conformed in all material respects with the requirements of the Act and, as of its date, has not included any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein not misleading; and on the effective date of the Registration Statement and at all times subsequent thereto up to each Closing Date, (A) the Registration Statement and the Prospectus, as they relate to such Selling Shareholder, did or will conform to the requirements of the Act, and (B) neither the Registration Statement nor the Prospectus as it relates to such Selling Shareholder did or will include any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading.

(viii) The information contained in the Selling Shareholder's Directors' and Officers' Questionnaire completed in connection with the proposed sale of the Shares and delivered to the Representatives was, as of the date of such questionnaire, and is, as of the date of this Agreement, true and correct.

3. PURCHASE, SALE AND DELIVERY OF SHARES.

(a) On the basis of the representations, warranties and agreements herein contained, and subject to the terms and conditions herein set forth, the Selling Shareholder agrees to sell the Firm Shares to the Underwriters, and each of the Underwriters agrees to purchase from the Selling Shareholder the number of Firm Shares as hereinafter set forth at the price per share of $________. The obligation of each Underwriter to the Selling Shareholder shall be to purchase from the Selling Shareholder the number of full Firm Shares set forth opposite the name of such Underwriter in Schedule I annexed hereto.

(b) On the Firm Closing Date (as hereinafter defined), the Custodian on behalf of the Selling Shareholder will deliver to the Representatives, at the offices of Cleary Gull, 100 East Wisconsin Avenue, Milwaukee, Wisconsin 53202, or through the facilities of The Depository Trust Company, for the accounts of the several Underwriters, certificates representing the Firm Shares against payment in Milwaukee, Wisconsin of the purchase price therefor by certified or official bank check or checks in New York Clearing House (next day) funds payable to the order of the Custodian. As referred to in this Agreement, the "Firm Closing Date" shall be on the third full business day after the date of the Prospectus, at 9:00 a.m., Milwaukee, Wisconsin time, or at such other date or time not later than ten full business days after the date of the Prospectus as the Representatives and the Attorneys-in-Fact (or either of them) may agree. The certificates for the Firm Shares to be so delivered will be in denominations and registered in such names as the Representatives request by notice to the Attorneys-in-Fact, or either of them, prior to the Firm Closing Date, and such certificates will be made available for checking and packaging at 9:00 a.m., Milwaukee, Wisconsin time on the

-13-

first full business day preceding the Firm Closing Date at a location to be designated by the Representatives.

(c) In addition, on the basis of the representations, warranties and agreements herein contained, and subject to the terms and conditions herein set forth, the Selling Shareholder hereby agrees to sell to the Underwriters, and the Underwriters, severally and not jointly, shall have the right at any time within thirty days after the date of the Prospectus to purchase up to the number of Option Shares from the Selling Shareholder at the purchase price per share to be paid for the Firm Shares, for use solely in covering any over-allotments made by the Underwriters in the sale and distribution of the Firm Shares. The option granted hereunder may be exercised upon notice by the Representatives to the Attorneys-in-Fact, or either of them, within thirty days after the date of the Prospectus setting forth the aggregate number of Option Shares to be purchased by the Underwriters and sold by the Selling Shareholder, the names and denominations in which the certificates for such shares are to be registered and the date and place at which such certificates will be delivered. Such date of delivery ("Option Closing Date") shall be determined by the Representatives, provided that the Option Closing Date, which may be the same as the Firm Closing Date, shall not be earlier than the Firm Closing Date and, if after the Firm Closing Date, shall not be earlier than three nor later than ten full business days after delivery of such notice to exercise. Certificates for the Option Shares will be made available for checking and packaging at 9:00 a.m., Milwaukee, Wisconsin time, on the first full business day preceding the Option Closing Date at a location to be designated by the Representatives. The manner of payment for and delivery of (including the denominations of and the names in which certificates are to be registered) the Option Shares shall be the same as for the Firm Shares.

(d) The Representatives have advised the Attorneys-in-Fact that each Underwriter has authorized the Representatives to accept delivery of the Shares and to make payment therefor. It is understood that the Representatives, individually and not as representatives of the Underwriters, may (but shall not be obligated to) make payment for any Shares to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the Firm Closing Date or the Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any obligation under this Agreement. As referred to in this Agreement, "Closing Date" shall mean either the Firm Closing Date or the Option Closing Date.

4. REPRESENTATION OF UNDERWRITERS. The Representatives will act as the representatives for the several Underwriters in connection with the public offering of the Shares, and any action under or in respect of this Agreement taken by the Representatives will be binding upon all of the Underwriters.

5. INFORMATION FURNISHED BY THE UNDERWRITERS. The information set forth in the last paragraph on the outside front cover page of the Prospectus concerning the terms of the offering by the Underwriters, the paragraphs on the inside front cover page of the Prospectus relating to stabilization practices and passive market making, and the concession and reallowance

-14-

amounts appearing under the caption "Underwriting" in the Prospectus constitute all of the information furnished to the Company by and on behalf of the Underwriters for use in connection with the preparation of the Registration Statement and the Prospectus, as such information is referred to in this Agreement.

6. COVENANTS OF THE COMPANY. The Company covenants and agrees with the several Underwriters that:

(a) If the effective time of the Registration Statement is not prior to the execution and delivery of this Agreement, then the Company will use its best efforts to cause the Registration Statement to become effective at the earliest possible time and, upon notification from the Commission that the Registration Statement has become effective, will so advise the Representatives and counsel to the Underwriters promptly. If the effective time of the Registration Statement is prior to the execution and delivery of this Agreement and any information shall have been omitted therefrom in reliance upon Rule 430A, the Company, at the earliest possible time, will furnish the Representatives with a copy of the Prospectus to be filed by the Company with the Commission to comply with Rule 424(b) and Rule 430A under the Act and, if the Representatives do not object to the contents thereof, will comply with such Rules. Upon compliance with such Rules, the Company will so advise the Representatives promptly. The Company will advise the Representatives and counsel to the Underwriters and the Attorneys-in-Fact promptly of the issuance by the Commission or any state securities commission of any stop order suspending the effectiveness of the Registration Statement or of the institution of any proceedings for that purpose, or of any notification of the suspension of qualification of the Shares for sale in any jurisdiction or the initiation or threatening of any proceedings for that purpose, and will also advise the Representatives and counsel to the Underwriters and the Attorneys-in-Fact promptly of any request of the Commission for amendment or supplement of the Registration Statement, of any Preliminary Prospectus or of the Prospectus, or for additional information, and the Company will not file any amendment or supplement to the Registration Statement (either before or after it becomes effective), to any Preliminary Prospectus or to the Prospectus (including a prospectus filed pursuant to Rule 424(b)), or file any document under the Exchange Act before the termination of the public offering of the Shares by the Underwriters if such document would be deemed to be incorporated by reference in the Registration Statement, if the Representatives have not been furnished with a copy prior to such filing (with a reasonable opportunity to review such amendment or supplement) or if the Representatives object to such filing.

(b) If, at any time when a prospectus relating to the Shares is required by law to be delivered in connection with sales by an Underwriter or dealer, any event occurs as a result of which the Prospectus would include an untrue statement of a material fact, or would omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, or if it is necessary at any time to supplement the Prospectus to comply with the Act or to file under the Exchange Act any document that would be deemed to be incorporated by reference in the Registration Statement to comply with the Act or the Exchange Act, the Company promptly will

-15-

advise the Representatives and counsel to the Underwriters and the Attorneys-in-Fact thereof and will promptly prepare and file with the Commission, at its expense, an amendment to the Registration Statement or file such document that will correct such statement or omission or an amendment that will effect such compliance; and, if any Underwriter is required to deliver a prospectus after the effective date of the Registration Statement, the Company, upon request of the Representatives, will prepare promptly such prospectus or prospectuses as may be necessary to permit compliance with the requirements of
Section 10(a)(3) of the Act. The Company consents to the use, in accordance with the provisions of the Act and with the Blue Sky Laws of the jurisdictions in which the Shares are offered by the several Underwriters and by dealers, of each Preliminary Prospectus.

(c) Neither the Company nor any Subsidiary will, prior to the Option Closing Date, if any, incur any liability or obligation, direct or contingent, or enter into any material transaction, other than in the ordinary course of business, or enter into any transaction with an "affiliate," as defined in Rule 405 under the Act, that is required to be described in the Prospectus pursuant to Item 404 of Regulation S-K under the Act, except as described in the Prospectus.

(d) Neither the Company nor any Subsidiary will, prior to the Option Closing Date, if any, acquire any of the Common Stock nor will the Company declare or pay any dividend or make any other distribution upon its Common Stock payable to shareholders of record on a date prior to the Option Closing Date, except as described in the Prospectus.

(e) The Company will make generally available to its security holders and the Representatives an earnings statement as soon as practicable, but in no event later than sixty days after the end of its fiscal quarter in which the first anniversary of the effective date of the Registration Statement occurs, covering a period of twelve consecutive calendar months beginning after the effective date of the Registration Statement, which will satisfy the provisions of the last paragraph of Section 11(a) of the Act and Rule 158 promulgated thereunder.

(f) During such period as a prospectus is required by law to be delivered in connection with sales by an Underwriter or dealer, the Company will furnish to the Representatives, at the expense of the Company, copies of the Registration Statement, the Prospectus, any Preliminary Prospectus and all amendments and supplements to any such documents, including any document filed under the Exchange Act and deemed to be incorporated by reference in the Registration Statement, in each case as soon as available and in such quantities as the Representatives may reasonably request.

(g) The Company will cooperate with the Representatives and counsel to the Underwriters in qualifying or registering the Shares for sale under the Blue Sky Laws of such jurisdictions as the Representatives designate and will continue such qualifications or registrations in effect so long as reasonably requested by the Representatives to effect the distribution of the Shares, except that the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any such jurisdiction where it

-16-

is not presently qualified. In each jurisdiction where any of the Shares shall have been qualified as provided above, the Company will file such reports and statements as may be required to continue such qualification for a period of not less than one year from the date of the Prospectus. The Company shall promptly prepare and file with the Commission, from time to time, such reports as may be required to be filed by the Act and the Exchange Act, and the Company shall comply in all respects with the undertakings given by the Company in connection with the qualification or registration of the Shares for offering and sale under the Blue Sky Laws.

(h) During the period of three years from the date of the Prospectus, the Company will furnish to each of the Representatives and to each of the other Underwriters who may so request, as soon as available, each report, statement or other document of the Company or its Board of Directors mailed to its shareholders or filed with the Commission, and such other information concerning the Company as the Representatives may reasonably request.

(i) The Company shall take all necessary or appropriate action within its power to maintain the authorization for trading of the Common Stock as a Nasdaq National Market security, or take such action to authorize the Common Stock for listing on the New York Stock Exchange or the American Stock Exchange, for a period of at least thirty-six months after the date of the Prospectus.

(j) Except for the issuance and sale by the Company of Common Stock upon exercise of presently existing outstanding stock options and the grant of employee stock options pursuant to the Company's 1996 Stock Option Plan (provided that none of such options shall be exercisable for a period of 90 days after the date of the Prospectus), the Company shall not, for a period of 90 days after the date of the Prospectus, without the prior written consent of Cleary Gull, directly or indirectly, offer, sell or otherwise dispose of, contract to sell or otherwise dispose of, or cause or in any way permit to be sold or otherwise disposed of, any: (i) shares of Common Stock; (ii) rights to purchase shares of Common Stock; or (iii) securities that are convertible or exchangeable into shares of Common Stock.

(k) The Company will maintain a transfer agent and, if required by law or the rules of The Nasdaq Stock Market or any national securities exchange on which the Common Stock is listed, a registrar (which, if permitted by applicable laws and rules, may be the same entity as the transfer agent) for its Common Stock.

(l) If at any time when a prospectus relating to the Shares is required to be delivered under the Act, any rumor, publication or event relating to or affecting the Company shall occur as a result of which, in the opinion of Cleary Gull, the market price of the Common Stock has been or is likely to be materially affected (regardless of whether such rumor, publication or event necessitates a supplement to the Prospectus), the Company will, after written notice from Cleary Gull advising the Company of any of the matters set forth above, promptly consult with Cleary Gull concerning the advisability and substance of, and, if the Company and Cleary Gull determine that it is appropriate, disseminate, a press release or other public statement responding to or commenting on, such rumor, publication or event.

-17-

(m) The Company will comply or cause to be complied with the conditions to the obligations of the Underwriters in Section 9 hereof.

7. COVENANTS OF THE SELLING SHAREHOLDER. The Selling Shareholder covenants and agrees with the several Underwriters and the Company as follows:

(a) If the effective time of the Registration Statement is not prior to the execution and delivery of this Agreement, the Selling Shareholder will cooperate to the extent necessary to cause the Registration Statement to become effective at the earliest possible time; and the Selling Shareholder will do and perform all things to be done and performed by such Selling Shareholder prior to each Closing Date, pursuant to this Agreement or the Durable Power of Attorney and Custody Agreement.

(b) The Selling Shareholder agrees to deliver to the Custodian on or prior to the First Closing Date a properly completed and executed United States Treasury Department Form W-9 (or other applicable substitute form or statement specified by Treasury Department regulations in lieu thereof).

(c) The Selling Shareholder will pay all federal and other taxes, if any, on the transfer or sale of the Shares.

(d) For a period of 360 days after the date of the Prospectus, the Selling Shareholder will not, without the prior written consent of Cleary Gull, directly or indirectly, offer, sell, transfer, or pledge, contract to sell, transfer or pledge or cause or in any way permit to be sold, transferred, pledged or otherwise disposed of any: (i) shares of Common Stock;
(ii) rights to purchase shares of Common Stock (including, without limitation, shares of Common Stock that may be issued upon exercise of a stock option, warrant or other convertible security); or (iii) securities that are convertible or exchangeable into shares of Common Stock, except that the Selling Shareholder may, during such 360-day period, make bona fide gifts of Common Stock to donees who agree in writing with the Underwriters to be subject to the same restrictions as set forth herein.

(e) The Selling Shareholder will furnish any documents, instruments or other information that the Representatives may reasonably request in connection with the sale and transfer of the Shares to the Underwriters.

(f) If the sale to the Underwriters of the Firm Shares is not consummated for any reason other than termination of this Agreement pursuant to Section 12 hereof or pursuant to Section 14(b) or 14(d) hereof, without limiting any other rights the Underwriters may have, the Company agrees to reimburse the Underwriters upon demand for all out-of-pocket expenses (including reasonable fees and expenses of counsel for the Underwriters) that shall have been incurred by the Underwriters in connection with the proposed purchase and sale of the Shares, and the provisions of Sections 8 and 11 hereof shall at all times be effective and apply.

-18-

(g) If the sale to the Underwriters of the Firm Shares is not consummated for any reason other than termination of this Agreement by the Underwriters pursuant to Section 14 hereof, then the Company and/or the Selling Shareholder, as the case may be, shall offer to hire, on customary terms and conditions, all Unreimbursed Representatives (as such term is defined below) as financial advisors in connection with the first sale, subsequent to the date hereof, of a material amount of securities of the Comany (without limitation, a transaction by the Selling Shareholder pursuant to Rule 144 under the Act would not be a sale of a material amount of Company securities, but a business combination involving the Company would be a sale of a material amount of Company securities) by the Company and/or the Selling Shareholder, as the case may be, in a private or public transaction made in good faith. For purposes of this Agreement, an "Unreimbursed Representative" shall be a Representative which has not been reimbursed for its allocated share of expenses in connection with the transactions contemplated hereby under Section 7(f) or otherwise, it being agreed that the Company and/or the Selling Shareholder can avoid the obligation imposed on each of them under this Section 7(g) as to any Representative by reimbursing such Representative for its allocated share of expenses relating to the transactions contemplated hereby.

8. PAYMENT OF EXPENSES. Whether or not the transactions contemplated hereunder are consummated or this Agreement becomes effective, or if this Agreement is terminated for any reason, the Selling Shareholder will pay the costs, fees and expenses incurred in connection with the public offering of the Shares. Such costs, fees and expenses to be paid by the Selling Shareholder include, without limitation:

(a) All costs, fees and expenses (excluding the expenses incurred by the Underwriters and the reasonable legal fees and disbursements of counsel for the Underwriters, but including such fees and disbursements described in subsection (b) of this Section 8) incurred in connection with the performance of the Company's obligations hereunder, including without limiting the generality of the foregoing: the registration fees related to the filing of the Registration Statement with the Commission; the fees and expenses related to the quotation of the Shares on the Nasdaq National Market or other national securities exchange; the fees and expenses incurred in connection with the preparation, printing, shipping and delivery of the Registration Statement, each Preliminary Prospectus and the Prospectus (including all exhibits and financial statements) and all agreements and supplements provided for herein, this Agreement and the Preliminary and Supplemental Blue Sky Memoranda and the Durable Power of Attorney and Custody Agreement, including, without limitation, shipping expenses via overnight delivery and/or courier service to comply with applicable prospectus delivery requirements; and the costs and expenses associated with the production of materials related to, and travel expenses incurred by the management of the Company in connection with, the various meetings to be held between the Company's management and prospective investors.

(b) All registration fees and expenses, including reasonable legal fees and disbursements of counsel for the Underwriters incurred in connection with qualifying or registering all or any part of the Shares for offer and sale under the Blue Sky Laws and the clearing of the public offering and the underwriting arrangements evidenced hereby with the NASD, provided that

-19-

Selling Shareholder shall not be liable for legal fees of counsel for the Underwriters under this subsection (b) to the extent such fees exceed $12,500 (which amount shall not include filing fees required under the Blue Sky Laws and the rules of the NASD or other disbursements).

(c) All transfer or sales tax imposed upon the transfer and sale of the Selling Shareholder's Shares to the Underwriters and for all fees and expenses of the Attorneys-in-Fact and the Custodian. All costs and expenses incident to the performance of the Selling Shareholder's obligations hereunder that are not otherwise specifically provided for in this Section will be borne and paid solely by the Selling Shareholder.

9. CONDITIONS TO THE OBLIGATIONS OF THE UNDERWRITERS. The obligations of the several Underwriters under this Agreement shall be subject to the accuracy of the representations and warranties on the part of the Company and the Selling Shareholder herein set forth as of the date hereof and as of each Closing Date, to the accuracy of the statements of the Company's officers, the Selling Shareholder and the Attorneys-in-Fact on behalf of the Selling Shareholder made pursuant to the provisions hereof, to the performance by the Company and the Selling Shareholder of their respective obligations hereunder, and to the following additional conditions, unless waived in writing by the Representatives:

(a) The Registration Statement shall have been declared effective by the Commission not later than 10:00 a.m., Washington, D.C. time, on the date of this Agreement, or such later time as shall have been consented to by the Representatives; all filings required by Rules 424(b) and 430A under the Act shall have been timely made; no stop order suspending the effectiveness of the Registration Statement shall have been issued by the Commission or any state securities commission nor, to the knowledge of the Company, shall any proceedings for that purpose have been initiated or threatened; and any request of the Commission or any state securities commission for including of additional information in the Registration Statement, or otherwise, shall have been complied with to the satisfaction of the Representatives.

(b) Since the dates as of which information is given in the Registration Statement:

(i) there shall not have occurred any adverse change, or development involving a prospective adverse change, in the condition (financial or otherwise), management, business, prospects, net worth or results of operations of the Company and the Subsidiaries, whether or not arising from transactions in the ordinary course of business; and

(ii) neither the Company nor any Subsidiary shall have sustained any loss or interference from any labor dispute, strike, fire, flood, windstorm, accident or other calamity (whether or not insured) or from any court or governmental action, order or decree,

-20-

the effect of which on the Company, in any such case described in clause (i) or
(ii) above, is in the opinion of the Representatives so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares on the terms and in the manner contemplated in the Registration Statement and Prospectus.

(c) The Representatives shall not have advised the Company that the Registration Statement or the Prospectus contains (or incorporates by reference) an untrue statement of fact that, in the opinion of the Representatives or counsel for the Underwriters, is material, or omits to state a fact that, in the opinion of the Representatives or such counsel, is material and is required to be stated therein or necessary to make the statements therein not misleading.

(d) The Representatives shall have received an opinion of Keating, Muething & Klekamp, counsel for the Company, addressed to the Representatives, as the representatives of the Underwriters, and dated the Firm Closing Date or the Option Closing Date, as the case may be, to the effect that:

(i) the Company and each of the Subsidiaries have been duly organized and are validly existing as corporations in good standing under the laws of their respective jurisdictions of incorporation and are duly qualified to transact business as foreign corporations and are in good standing under the laws of all other jurisdictions where the ownership or leasing of their respective properties or the conduct of their respective businesses requires such qualification, except where the failure to be so qualified does not amount to a material liability or disability to the Company and the Subsidiaries, taken as a whole;

(ii) the Company and each of the Subsidiaries have corporate power to own or lease their respective properties and conduct their respective businesses as described in the Registration Statement and the Prospectus, and the Company has corporate power to enter into this Agreement and to carry out all the terms and provisions hereof to be carried out by it;

(iii) the issued shares of capital stock of each of the Subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned beneficially by the Company free and clear of any perfected security interests or, to the best knowledge of such counsel, any other security interests, liens, encumbrances, equities or claims; the outstanding quotas of MDE, to the extent necessary or applicable, have been duly authorized and validly issued, are fully paid and nonassessable and are owned beneficially as set forth in Exhibit A hereto free and clear of any security interests, liens, encumbrances, equities or claims; there are no preemptive, preferential or, to such counsel's knowledge, other rights to subscribe for or purchase any shares of capital stock of any Subsidiary; and to such counsel's knowledge, no shares of capital stock of any Subsidiary have been issued in violation of such rights;

-21-

(iv) the authorized, issued and outstanding capital stock of the Company is as set forth in the Prospectus; all of the issued shares of capital stock of the Company, including, without limitation, the Shares, have been duly authorized and validly issued and are fully paid and nonassessable, have been issued in compliance with all applicable federal and state securities laws and were not issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities; no holders of outstanding shares of capital stock of the Company are entitled as such to any preemptive or other rights to subscribe for any of the Shares; and no holders of securities of the Company are entitled to have such securities registered under the Registration Statement; and the certificates for the Shares to be delivered hereunder are in due and proper form and conform to the requirements of applicable law;

(v) the statements set forth under the heading "Description of Capital Stock" in the Prospectus, insofar as such statements purport to summarize certain provisions of the capital stock of the Company, provide a fair summary of such provisions; and the statements set forth under the headings "Business - Government Regulations" and "Business - Legal Proceedings" in the Prospectus, insofar as such statements constitute a summary of the legal matters, documents or proceedings referred to therein, provide a fair summary of such legal matters, documents and proceedings therein discussed;

(vi) the execution, delivery and performance of this Agreement have been duly authorized by all necessary corporate action of the Company and this Agreement has been duly executed and delivered by the Company; and this Agreement is a legal, valid and binding agreement of the Company enforceable against the Company in accordance with its terms, except that rights to indemnity or contribution may be limited by applicable law and except as enforceability of this Agreement may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors' rights generally, and by equitable principles limiting the right to specific performance or other equitable relief;

(vii) after due inquiry and to the best knowledge of such counsel, no legal or governmental proceedings are pending to which the Company or any of the Subsidiaries is a party or to which the property of the Company or any of the Subsidiaries is subject that are required to be described in the Registration Statement or the Prospectus and that are not described therein, and, to the best knowledge of such counsel, no such proceedings have been threatened against the Company or any of the Subsidiaries or with respect to any of their respective properties; and no contract or other document is required to be described in the Registration Statement or the Prospectus or to be filed as an exhibit to the Registration Statement that is not described therein or filed as required;

(viii) the compliance by the Company with the provisions of this Agreement and the consummation of the transactions herein contemplated do not (A)

-22-

require the consent, approval, authorization, registration or qualification of or with any governmental authority or regulatory body, except such as have been obtained and such as may be required under the Blue Sky Laws or by the NASD, as to which counsel need not express an opinion, or (B) conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under, any indenture, mortgage, deed of trust, lease or other agreement or instrument, known to such counsel, to which the Company or any of the Subsidiaries is a party or by which the Company or any of the Subsidiaries or any of their respective properties are bound, or the charter documents, Code of Regulations or by-laws of the Company or any of the Subsidiaries, or any statute or any judgment, decree, order, rule or regulation of any court or other governmental authority or any arbitrator known to such counsel and applicable to the Company or any of the Subsidiaries;

(ix) the Registration Statement is effective under the Act; any required filing of the Prospectus pursuant to Rule 424(b) has been made in the manner and within the time period required by Rule 424(b); no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto and no order directed at any document incorporated by reference in the Registration Statement or the Prospectus or any amendment or supplement thereto has been issued; and no proceedings for that purpose have been instituted or threatened or, to the best knowledge of such counsel, are contemplated by the Commission;

(x) the Registration Statement originally filed with respect to the Shares and each amendment thereto and the Prospectus (in each case, including the documents incorporated by reference therein but not including the financial statements and other financial information contained therein, as to which such counsel need express no opinion) comply as to form in all material respects with the applicable requirements of the Act, the Exchange Act and the respective rules and regulations of the Commission thereunder;

(xi) the Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses;

(xii) this transaction will not cause the Company to become an "investment company" subject to registration as such term is defined under the 1940 Act; and

(xiii) the Common Stock is a Nasdaq National Market security on The Nasdaq Stock Market and is registered under the Exchange Act.

Such counsel shall also state that they have no reason to believe that the Registration Statement, as of its effective date, contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements therein not misleading or that the Prospectus, as of its date or the date of such opinion, included or includes any untrue statement of a material fact or omitted or omits to state

-23-

a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

In rendering any such opinion, such counsel may rely, as to matters of fact, to the extent such counsel deems proper, on certificates of responsible officers of the Company and public officials and, as to matters involving the application of laws of any jurisdiction other than the State of Ohio or the United States, to the extent satisfactory in form and scope to counsel for the Underwriters, upon the opinion of local counsel reasonably satisfactory to counsel for the Underwriters, and copies of such opinion shall be delivered to the Underwriters and counsel for the Underwriters. Such counsel may state that they are not passing on matters relating to patents and trademarks.

References to the Registration Statement and the Prospectus in this subsection (d) shall include any amendment or supplement thereto at the date of such opinion.

(e) The Representatives shall have received an opinion from Keating, Muething & Klekamp, counsel for the Selling Shareholder, dated the Firm Closing Date or the Option Closing Date, as the case may be, to the effect that:

(i) each of this Agreement and the Durable Power of Attorney and Custody Agreement has been duly authorized, executed and delivered by or on behalf of the Selling Shareholder and such agreement constitutes the valid and binding agreement of the Selling Shareholder, enforceable in accordance with its respective terms, except that rights to indemnity or contribution thereunder may be limited by applicable law and except as enforceability of such agreement may be limited by bankruptcy or similar laws generally affecting the rights of creditors and by equitable principles limiting the right to specific performance or other equitable relief;

(ii) the execution and delivery of this Agreement and the Durable Power of Attorney and Custody Agreement and the consummation of the transactions herein and therein contemplated will not constitute a breach, or be in contravention, of any provision of any agreement, franchise, license, mortgage, deed of trust or other instrument to which the Selling Shareholder is a party or by which the Selling Shareholder or the Selling Shareholder's property may be bound or affected, or violate any order or decree of any court, regulatory or governmental body, administrative body or instrumentality of the United States or other jurisdiction having jurisdiction over the Selling Shareholder;

(iii) the Selling Shareholder has full legal right, power and authority, and has secured any consent, approval, authorization and order required to enter into and perform this Agreement and the Durable Power of Attorney and Custody Agreement and to sell, assign, transfer and deliver title to the Shares to be sold by the Selling Shareholder as provided herein; and upon delivery to the Underwriters or upon the order of the Representatives against payment of the agreed consideration therefor in accordance with the provisions of this Agreement, the Underwriters will acquire good and

-24-

marketable title to the Shares to be sold hereunder by such Selling Shareholder, free and clear of all voting trust arrangements, liens, encumbrances, security interests, equities, claims and community or marital property rights; and

(iv) to such counsel's knowledge, the information concerning the Selling Shareholder contained in the Prospectus under the caption "Principal Shareholders and Selling Shareholder" complies in all material respects with the Act.

In rendering such opinion, counsel for the Selling Shareholder may rely, to the extent counsel deems such reliance proper, as to matters of fact upon a certificate of the Selling Shareholder, and copies of such certificate shall be furnished to the Representatives and counsel for the Underwriters on or before each Closing Date.

(f) The Representatives shall have received an opinion of Foley & Lardner, counsel for the Underwriters, dated the Firm Closing Date or the Option Closing Date, as the case may be, with respect to the issuance and sale of the Shares, the Registration Statement and other related matters as the Representatives may require, and the Company shall have furnished to such counsel such documents and shall have exhibited to them such papers and records as they request for the purpose of enabling them to pass upon such matters.

(g) The Representatives shall have received on each Closing Date, a certificate of John A. Kraeutler, President and Chief Operating Officer, and Gerard Blain, Vice President and Chief Financial Officer, of the Company, to the effect that:

(i) The representations and warranties of the Company and the Selling Shareholder set forth in Section 2(a) hereof are true and correct as of the date of this Agreement and as of the date of such certificate, and the Company has complied with all the agreements and satisfied all the conditions to be performed or satisfied by it at or prior to the date of such certificate;

(ii) The Commission has not issued an order preventing or suspending the use of the Prospectus or any Preliminary Prospectus or any amendment or supplement thereto; no stop order suspending the effectiveness of the Registration Statement has been issued; and to the knowledge of the respective signatories, no proceedings for that purpose have been initiated or are pending or contemplated under the Act or under the Blue Sky Laws of any jurisdiction;

(iii) Each of the respective signatories has carefully examined the Registration Statement and the Prospectus, and any amendment or supplement thereto, including any documents filed under the Exchange Act and deemed to be incorporated by reference in the Registration Statement, and such documents contain all statements required to be stated therein, and do not include any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading, and since the date on which the Registration Statement

-25-

was initially filed, no event has occurred that was required to be set forth in an amendment or supplement to the Prospectus or in an amendment to the Registration Statement that has not been so set forth, and there has been no document required to be filed under the Exchange Act that upon such filing would be deemed to be incorporated by reference in the Registration Statement that has not been so filed; and

(iv) Since the date on which the Registration Statement was initially filed with the Commission, there has not occurred any Material Adverse Change or development involving, or which could be expected to involve, a Material Adverse Change, whether or not arising from transactions in the ordinary course of business, except as disclosed in the Prospectus and the Registration Statement as heretofore amended or (but only if the Representatives expressly consent thereto in writing) as disclosed in an amendment or supplement thereto filed with the Commission and delivered to the Representatives after the execution of this Agreement; since such date and except as so disclosed or in the ordinary course of business, the Company has not incurred any liability or obligation, direct or indirect, or entered into any transaction which is material to the Company; since such date and except as so disclosed, there has not been any change in the outstanding capital stock of the Company, or any change that is material to the Company in the short-term debt or long-term debt of the Company; since such date and except as so disclosed, the Company has not acquired any of the Common Stock or other capital stock of the Company nor has the Company declared or paid any dividend, or made any other distribution, upon its outstanding Common Stock payable to shareholders of record on a date prior to such Closing Date; since such date and except as so disclosed, the Company has not incurred any material contingent obligations, and no material litigation has commenced or been threatened against the Company; and, since such date and except as so disclosed, the Company has not sustained any material loss or interference from any strike, fire, flood, windstorm, accident or other calamity (whether or not insured) or from any court or governmental action, order or decree.

The delivery of the certificate provided for in this subsection (g) shall be and constitute a representation and warranty of the Company as to the facts required in the immediately foregoing clauses (i),
(ii), (iii) and (iv) to be set forth in said certificate.

(h) The Representatives shall have received a certificate from the Selling Shareholder (which may be signed by such Selling Shareholder's Attorneys-in-Fact, or either of them), dated the Firm Closing Date or the Option Closing Date, as the case may be, to the effect that: (i) the representations and warranties of such Selling Shareholder in Sections 2 and 3 of this Agreement are true and correct as of the date of this Agreement and as of the date of such certificate, as if again made on and as of such Closing Date, and the Selling Shareholder has complied with all of the agreements and satisfied all of the conditions to be performed or satisfied by the Selling Shareholder at or prior to such Closing Date; and (ii) the Selling Shareholder has no reason to believe that the Registration Statement or any amendment thereto, including any documents filed under the Exchange Act and deemed to be incorporated by

-26-

reference in the Registration Statement, at the time it was declared effective by the Commission contained any untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements therein not misleading, or that the Prospectus, as amended or supplemented, including any documents filed under the Exchange Act and deemed to be incorporated by reference in the Registration Statement, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

(i) At the time this Agreement is executed and also on each Closing Date, there shall be delivered to the Representatives a letter addressed to the Representatives, as representatives of the Underwriters, from Arthur Andersen LLP, the Company's independent accountants, the first letter to be dated the date of this Agreement, the second letter to be dated the Firm Closing Date and the third letter (if applicable) to be dated the Option Closing Date, which shall be in form and substance satisfactory to the Representatives and shall, without limitation, contain financial information concerning the Company and the Subsidiaries as of a date within five days of the date of such letter. There shall not have been any change or decrease set forth in any of the letters referred to in this subsection (i) that makes it impracticable or inadvisable in the judgment of the Representatives to proceed with the public offering or purchase of the Shares as contemplated hereby.

(j) The Shares shall have been qualified or registered for sale under the Blue Sky Laws of such jurisdictions as shall have been specified by the Representatives, and the underwriting terms and arrangements for the offering shall have been cleared by the NASD.

(k) Such further certificates and documents as the Representatives may reasonably request (including certificates of officers of the Company).

All such opinions, certificates, letters and documents shall be in compliance with the provisions hereof only if they are satisfactory to the Representatives and to Foley & Lardner, counsel for the Underwriters, which Representatives and Firm agree to act reasonably in so determining. The Company and the Selling Shareholder shall furnish the Representatives with such manually signed or conformed copies of such opinions, certificates, letters and documents as the Representatives may reasonably request.

If any condition to the Underwriters' obligations hereunder to be satisfied prior to or at either Closing Date is not so satisfied, this Agreement at the election of the Representatives will terminate upon notification to the Company and the Attorneys-in-Fact, or any one of them, for the Selling Shareholder, without liability on the part of any Underwriter, including the Representatives, the Company or the Selling Shareholder except for the provisions of Section 7(f) hereof, the expenses to be paid by the Selling Shareholder pursuant to Section 8 hereof and except to the extent provided in Section 11 hereof.

10. MAINTAIN EFFECTIVENESS OF REGISTRATION STATEMENT. The Company will use its best efforts and the Selling Shareholder will use his best efforts to prevent the issuance of any

-27-

stop order suspending the effectiveness of the Registration Statement and, if such stop order is issued, to obtain as soon as possible the lifting thereof.

11. INDEMNIFICATION.

(a) The Company and the Selling Shareholder, jointly and severally, agree to indemnify and hold harmless each Underwriter and each person, if any, who controls any Underwriter within the meaning of the Act or the Exchange Act from and against any losses, claims, damages, expenses, liabilities or actions in respect thereof ("Claims"), joint or several, to which such Underwriter or each such controlling person may become subject under the Act, the Exchange Act, Blue Sky Laws or other federal or state statutory laws or regulations, at common law or otherwise (including payments made in settlement of any litigation), insofar as such Claims arise out of or are based upon any breach of any representation, warranty or covenant made by the Company and/or the Selling Shareholder in this Agreement, or any untrue statement or alleged untrue statement of any material fact contained in the Registration Statement, any Preliminary Prospectus, the Prospectus or any amendment or supplement thereto, or in any application filed under any Blue Sky Law or other document executed by the Company for that purpose or based upon written information furnished by the Company and filed in any state or other jurisdiction to qualify any or all of the Shares under the securities laws thereof (any such document, application or information being hereinafter called a "Blue Sky Application") or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading. The Company and the Selling Shareholder, jointly and severally, agree to reimburse each Underwriter and each such controlling person for any legal fees or other expenses incurred by such Underwriter or any such controlling person in connection with investigating or defending any such Claim; provided, however, that the Company and the Selling Shareholder will not be liable in any such case to the extent that any such Claim arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Prospectus or supplement thereto or in any Blue Sky Application in reliance upon and in conformity with the written information furnished to the Company pursuant to
Section 5 of this Agreement and provided, further, that with respect to any untrue statement or omission, or alleged untrue statement or omission, made in any Preliminary Prospectus, the indemnity agreement contained in this subsection 11 (a) shall not inure to the benefit of any Underwriter from whom the person asserting any such losses, claims, damages or liabilities purchased shares if such untrue statement or omission or alleged untrue statement or omission made in such Preliminary Prospectus is eliminated or remedied in the Prospectus (as amended or supplemented if the Company shall have furnished any amendments or supplements thereto to the Underwriters) and such loss, claim, damage or liability of such Underwriter results from the fact that there was not furnished to such person, at or prior to the written confirmation of the sale of such Shares to such person, a copy of the Prospectus (as so amended or supplemented) if the Company had previously furnished copies thereof to such Underwriter. The indemnification obligations of the Company and the Selling Shareholder as provided above are in addition to and in no way limit any liabilities the Company and the Selling Shareholder may otherwise have.

(b) Each Underwriter, severally and not jointly, will indemnify and hold harmless the Company, each of its directors and each of its officers who signs the Registration Statement, and each person, if any, who controls the Company within the meaning of the Act or the Exchange Act and the Selling Shareholder against any Claim to which the Company, or any such director, officer, controlling person or the Selling Shareholder may become subject under the Act, the Exchange Act, Blue Sky Laws or other federal or state statutory laws or regulations, at common law or otherwise (including payments made in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter and Cleary Gull), insofar as such Claim arises out of or is based upon any untrue or alleged untrue statement of any material fact contained in the Registration Statement, any Preliminary

-28-

Prospectus, the Prospectus, or any amendment or supplement thereto, or in any Blue Sky Application, or arises out of or is based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any Preliminary Prospectus, the Prospectus, or any amendment or supplement thereto, or in any Blue Sky Application, in reliance solely upon and in conformity with the written information furnished by the Representatives to the Company pursuant to Section 5 of this Agreement. Each Underwriter will severally reimburse any legal fees or other expenses incurred by the Company, or any such director, officer, controlling person or the Selling Shareholder in connection with investigating or defending any such Claim, and from any and all Claims solely resulting from failure of an Underwriter to deliver a Prospectus, if the person asserting such Claim purchased Shares from such Underwriter and a copy of the Prospectus (as then amended if the Company shall have furnished any amendments thereto) was not sent or given by or on behalf of such Underwriter to such person, if required by law so to have been delivered, at or prior to the written confirmation of the sale of the Shares to such person, and if the Prospectus (as so amended) would have cured the defect giving rise to such Claim. The indemnification obligations of each Underwriter as provided above are in addition to any liabilities any such Underwriter may otherwise have. Notwithstanding the provisions of this section, no Underwriter shall be required to indemnify or reimburse the Company, or any officer, director, controlling person or Selling Shareholder in an aggregate amount in excess of the total price at which the Shares purchased by any such Underwriter hereunder were offered to the public, less the amount of any damages such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.

(c) Promptly after receipt by an indemnified party under this section of notice of the commencement of any action in respect of a Claim, such indemnified party will, if a Claim in respect thereof is to be made against an indemnifying party under this section, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve an indemnifying party from any liability it may have to any indemnified party under this section or otherwise, except to the extent the indemnifying party is actually prejudiced by the failure to give such notice. In case any such action is brought against any indemnified party, and such indemnified party notifies an indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate in and, to the extent that he, she or it may wish, jointly with all other indemnifying parties, similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party; provided, however, if the defendants in any such action include both the indemnified party and any indemnifying party and the indemnified party shall have reasonably concluded that there may be legal defenses available to the indemnified party and/or other indemnified parties which are different from or additional to those available to any indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened action in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party unless such settlement includes an unconditional release of such indemnified party from all liability on any claims that are the subject matter of such action.

(d) Upon receipt of notice from the indemnifying party to such indemnified party of the indemnifying party's election to assume the defense of such action and upon

-29-

approval by the indemnified party of counsel selected by the indemnifying party, the indemnifying party will not be liable to such indemnified party under this section for any legal fees or other expenses subsequently incurred by such indemnified party in connection with the defense thereof, unless:

(i) the indemnified party shall have employed separate counsel in connection with the assumption of legal defenses in accordance with the proviso to the last sentence of subsection (c) of this Section (it being understood, however, that the indemnifying party shall not be liable for the legal fees and expenses of more than one separate counsel, approved by Cleary Gull, if one or more of the Underwriters or their controlling persons are the indemnified parties);

(ii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after the indemnified party's notice to the indemnifying party of commencement of the action; or

(iii) the indemnifying party has authorized the employment of counsel at the expense of the indemnifying party.

(e) If the indemnification provided for in this section is unavailable to an indemnified party under subsection (a) or (b) hereof in respect of any Claim referred to therein, then each indemnifying party, in lieu of indemnifying such indemnified party, shall, subject to the limitations hereinafter set forth, contribute to the amount paid or payable by such indemnified party as a result of such Claim:

(i) in such proportion as is appropriate to reflect the relative benefits received by the Company, the Selling Shareholder and the Underwriters from the offering of the Shares; or

(ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above, but also the relative fault of the Company, the Selling Shareholder and the Underwriters in connection with the statements or omissions which resulted in such Claim, as well as any other relevant equitable considerations.

The relative benefits received by each of the Company, the Selling Shareholder and the Underwriters shall be deemed to be in such proportion so that the Underwriters are responsible for that portion represented by the percentage that the amount of the underwriting discounts and commissions per share appearing on the cover page of the Prospectus bears to the public offering price per share appearing thereon, and the Company (including its officers and directors and controlling persons), and the Selling Shareholder is responsible for the remaining

-30-

portion. The relative fault of the Company, the Selling Shareholder and the Underwriters shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company, the Selling Shareholder or the Underwriters and the parties' relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the Claims referred to above shall be deemed to include, subject to the limitations set forth in subsections (c) and (d) of this section, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim.

(f) The Company, the Selling Shareholder and the Underwriters agree that it would not be just and equitable if contribution pursuant to this section were determined by pro rata or per capita allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method or allocation which does not take into account the equitable considerations referred to in subsection (e) of this Section. Notwithstanding the other provisions of this section, no Underwriter shall be required to contribute any amount that is greater than the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of section 11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters' obligations to contribute pursuant to this section are several in proportion to their respective underwriting commitments and not joint.

12. DEFAULT OF UNDERWRITERS. It shall be a condition to the obligations of each Underwriter to purchase the Shares in the manner as described herein, that, except as hereinafter provided in this section, each of the Underwriters shall purchase and pay for all the Shares agreed to be purchased by such Underwriter hereunder upon tender to the Representatives of all such Shares in accordance with the terms hereof. If any Underwriter or Underwriters default in their obligations to purchase Shares hereunder on either the Firm Closing Date or the Option Closing Date and the aggregate number of Shares which such defaulting Underwriter or Underwriters agreed but failed to purchase does not exceed ten percent (10%) of the total number of Shares which the Underwriters are obligated to purchase on such Closing Date, the Representatives may make arrangements for the purchase of such Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such Closing Date the nondefaulting Underwriters shall be obligated severally, in proportion to their respective commitments hereunder, to purchase the Shares which such defaulting Underwriters agreed but failed to purchase on such Closing Date. If any Underwriter or Underwriters so default and the aggregate number of Shares with respect to which such default or defaults occur is greater than ten percent (10%) of the total number of Shares which the Underwriters are obligated to purchase on such Closing Date, and arrangements satisfactory to the Representatives for the purchase of such Shares by other persons are not made within thirty-six hours after such default, then this Agreement will terminate without liability on the part of any nondefaulting

-31-

Underwriter, the Company or the Selling Shareholder, except for the expenses to be paid by the Company and the Selling Shareholder pursuant to Section 8 hereof and except to the extent provided in Section 11 hereof.

In the event that Shares to which a default relates are to be purchased by the nondefaulting Underwriters or by another party or parties, the Representatives shall have the right to postpone the Firm Closing Date or the Option Closing Date, as the case may be, for not more than seven business days in order that the necessary changes in the Registration Statement, Prospectus and any other documents, as well as any other arrangements, may be effected. As used in this Agreement, the term "Underwriter" includes any person substituted for an Underwriter under this Section. Nothing herein will relieve a defaulting Underwriter from liability for its default.

13. EFFECTIVE DATE. This Agreement shall become effective upon the execution and delivery of this Agreement by the parties hereto. Such execution and delivery shall include an executed copy of this Agreement sent by telecopier, facsimile transmission or other means of transmitting written documents.

14. TERMINATION. Without limiting the right to terminate this Agreement pursuant to any other provision hereof, this Agreement may be terminated by the Representatives prior to or on the Firm Closing Date and the over-allotment option from the Company and the Selling Shareholder referred to in Section 3(c) hereof, if exercised, may be cancelled by the Representatives at any time prior to or on the Option Closing Date, if in the judgment of the Representatives, payment for and delivery of the Shares is rendered impracticable or inadvisable because:

(a) trading in the Common Stock shall have been suspended by the Commission or the Nasdaq National Market; additional restrictions, not in force and effect on the date hereof, shall have been imposed upon trading in securities generally; minimum or maximum prices shall have been established on the New York Stock Exchange, the American Stock Exchange or the Nasdaq National Market; or trading in securities generally shall have been suspended or materially limited on either such exchange or on the Nasdaq National Market;

(b) a general banking moratorium shall have been established by either federal or state authorities in New York, Ohio or Wisconsin;

(c) any event shall have occurred or shall exist which makes untrue or incorrect in any material respect any statement or information contained in the Registration Statement or which is not reflected in the Registration Statement but should be reflected therein to make the statements or information contained therein not misleading in any material respect; or

(d) an outbreak or escalation of hostilities or other national or international calamity, crisis or emergency or any substantial change in political, financial or economic

-32-

conditions shall have occurred or shall have accelerated to such extent, in the judgment of the Representatives, as to have a material adverse effect on the financial markets of the United States, or to make it impracticable or inadvisable to proceed with completion of the sale of and payment for the Shares as provided in this Agreement.

Any termination pursuant to this Section shall be without liability on the part of any Underwriter to the Company or the Selling Shareholder, or on the part of the Company or the Selling Shareholder to any Underwriter, except for expenses to be paid by the Selling Shareholder pursuant to Section 8 hereof or reimbursed by the Selling Shareholder pursuant to
Section 7(f) hereof and except as to indemnification to the extent provided in
Section 11 hereof.

15. REPRESENTATIONS AND INDEMNITIES TO SURVIVE DELIVERY. The respective indemnities, agreements, representations, warranties, covenants and other statements of the Company, of its officers or directors, of the Selling Shareholder, and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on behalf of any Underwriter, the Selling Shareholder or the Company or any of its or their partners, officers, directors or any controlling person, as the case may be, and will survive delivery of and payment for the Shares sold hereunder.

16. NOTICES. All communications hereunder will be in writing and, if sent to the Representatives, will be mailed, delivered, telecopied (with receipt confirmed) or telegraphed and confirmed to Cleary Gull Reiland & McDevitt Inc. at 100 East Wisconsin Avenue, Milwaukee, Wisconsin 53202, Attention: Chris Barnes, Vice President, with a copy to Patrick G. Quick, Esq., Foley & Lardner, 777 East Wisconsin Avenue, Milwaukee, Wisconsin 53202-5367; and if sent to the Company, will be mailed, delivered, telecopied (with receipt confirmed) or telegraphed and confirmed to the Company at Meridian Diagnostics, Inc., Attention: Gerald Blain, 3471 River Hills Drive, Cincinnati, Ohio 45244, with a copy to Edward E. Steiner, Esq., Keating, Muething & Klekamp, 1800 Provident Tower, One East Fourth Street, Cincinnati, Ohio 45202; and, if sent to the Selling Shareholder, will be mailed, delivered, telecopied (with receipt confirmed) or telegraphed and confirmed to the Attorneys-in-Fact, or either of them, in care of the Company, with copies to J. Jeffrey Brausch, J. Jeffrey Brausch and Company, 203 South Court Street, Medina, Ohio 44256 and Edward E. Steiner, Esq., Keating, Muething & Klekamp, 1800 Provident Tower, One East Fourth Street, Cincinnati, Ohio 45202

17. SUCCESSORS. This Agreement will inure to the benefit of and be binding upon the parties hereto and their respective successors, personal representatives and assigns, and to the benefit of the officers and directors and controlling persons referred to in Section 11 hereof and no other person will have any right or obligation hereunder. The term "successors" shall not include any purchaser of the Shares as such from any of the Underwriters merely by reason of such purchase.

18. PARTIAL UNENFORCEABILITY. If any section, paragraph, clause or provision of this Agreement is for any reason determined to be invalid or unenforceable, such

-33-

determination shall not affect the validity or enforceability of any other section, paragraph clause or provision hereof.

19. APPLICABLE LAW; COUNTERPARTS. This Agreement shall be governed by and construed in accordance with the internal laws of the State of Wisconsin without reference to conflict of law principles thereunder. This Agreement may be signed in various counterparts which together shall constitute one and the same instrument, and shall be effective when at least one counterpart hereof shall have been executed by or on behalf of each party hereto.

If the foregoing is in accordance with your understanding of our agreement, kindly sign and return to us the enclosed duplicates hereof, whereupon it will become a binding agreement among the Company, the Selling Shareholder and the several Underwriters, including the Representatives, all in accordance with its terms.

Very truly yours,

MERIDIAN DIAGNOSTICS, INC.
(the "Company")

By: _______________________________
William J. Motto
Chairman and Chief Executive Officer


Jerry L. Ruyan
(the "Selling Shareholder")

The foregoing Underwriting Agreement
is hereby confirmed and accepted as of
the date first above written.

CLEARY GULL REILAND & MCDEVITT INC.
THE OHIO COMPANY
RONEY & CO.
Acting as Representatives of the
several Underwriters (including themselves)

-34-

identified in Schedule I annexed hereto.

By: CLEARY GULL REILAND & MCDEVITT INC.

By: ____________________________________

Chris Barnes, Vice President

-35-

MERIDIAN DIAGNOSTICS, INC.

EXHIBIT A

        Subsidiary                                 Ownership
        ----------                                 ---------

Omega Technologies, Inc.                           100% owned by the Company

Meridian Diagnostics International, Inc.           100% owned by the Company

Meridian Diagnostics Europe s.r.l.                 99% (22,500 quotas) owned
                                                   by the Company and 1% owned
                                                   (225 quotas) owned by
                                                   Todd Motto

-36-

                         MERIDIAN DIAGNOSTICS, INC.

                                 SCHEDULE I
                                 ----------
                                                         NUMBER OF FIRM
                                                            SHARES TO
      NAME OF UNDERWRITER                                 BE PURCHASED
      -------------------                                 ------------

Cleary Gull Reiland & McDevitt Inc.
The Ohio Company
Roney & Co.

-37-

Exhibit 3.1

AMENDED ARTICLES OF INCORPORATION
OF
MERIDIAN DIAGNOSTICS, INC.

MERIDIAN DIAGNOSTICS, INC. hereby adopts the following Amended Articles of Incorporation to supersede and take the place of the existing Articles and all Amendments thereto:

FIRST. The name of the Corporation shall be Meridian Diagnostics, Inc.

SECOND. The place in Ohio where its principal office is to be located is 3476 Riverhills Drive, Cincinnati, Hamilton County, Ohio 45244.

THIRD. The purpose for which the Corporation is organized shall be:

To develop, manufacture and sell medical diagnostic products and to do any other lawful act or acts for which corporations may be formed under Sections 1701.01 to 1701.98, inclusive, of the Ohio Revised Code.

FOURTH. The maximum number of shares which the Corporation is authorized to have outstanding is:

A. 101,000 shares of Common Stock, without par value and

B. 10,000 shares of Preferred Stock, without par value.

The holders of the Preferred Stock shall be entitled to receive dividends out of any funds of the corporation at the time legally available for dividends when and as declared by the Board of Directors at such rate as shall be fixed by the Board of Directors before any sum shall be set apart or applied to the redemption or purchase of or any dividends shall be declared or paid upon or set apart for any class or series of Common Stock. In the event of any liquidation, dissolution or winding up of the Corporation, the holders of Preferred Stock shall be entitled to receive out of the assets of the Corporation payment of an amount per share as determined by the Board of Directors as a liquidation price (including accrued dividends, if any) before any distribution of assets shall be made to the holders of any class or series of Common Stock.

The Board of Directors shall have he express authority from time-to-time to adopt amendments to these Articles of Incorporation with respect to any unissued or treasury shares of Preferred Stock and thereby to fix or change the division of such shares into series and the designation and authorized number of shares of each series and to provide for each such series:
voting powers, full or limited or no voting powers; dividend rates; dates of payment of dividends; dates from which dividends


are cumulative; liquidation prices; redemption rights and prices; sinking fund requirements; conversion rights; restrictions on the issuance of shares of other series of Preferred Stock; and such other designations, preferences and relative participating options or other special rights and qualifications, powers, limitations or restrictions thereon as may be determined by the Board of Directors.

FIFTH. No holder of any shares of this Corporation shall have any pre-emptive rights to subscribe for or to purchase any shares of this Corporation of any class whether such shares or such class be now or hereafter authorized or to purchase or subscribe for securities convertible into or exchangeable for shares of any class or to which shall be attached or appertained any warrants or rights entitling the holder thereof to purchase or subscribe for shares of any class.

SIXTH. This Corporation, through its Board of Directors, shall have the right and power to purchase any of its outstanding shares at such price and upon such terms as may be agreed upon between the Corporation and any selling shareholder.

SEVENTH. The provisions of Ohio Revised Code Section 1701.831 relating to control share acquisitions shall not be applicable to this Corporation.


CERTIFICATE OF AMENDMENT
By Shareholders
to the Articles of Incorporation of
MERIDIAN DIAGNOSTICS, INC.

William J. Motto, who is President, and Richard H. Walter, who is Secretary, of the above named Ohio corporation for profit with its principal location at 3471 Riverhills Drive, Cincinnati, Hamilton Co., Ohio, do hereby certify that a meeting of the shareholders was duly called for the purpose of adopting this amendment and held on May 16, 1986, at which meeting a quorum of the shareholders was present in person or by proxy, and by the affirmative vote of the holders of shares entitling them to exercise 99% of the voting power of the corporation, the following resolution to amend the articles was adopted:

RESOLVED: That the Amended Articles of Incorporation in ARTICLE FOURTH be amended so that subparagraphs A and B shall read hereafter as follows:

A. 15,000,000 shares of Common Stock, without par value and

B. 1,000,000 shares of Preferred Stock, without par value.

IN WITNESS WHEREOF, the above named officers, acting for and on the behalf of the corporation, have hereto subscribed their names this 21st day of May, 1986.

BY: William J. Motto
William J. Motto President

BY: Richard H. Walter

Richard H. Walter

CERTIFICATE OF AMENDMENT
By Shareholders
to the Articles of Incorporation of
MERIDIAN DIAGNOSTICS, INC.

William J. Motto, who is Chairman of the Board, and Frank J. Seurkamp, who is Secretary, of the above named Ohio corporation for profit with its principal location at 3471 Riverhills Drive, Cincinnati, Hamilton Co., Ohio, do hereby certify that a meeting of the shareholders was duly called for the purpose of adopting this amendment and held on February 16, 1993, at which meeting a quorum of the shareholders was present in person or by proxy, and by the affirmative vote of the holders of shares entitling them to exercise 87.6% of the voting power of the corporation, the following resolution to amend the articles was adopted:

RESOLVED: That the Amended Articles of Incorporation in Article Fourth be amended so that subparagraphs A and B shall read as follows:

A. 25,000,000 shares of Common Stock, without par value and

B. 1,000,000 shares of Preferred Stock, without par value.

IN WITNESS WHEREOF, the above named officers, acting for and on the behalf of the corporation, have hereto subscribed their names this 16th day of February, 1993.

BY: William J. Motto
William J. Motto Chairman

BY: Frank J. Seurkamp
Frank J. Seurkamp Secretary

CERTIFICATE OF AMENDMENT
By Shareholders
to the Articles of Incorporation of
MERIDIAN DIAGNOSTICS, INC.

William J. Motto, who is Chairman of the Board, and Jerry L. Ruyan, who is Secretary, of the above named Ohio corporation for profit do hereby certify that a meeting of the shareholders was duly called for the purpose of adopting this amendment and held on January 25, 1996, at which meeting a quorum of the shareholders was present in person or by proxy, and by the affirmative vote of the holders of shares entitling them to exercise 83% of the voting power of the corporation.

RESOLVED: That the Amended Articles of Incorporation in Article Fourth be amended to that subparagraphs A and B shall read as follows:

A. 50,000,000 shares of Common Stock, without par value and

B. 1,000,000 shares of Preferred Stock, without par value.

IN WITNESS WHEREOF, the above named officers, acting for and on the behalf of the corporation, have hereto subscribed their names this 30th day of January, 1996.

BY: /s/William J. Motto
    ---------------------
    William J. Motto
    Chairman


BY: /s/Jerry L. Ruyan
    ---------------------
    Jerry L. Ruyan


    Secretary


EXHIBIT 5
KEATING, MUETHING & KLEKAMP
ATTORNEYS AT LAW
1800 PROVIDENT TOWER
ONE EAST FOURTH STREET
CINCINNATI, OHIO 45202
TELEPHONE (513) 579-6400
TDD (513) 579-6461

FACSIMILE (513) 579-6956

April 18, 1996

Direct Dial: (513) 579-6468

Meridian Diagnostics, Inc.
3471 River Hills Drive
Cincinnati, Ohio 45246

Gentlemen:

We have examined the corporate records and proceedings of Meridian Diagnostics, Inc. (the "Corporation") with respect to:

1. The organization of the Corporation; and

2. The legal sufficiency of all corporate proceedings of the Corporation in connection with the creation and issuance of all of the present outstanding and issued shares of Common Stock, no par value, of the Corporation (the "Common Stock").

Based upon such examination, we are of the opinion:

1. That the Corporation is a duly organized and validly existing corporation in good standing under the laws of the State of Ohio; and

2. That the 1,500,000 shares of Common Stock, plus up to 225,000 which may be sold pursuant to an over-allotment option, all of which are being sold by the selling shareholder are duly authorized, legally issued, fully paid and non-assessable shares of Common Stock free of any claim of pre-emptive rights.


We hereby consent to be named in the Registration Statement and the Prospectus part thereof as the attorneys who will pass upon legal matters in connection with the aforesaid shares of Common Stock and to the filing of this opinion as an exhibit to the Registration Statement, and furthermore consent to all references made to this firm in the Registration Statement.

Yours truly,

KEATING, MUETHING & KLEKAMP

BY: /s/ EDWARD E. STEINER
   --------------------------

     Edward E. Steiner


EXHIBIT 23.1

CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

As independent public accountants, we hereby consent to the use of our reports and to all references to our Firm included in or made a part of this registration statement.

                                          /s/ Arthur Andersen LLP
                                          ARTHUR ANDERSEN LLP

Cincinnati, Ohio


April 15, 1996